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Introduction 1
1. Introduction - DNA Topoisomerases
Already at the discovery of the double helix structure of DNA it was recognized that
unwinding of intertwined DNA-strands would be necessary during semi-conservative
replication of the molecule. With the discovery of ring-shaped double stranded DNA, the
unwinding problem became a topological one: the two multiply linked circular parental
strands must be unlinked after each round of replication. A unique class of enzymes known as
DNA topoisomerases, which catalyse the breakage and rejoining of DNA strands by two
successive transesterification reactions, are nature’s tool for solving these topological
problems of replication (reviewed in (Champoux, 2001; Nitiss, 1998; Wang, 1996; Wang,
2002)).
In this section, I will briefly introduce DNA topoisomerases in general, followed by a
detailed description of human topoisomerases (topo) I and II, respectively. Subsequently, the
current knowledge about the biological functions of these enzymes will be discussed in a
joined section, since it is misguiding to separate these enzymes in this respect. Finally, present
knowledge on the sub-cellular localization of the enzymes will be presented, with most
attention paid to the topo II isoforms, because their localization has proven to be a particularly
controversial subject.
1.1 DNA Topology and DNA Topoisomerases
Supercoiling of the genomic DNA is an essential feature of all living organisms and
can be considered as one level of organization, which helps to pack the genome into a small
volume so it fits the dimension of a cells nucleus. A prerequisite for supercoiling to occur is
that the DNA must be constrained into closed structures. This is indeed the case for plasmids,
bacterial chromosomes, mitochondria and chloroplasts, where the DNA exists as closed-
circular DNA. Although eukaryotic chromosomes consist of linear DNA, the genome appears
to be organized into constrained domains or loops that in a topological sense behave as
closed-circular domains. These closed chromatin domains are mediated by the so-called
scaffold/matrix attached regions (S/MARs) that are anchored to the nuclear matrix at a
number of sites, thus generating chromatin loops of approximately 50-100 kb of DNA
(reviewed in (Laemmli et al., 1992)).
The topological state of a constrained DNA molecule or domain is described by its
linking number (Lk). The linking number is defined as the number of times that two DNA
double helices are intertwined. It is the sum of twist (Tw) and writhe (Wr). Tw represents the
total number of helical repeats and therefore determines the number of base pairs per turn in
the basic Watson-Crick structure. Wr is a measurement of the contortion of the helix in space,
describing the pathway of the DNA in space. In living cells, the characteristic organization of
the DNA is a negative supercoil, in which the Wr is increased and Tw is lowered in
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Figure 1.1: Topological transformations performed by eukaryotic DNA topoisomerases on the
example of circular plasmid DNA. (A) Relaxation of supercoiled DNA (type I and type II
topoisomerases). (B) Catenation/decatenation (type II topoisomerases). (C) Knotting/unknotting (type II
topoisomerases). Figure is adapted from (Boege, 1996).
comparison to a DNA domain that is not supercoiled and has the same Lk (reviewed in (Bates
and Maxwell, 1993)).
A common feature of all known eukaryotic topoisomerases is their ability to relax
negatively supercoiled DNA. In addition, type II topoisomerases are able to catalyse
knotting/unknotting- and catenation/decatenation reactions on intact duplex DNA. Knots are
probably occurring rarely in nature, whereas catenates are found frequently. Indeed, all
natural populations of DNA rings are to some extent interlocked as catenates (Bates and
Maxwell, 1993). The process described best, in which catenation occurs, is the replication of
genomic DNA, where the two sister chromatids are catenated after replication. It is the ability
of type II topoisomerases to decatenate the intermediate interlocked DNA after replication
that makes these enzymes essential in all living organisms. Fig. 1.1 summarizes the
topological changes of the DNA that can be catalysed by these enzymes.
The first DNA topoisomerase was discovered in 1971 in E.coli by James Wang
(Wang, 1971). Since then, extensive studies have focused on identifying new members of the
family, and on elucidating their structures, enzymatic mechanisms, and cellular functions.
DNA topoisomerases are classified according to their catalytic mechanism of action into four
categories (see table 1.1): Type I topoisomerases relax DNA by introducing a single strand
break, through which the other strand of DNA can pass, followed by religation of the broken
strand. Thus, they change the linkage number of the DNA in steps of one. They are monomers
and act in an ATP-independent manner. Type I topoisomerases fall into two subtypes, IA and
IB. Type IA topoisomerases require Mg2+ for their activity and relax preferentially negative
supercoils. This group comprises E. coli topo I and III, yeast topo III and mammalian topo
IIIα and IIIβ. Type IB topoisomerases are also monomers and act also in an ATP independent
manner. However, unlike type IA topoisomerases they are independent of Mg2+ and can relax
positive as well as negative DNA supercoils. This group includes topo I of yeast and
mammals.
Type IIA DNA topoisomerases catalyse double-strand breaks in DNA by transiently
cleaving the two strands in one DNA duplex to form an enzyme-operated DNA gate, through
which a second DNA helix can pass. Thus, the linkage number is changed in steps of two.
The reaction of type IIA DNA topoisomerases is ATP dependent and requires the presence of
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Type Tyrosyl linkage      Enzymes      Catalytical activity         ATP      Mg2+
IA 5’phosphate       Bacterial DNA topo I Weak relaxation of         No         Yes
      Bacterial DNA topo III negative supercoils.
      DNA topo III Preference for single
      Reverse gyrase stranded DNA.
IB 3’phosphate       DNA topo I Relaxation of posistive         No         No
      DNA topo V and negative supercoils.
Decatenation of nicked
Substrate.
IIA 5’phosphate       Bacterial DNA gyrase Relaxation of negative         Yes        Yes
      DNA topo II and positive supercoils.
      T4 DNA topo II Catenation/decatenation
And knotting/unknotting
of double-stranded DNA.
IIB 5’phosphate       Archeal DNA topo VI Generation of double         Yes        Yes
strand breakage
during meiosis.
Tabel 1.1: Types of DNA Topoisomerases and Representative Examples. ATP: requirement for
ATP. Mg2+: requirement for Mg2+. (Bergerat et al., 1997; Bergerat et al., 1994; Confalonieri et al., 1993;
Giaever et al., 1986; Goto and Wang, 1984; Goto and Wang, 1985; Hanai et al., 1996; Huang et al.,
1988; Jenkins et al., 1992; Kato et al., 1990; Slesarev et al., 1993; Tsai-Pflugfelder et al., 1988; Tse-
divalent cations, preferentially Mg2+. The type IIA family includes E. coli DNA gyrase, yeast
topo II and mammalian topos IIα and IIβ. Type IIB DNA topoisomerases include DNA topo
VI from Archea and are ATP and Mg2+ dependent. This class of enzymes catalyses the
relaxation of positively and negatively supercoiled DNA and possesses a potent DNA
decatenase activity. The division of type II into type IIA and IIB is based on a lack in
sequence and structure similarities. Common for the reactions of all types of DNA-
topoisomerases is the formation of transient, covalent phosphor tyrosyl-linkages between
DNA and enzyme, thereby preserving the energy from the broken phosphodiester bridge.
This thesis is dealing with the two most prominent topoisomerase classes expressed in
mammalian cells: topo I belonging to type IB, and topo IIα and IIβ belonging to type IIA.
These enzymes will subsequently be introduced in more detail, whereas the other types (IA
and IIB) will not be discussed further. Although this thesis is not about the catalytic
mechanism of DNA-topoisomerases, I feel that it is necessary to introduce these complex
enzymatic reactions since they are essential for an understanding of what these enzymes
actually are doing in the cell. Therefore, the next chapters will summarise what is known
about the domain organisation, crystal structure, and catalytic cycle of the two types of
topoisomerases under investigation here.
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1.2 Type IB DNA Topoisomerases
Eukaryotic topo IB are monomeric enzymes identified in a variety of eukaryotic
species from yeast to human (Wang, 1996). In addition to the nuclear forms, variants of this
enzyme have been identified in mitochondria (Brun et al., 1981; Castora and Lazarus, 1984),
in chloroplasts (Fukata et al., 1991; Mukherjee et al., 1994) and in a number of poxviruses
(Krogh et al., 1999; Shuman and Moss, 1987). The molecular weight of eukaryotic topo I
typically ranges in size from 90 to 135 kDa. Contrary to type II enzymes, topo IB enzymes do
not require high-energy cofactors in order to relax supercoiled DNA. Divalent cations
stimulate these enzymes, but are not essential (Attardi et al., 1981; Riou et al., 1986; Rowe et
al., 1981; Svejstrup et al., 1991). Whereas the domain and crystal structure of topo II is better
described for the yeast enzyme, topo I from human is the type IB enzyme studied best.
Accordingly, the following section will first introduce human topo I as a prototypic IB
enzyme and then discuss its domain organization, protein structure and the catalytical cycle as
an example for type IB topoisomerases in general.
1.2.1 Characteristics of Human DNA Topoisomerase I
Human topo I is encoded by a single copy gene located in chromosome region 20q12-
13.2 (Juan et al., 1988). The cDNA encodes a protein with a size of 91 kDa, which is present
in the nucleus at approximately 105 to 106 copies (Meyer et al., 1997). Topo I is a long-lived
protein with a half-life time of 10 - 16 hours in mammalian cells (Desai et al., 1997), and it is
expressed at a constant level throughout the cell cycle (Heck et al., 1988).
The catalytic activity of cellular topo I is partly regulated by post-translational
modifications. It is known that topo I is poly(ADP-ribosylated) by poly(ADP-
ribose)polymerase (PARP) resulting in a 3-5 fold decrease in its activity (Ferro et al., 1983;
Ferro and Olivera, 1984; Jongstra-Bilen et al., 1983; Kasid et al., 1989). However, PARP has
also a stimulatory effect on topo I. In the absence of NAD+ a direct binding of PARP to topo I
coincides with an activation of the enzyme (Bauer et al., 2000; Bauer et al., 2001). The
biological role of this interaction remains elusive. As PARP plays a role in DNA repair and
requires nicks or free DNA ends in order to be activated (Jeggo, 1998), it has been suggested
that it may be involved in repairing topo I trapped on DNA (Sastry and Ross, 1998). In
keeping with this, cells deficient in PARP are hypersensitive to camptothecin - an agent
stabilizing topo I covalently bound to DNA (see below)(Chatterjee et al., 1989).
A second post-translational modification of topo I is phosphorylation. The enzyme is
found to be a phosphoprotein in vivo and a substrate for PKC and PK CK2 phosphorylation in
vitro (Durban et al., 1985; Pommier et al., 1990). Phosphorylation stimulates the enzyme’s
relaxation activity and dephosphorylation almost abolishes enzymatic activity (Durban et al.,
1983; Kaiserman et al., 1988). More recently, a cell cycle-specific and transcription-related
phosphorylation of mammalian topo I was observed, which, however, did not to affect
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Figure 1.2: Domain structure of human topoisomerase I. Human topo I comprises an N-terminal
domain (open box), a core domain (grey box), a linker domain (diagonally striped box), and a C-
terminal domain (black box). The properties of the four domains are summarized in the lower portion
of the figure. Figure reproduced from (Champoux, 2001).
catalytic activity (D'Arpa and Liu, 1995). The physiological relevance of this modification is
unknown, but it seemed to be coupled to mitosis, which is supported by other investigations
showing that exposure of cultured mammalian cells to mitogenic agents yield a similar effect
on the phosphorylation state (Samuels et al., 1994). Although the mitosis-coupled
phosphorylation of topo I has no effect on the catalytic activity of the enzyme, it is reasonable
to suggest that this modification could regulate topo I function in other aspects, such as its
interaction with DNA or other proteins.
Indeed it is becoming increasingly evident that topo I is regulated by its interaction
with other proteins. Our group has recently shown that the RNA splicing factor PSF/p54nrb
interacts with topo I thereby stimulating the relaxation activity of topo I by 16 fold (Straub et
al., 2000). Moreover, the cleavage specificity of topo I was found to change markedly by its
interaction with SV40 large T antigen during replication (Simmons et al., 1996; Simmons et
al., 1998a; Simmons et al., 1998b). p53 has also been shown to interact with topo I, and cell
extracts containing p53 have higher relaxation activity than cell extracts from p53-deficient
cells (Gobert et al., 1996; Gobert et al., 1999; Mao et al., 2000b). A number of other proteins
(histone H1, casein kinase II, non histone HMG, nucleolin, certain transcription factors and
the WRN protein) have been shown to physically interact with topo I in vitro (Albor et al.,
1998; Bharti et al., 1996; Haluska and Rubin, 1998; Kretzschmar et al., 1993; Lebel et al.,
1999; Merino et al., 1993; Shaiu et al., 1999; Shykind et al., 1997; Wang and Roeder, 1998).
1.2.2 Domain Organization and Protein Structure of Topoisomerase I
Based on conservation of sequence, limited proteolysis and fragment reconstitution
experiments, and crystallographic data, human topo I protein can be divided into four distinct
domains (Redinbo et al., 1998; Stewart et al., 1996a; Stewart et al., 1997; Stewart et al.,
1996b; Stewart et al., 1998): The enzyme comprises (i) a highly charged N-terminal domain,
(ii) a highly conserved core domain, (iii) a linker region, and (iv) a highly conserved C-
terminal domain, which contains the active site tyrosine (Fig. 1.2).
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Figure 1.3: Structure of human topoisomerase I in
complex with DNA. The bi-lobed protein tightly
clamps around the DNA. Core subdomain I (residues
215-232 and 320-433), II (residues 233-319) and III
(residues 434-633) are coloured yellow, blue and red,
respectively. The linker (residues 641-712) and C-
terminal domain (residues 713-765) are shown in
orange and green, respectively. Core subdomains I
and II forms the CAP lobe. Core subdomain II and C-
terminal domain forms the base lobe. The lip regions
where the protein opens during DNA binding and
release, are marked by arrows, and the hinge region
is labelled ‘putative hinge’. Figure adapted from
(Champoux, 2001)
The N-terminal domain (the first 214 amino acids) is dispensable for relaxation
activity in vitro and it is poorly conserved through evolution (Stewart et al., 1997; Stewart et
al., 1996b). Despite the fact it is not required for in vitro activity, it may have essential roles
in vivo. Indeed, the N-terminal domain contains four NLS (Alsner et al., 1992; Mo et al.,
2000a) and in drosophila this domain alone is sufficient to target topo I to transcriptionally
active loci (Shaiu and Hsieh, 1998). Next to the N-terminal domain, the highly conserved core
domain of 421 amino acids follows which contains all catalytic residues except the active site
tyrosine (Cheng and Shuman, 1998; Jensen and Svejstrup, 1996; Megonigal et al., 1997;
Redinbo et al., 1998). The core domain constitutes the principal DNA binding region. This
domain alone exhibits DNA binding properties similar to that of the full-length enzyme. It
interacts with high affinity and selectivity to supercoiled DNA (Madden et al., 1995). A
protease-sensitive and poorly conserved linker domain comprising 77 amino acids connects
the core to the C-terminal domain. The linker region is not required for relaxation activity in
vitro (Stewart et al., 1997). The C-terminal domain (last 53 amino acids) contains the active
site Tyrosine723 (Eng et al., 1989). Interestingly, catalytic topo I-activity can be reconstituted
from fragments corresponding approximately to the core domain and the C-terminal domain
(Stewart et al., 1997). In agreement with this, a topo I variant of Vaccinia virus consists of a
reduced core and the C-terminal domain only (Redinbo et al., 1999a; Shuman and Moss,
1987). Thus, Vaccinia topo I is considered as the minimal functional unit of DNA topo I with
respect to relaxation activity.
Recently the crystal structure of several forms of human topo I has been determined in
the non-covalently and the covalently DNA-bound state (Redinbo et al., 2000; Redinbo et al.,
1999b; Redinbo et al., 1998; Stewart et al., 1998). The entire N-terminal region is missing
from the structure, because the X-ray density was not interpretable due to a very high
flexibility. The structure of topo I in complex with DNA is shown in Fig. 1.3, including the
subdivision of the core domain into core sub domain I, II and III. Human topo I is a bi-lobed
protein that wraps completely around the DNA substrate which it buries in a DNA-binding
pore. The central pore of the protein is 20 Å in diameter and provides an extensive, highly
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positively charged region for binding of a DNA helix (Redinbo et al., 1998). The bi-lobed
protein tightly clamps around the DNA with contacts between the protein and the DNA
phosphate backbone extending over 14 base pairs. One of the lobes comprises core sub-
domains I and II and forms what has been referred to as the “cap” of the protein (Redinbo et
al., 1998). The other lobe forms a “base” that cradles the DNA and consists of core sub-
domain II and the C-terminal domain. The two lobes are connected by a so-called hinge
region believed to be involved in opening and closing of the protein clamp during DNA
binding and release. Opposite to the hinge region are the cap lobe and the base lobe in close
proximity, interacting via six amino acids and one salt bridge to connect the lobes, thereby
forming the so-called “lips”, which enclose the DNA helix. Opening and closing of the
protein clamp during DNA binding or release must involve the breaking of this interaction
between the lips. The dispensable linker domain protrudes from the base of the protein, and
has been suggested to be involved in controlling the rotation of the DNA by interacting with
DNA downstream to the cleavage site (Ireton et al., 2000; Redinbo et al., 1998; Stewart et al.,
1999). Thus, topo I must be highly flexible to perform its catalytic function. Indeed non-
isomorphous crystal structures have shown that there is a high structural elasticity in human
topo I (Redinbo et al., 1999b). Especially the cap domain shows a large degree of
conformational flexibility consistent with a separation of the lips and a rotation around the
hinge region. Interestingly, the linker region showed the greatest degree of flexibility,
consistent with the idea of controlled strand rotation as discussed in the next section.
1.2.3 Catalytic Cycle of Human Topoisomerase I
Extensive biochemical studies and the above described crystal structure have led to a
model for the catalytic mechanism for topo I. According to this ‘controlled rotation’ model
(Fig. 1.4) DNA relaxation catalysed by topo I can be divided into a number of consecutive
steps. These are DNA binding (A to B), cleavage and covalent attachment of the enzyme to
the scissile strand (B to C), strand rotation (D), religation (E to F) and DNA release from the
enzyme (F to G).
Topoisomerization begins with the binding of topo I to the DNA duplex substrate (Fig.
1.4.A). The closed clamp structure of topo I in complex with DNA (Fig. 1.3) suggests that the
enzyme must exist in an open conformation before DNA binding in order to allow entry of
DNA into the central cavity of the enzyme (Fig. 1.4. A-B). This conformation is most likely
achieved by a bending motion in the hinge region (Redinbo et al., 1999b; Redinbo et al.,
1998). In support of this hypothesis, the hinge region has been observed to be sensitive to
proteolysis in the absence of DNA and resistant to it upon binding of DNA (Stewart et al.,
1996a). The binding event is directed in large part by the surface and charge
complementarities of the enzyme cavity and the DNA, and culminates in the complete
embrace of the DNA in a noncovalent complex (Fig. 1.4. B). The substrate specificity of
eukaryotic topo I has been characterized at nucleotide sequence level and at the level of DNA
tertiary structure. The preferred nucleotides in the scissile strand are 5’-(A/T)(G/C)(A/T)T-3’
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Figure 1.4:  T h e
controled rotation
mechanism of human
topoisomerase I. The
cap and base lobes  are
coloured blue and
magenta, respectively.
T h e  s u p e r c o i l e d
substate DNA (red)
becomes  pa r t i a l l y
relaxed through steps
(A) through (G) and is
converted to the less
s u p e r c o i l e d  s t a t e
depicted in green. (A-B)
Binding of DNA. (B-C)
Cleavage of scissile
strand. (D) Strand
rotation. (E-F) Religation
of DNA. (F-G) Release
of substrate DNA. Figure
adapted from (Stewart et
al., 1998)
with the enzyme covalently attached to the –1T residue (Been et al., 1984; Bonven et al.,
1985; Tanizawa et al., 1993). A particular strong cleavage site for all eukaryotic topo I species
was identified in the rDNA repeats of Tetrahymena pyriformis (Andersen et al., 1985). At the
level of tertiary DNA-structure, a number of studies have shown that topo I prefers
supercoiled over relaxed DNA as substrate (Camilloni et al., 1989; Muller, 1985), a property
conferred by the core domain (Madden et al., 1995). Electron microscopy studies showed that
topo I binds to supercoiled DNA at helix crossovers (Zechiedrich and Osheroff, 1990). Since
the number of DNA crossovers increase with the degree of supercoiling, this result may
explain the selectivity of topo I for supercoiled DNA.
As a result of topo I embracing a piece of DNA, the active site residues are brought into
position for attack on the scissile phosphate, leading to cleavage of the scissile strand and to
covalent attachment of the enzyme to the 3’ end of the cleaved DNA (Fig 1.4.C). Topo I
mediated cleavage proceeds by an in-line displacement reaction according to a classical SN2
pathway: Topo I directs a nucleophilic attack of the active site tyrosine residue to the
phosphorous of the phosphodiester linkage thereby mediating a transesterification reaction
(Eng et al., 1989; Lynn et al., 1989; Lynn and Wang, 1989; Shuman et al., 1989). A number
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of residues beside the active site tyrosine are required for the catalysis of transesterification
((Cheng and Shuman, 1998; Jensen and Svejstrup, 1996; Levin et al., 1993; Megonigal et al.,
1997; Redinbo et al., 2000; Redinbo et al., 1998) and reviewed in (Champoux, 2001; Sherratt
and Wigley, 1998)).
After the cleavage reaction, topo I may proceed right away to religation. Alternatively
it performs a number of topoisomerization steps before resealing the broken strand (Fig.
1.4. D). Since ATP is not required, relaxation by human topo I is believed to be driven by
topological tension in the DNA (Champoux, 1981). Previous studies have suggested that
changes in linkage number (relaxation) mediated by topo I could precede either through
strand passage or free rotation (reviewed in (Darby et al., 1985)). However, more recent
biochemical and structural data suggest that topo I changes the linkage number of DNA by a
mechanism of controlled relaxation (Stewart et al., 1998). In the controlled rotation model, the
release of superhelical tension can occur through one or more cycles of controlled rotation
(Fig 1.4.D). Stewart and colleagues suggested that the rotation of DNA is controlled by
interaction of the enzyme with DNA downstream of the cleavage site. Indeed, filter binding
assays showed that the N-terminal region of topo I binds to DNA, although with a
significantly lower affinity than full-length topo I (Lisby et al., 2001). In vitro, religation
experiments have shown that both the linker and the N-terminal domains are interacting with
downstream DNA (Ireton et al., 2000; Lisby et al., 2001; Stewart et al., 1999). Taking all
these findings together, it appears that the rotation of the DNA is controlled by interactions
with DNA downstream to the cleavage site
Subsequent to strand rotation, the covalent intermediate (Fig. 1.4.E) is religated with
concomitant release of the Tyr723 from the end of the DNA (Fig. 1.4.F). Finally, a DNA
molecule with reduced superhelicity is released (Fig 1.4.G), allowing the enzyme to undergo
another cycle of DNA binding and relaxation.
1.2.4 Camptothecin- a Drug Targeting Human Topoisomerase I
Topo I is the specific cellular target of a family of chemical compounds derived from
the natural alkaloid camptothecin (CpT) that was originally identified in extracts of the
Chinese tree Camptotheca acuminata, to which ancient Chinese drug lore has assigned anti-
cancer activity for a long time. Biochemical studies showed that CpT inhibits topo I mediated
relaxation by inhibiting specifically the religation half-reaction thereby inducing accumulation
of covalent cleavage complexes (Svejstrup et al., 1991). The cytotoxic effect of CpT seems to
be specifically linked to inhibition of topo I, since a point mutation of the enzyme can confer
drug resistance in a mammalian cell line (Tamura et al., 1991). It has been proposed that topo
I-mediated single stranded DNA nicks created by CpT are reversible unless they are
processed into permanent double-strand breaks in vivo by at least two different mechanisms.
The traditional mechanism involves collision of a DNA replication fork with the covalently
trapped topo I thereby converting the transient nick into a double-strand break (Hsiang et al.,
1989). It is now evident that CpT also has the capacity to induce DNA breaks in an S-phase
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independent manner (Voigt et al., 1998): The authors suggest that these breaks could be
generated by the transcription machinery or by several topoisomerases cleaving in close
proximity of each other. In mammalian cells, the generation of significant amounts of double-
stranded DNA breaks ultimately results in apoptosis or necrosis (Ryan et al., 1991; Solary et
al., 1994). The high activity of topo I in rapidly dividing cells of most cancers results in a
preferential killing of malignant cells (D'Arpa and Liu, 1989; Waldman et al., 1996).
Cellular resistance to CpT and other cytostatic drugs has turned out to be a significant
complication in cancer treatment (Dingemans et al., 1998). Beside point mutations in topo I
that confer resistance to CpT at the molecular level, a number of conditions have been
identified that cause resistance to CpT on a higher level of the cell. In some cases, the
resistance is found to correlate with reduced expression of the TOP1 gene. This was explained
by reduced gene transcription, due to hyper-methylation at the gene locus (Fujimori et al.,
1996). CpT resistance has also been observed in human cancer cells overexpressing the P-
glycoprotein transporter (MDR), which presumably prevents CpT from accumulating
intracellularly by actively exporting the drug out of the cell in an energy-dependent manner
(Germann et al., 1993; Gottesman, 1993).
Treatment of cells with CpT results in a down regulation of topo I protein levels. This
down regulation is believed to be mainly due to increased degradation bringing down half-life
time to approximately 1-2 hours. CpT-induced degradation of topo I has been suggested to be
mediated by multiple ubiquitination and subsequent degradation by the 26S proteosome
pathway (Desai et al., 1997; Fu et al., 1999). However, the high molecular weight ladder of
topo I immunoreactivity observed by Fu and colleagues did not correspond well with the 8.6
kDa adducts expected from ubiquitination which suggested that another pathway could be
involved in topo I degradation. Accordingly, it was later reported that the topo I conjugated
protein found in CpT treated cells is not ubiquitin but rather an ubiquitin related protein,
SUMO-1/Smt3p (Mao et al., 2000a). CpT and similar drugs cause a relocation of topo I from
the nucleoli to the nucleoplasm (Danks et al., 1996), and it has recently been suggested that
sumoylation of topo I also plays a major role in this process (Mo et al., 2002).
Recently a specific repair enzyme has been discovered in S. cerevisiae, which has
homologues in C.elegans, human, mouse and D.melanogaster. This enzyme, termed tyrosyl-
DNA phosphodiesterase (Tdp1), may have important implications for the cellular effects of
CpT (Yang et al., 1996). Tdp1 catalyses the hydrolysis of phosphotyrosyl linkage between
tyrosine and 3’-ends of DNA thereby, releasing topo I from the DNA (Pouliot et al., 2001;
Pouliot et al., 1999). Tdp1 is poorly active in releasing full-length topo I covalently attached
to DNA, but is very efficient in releasing a small fragment of topo I left after proteolytic
processing of the topo I•DNA complex (Debethune et al., 2002). This suggests that Tdp1 acts
after topo I has been proteolyzed in vivo. The ability of Tdp1 to release topo I stalled on DNA
suggests that Tdp1 may be involved in removing CpT induced topo I complexes, thus making
the cells less sensitive to CpT. Indeed, survival of yeast after induction of covalent topo I
DNA complexes is substantially reduced by inactivation of the TDP1 gene (Pouliot et al.,
2001). Moreover, unpublished results of our own group suggest that overexpression of Tdp1
renders human cells CpT-resistant. Thus, the development of a drug inhibiting Tdp1 is of
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clinical interest, since it could increase cellular sensitivity to CpT, thereby acting as a
sensitizer for CpT-analogues such as topotecan or irinotecan currently used in clinical cancer
therapy.
1.3 Type IIA DNA Topoisomerases
So far, type IIA topoisomerases have been identified in a wide variety of eukaryotic
organisms including S.pombe (Shiozaki and Yanagida, 1991; Uemura et al., 1986), S .
cerevisiae (Giaever et al., 1986; Goto et al., 1984; Goto and Wang, 1984), Drosophila
(Wyckoff et al., 1989) and mammals such as mouse (Adachi et al., 1992), rat (Park et al.,
1993) and human (Jenkins et al., 1992; Tsai-Pflugfelder et al., 1988). In bacteria, several type
II topoisomerases have been found, including DNA gyrase and topo IV (Gellert et al., 1979;
Kato et al., 1990).
Since its discovery, eukaryotic topo II has attracted much attention because it became
evident from early on that it is an essential enzyme. The discovery that human type II
topoisomerases are the primary target of many anticancer agents already applied in the clinic
has further increased the interest in the enzyme. Eventually, this has led to a detailed
description of topo II on the level of DNA-sequence and protein structure. In addition to its
enzymatic function, topo II is considered to play a structural role in the chromosomal scaffold
and the interphase nuclear matrix. Throughout the introduction, I have put a certain emphasis
on the presentation of data supporting this hypothesis (Berrios et al., 1985; Earnshaw et al.,
1985; Gasser et al., 1986; Strick et al., 2001), because recently, we have shown that such an
architectural role for topo II is unlikely (Christensen et al., 2002b) and these findings are a
major component of this thesis.
In this chapter the two human isoforms of topo II will be introduced, followed by a
general characterization of the domain organization, protein structure and the catalytic cycle
of type IIA topoisomerases, comprising of data from type II enzymes from E.coli, yeast, and
human.
1.3.1 Characteristics of Human Topoisomerases IIα and IIβ
Whereas lower eukaryotes only encode one form of topo II, mammalian cells express
two related but genetically distinct isoforms of topo II, designated IIα and IIβ (Chung et al.,
1989; Jenkins et al., 1992; Tsai-Pflugfelder et al., 1988). The cDNAs for topo IIα and IIβ
encode proteins with a molecular weight of 170 and 180 kDa, respectively. The human topo
IIα gene has been mapped to chromosome 17q21-22 (Tan et al., 1992; Tsai-Pflugfelder et al.,
1988) whereas the gene encoding the IIβ isoform is located on chromosome 3p24 (Jenkins et
al., 1992; Tan et al., 1992). A small fraction of topo IIβ RNA has been reported to undergo
differential splicing in various human cell lines generating a minor protein by-product named
IIβ-2 (Davies et al., 1993), which has an insertion of additional 5 amino acids at its N-
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terminus. No specific role could be assigned to the IIβ-2 splice variant so far, and data about
its biochemical properties are lacking.
The two topo II isoforms in higher eukaryotes are believed to have arisen from a gene-
duplication event relatively recent in evolutionary time (Coutts et al., 1993; Lang et al., 1998;
Sng et al., 1999). Gene structure analysis has shown that the topo IIα (TOP2A) and IIβ
(TOP2B) genes contain 35 and 36 exons, respectively (Lang et al., 1998; Sng et al., 1999). An
alignment to the amino acid-sequence demonstrates that the intron/exon boundaries of human
TOP2A and TOP2B are highly conserved between the two genes. Interestingly, the only cases
where the introns are not conserved lie within regions that encode the more divergent NH2-
and COOH-terminal regions of the proteins. The high degree of conservation of the intron
position in TOP2A and TOP2B supports the view that the two genes are derived from the
duplication of a single genetic ancestor.
Human topo IIα and IIβ are close homologues with a sequence identity of 68%
(Austin et al., 1993; Jenkins et al., 1992; Lang et al., 1998; Sng et al., 1999). Besides having a
high sequence identity, both isoforms can complement the essential functions of yeast topo II
in a temperature-sensitive Saccharomyces cerevisiae topo II-deletion mutant (Jensen et al.,
1996b). In addition to human topo IIα and IIβ, several type II topoisomerases from other
organisms are also able to complement a yeast topo II enzyme, including topo II from
Drosophila (Wyckoff et al., 1989) and mouse (Adachi et al., 1994; Adachi et al., 1992). The
fact that topo II from a wide variety of organisms is able to complement the yeast counterpart
demonstrates an exceptional functional conservation of these enzymes. Indeed, the sequences
of topo II from various organisms show a high degree of homology. However, although both,
topo IIα and IIβ are able to complement the yeast topo II enzyme and can be considered as
functional equivalents in this system, this might not be the case in their natural environment in
higher eukaryotic cells, because isoform-specific functions could be missing or dispensable in
the yeast system.
On the other hand, the fact that both human isoforms are able to complement a
defective topo II in yeast proves that the two isoforms must possess the same basic enzymatic
activities, although an early report showed that a topo II-specific inhibitor preferentially
targeted the IIα isoform and that the two isoforms were biochemically distinguishable (Drake
et al., 1989). Based on more recent in vitro studies using purified enzymes, it was, however,
concluded that the enzymatic properties of the two isoforms are essentially indistinguishable
(Austin et al., 1995; Wang, 1996). This view may however again be changing since a new
topo II poison has been recently presented which only affected the IIβ isoform (Barthelmes et
al., 2001). Based on the available data however, it is still reasonable to conclude that potential
isoform specific functions of the two human isoforms must arise from other sources than their
enzymatic properties. Different expression patterns, cellular localization and protein
interaction partners have been suggested to mediate isoform specific functions.
In addition to differences in their gene sequence and structure, the expression levels of
human topo IIα and IIβ differ as cells traverse through the cell cycle. These differences are
mediated by different transcription rates and changes in mRNA and protein stability
(reviewed in (Isaacs et al., 1998). Topo IIα undergoes significant cell-cycle dependent
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alterations in both its amount and stability. The protein level starts to increase at the onset of
replication, accumulates during S and G2 phase, peaks in late G2/M phase, which is then
followed by a rapid decline after exit from mitosis (Goswami et al., 1996; Heck et al., 1988).
Topo IIβ, on the other hand, has been reported to be present at a constant level throughout the
cell cycle (Drake et al., 1989; Kimura et al., 1994b; Prosperi et al., 1996; Prosperi et al., 1992;
Woessner et al., 1991). In addition, the expression of topo IIα in tissues of human, mouse, and
rat is highest in proliferating compartments, such as thymus, spleen and bone marrow, whilst
in non-proliferating tissue types the expression of topo IIα is barely detectable. The level of
topo IIβ mRNA does not correlate with proliferation state but rather remains constant in all
types of tissue (Boege et al., 1995; Capranico et al., 1992; Isaacs et al., 1996; Turley et al.,
1997; Zandvliet et al., 1996). This suggests that the α -isoform is more involved in
proliferation, whereas topo IIβ can be considered more as a housekeeping gene likely
involved in processes like transcription or DNA-repair. The fact that expression levels of topo
IIα are apparently higher in a variety of tumours in comparison with adjacent normal tissue
(Hasegawa et al., 1993; Kim et al., 1991) further supports the view that topo IIα is linked to
the proliferation state of the cell. 
Even though the characteristic expression pattern of the two isoforms suggests
isoforms-specific functions, direct evidence to whether topo IIα and IIβ fulfil different
cellular roles is still lacking. This is partly due to the lack of mammalian cell mutants
defective for either topo IIα or IIβ. This problem has been partly overcome by Wang and co-
workers, who have constructed gene targeting vectors to knock out topo IIβ in mouse (Yang
et al., 2000). They found that topo IIβ in mouse is essential for viability since homozygous
TOP2β- embryos are stillborn. Interestingly, the embryos survive almost to term, indicating
that most steps of embryogenesis can occur without the β-isoform. It was also possible to
isolate mouse embryo fibroblasts from the TOP2β- embryos and propagate them in culture,
indicating that topo IIβ is not required for the viability of all cells, but rather plays an essential
function in some cell types. Since the enzyme constantly exists in cell types independent of
proliferation, topo IIβ may play an essential function in differentiated cells, where topo IIα is
not expressed. The high level of topo IIα in proliferating cells further suggests that knockouts
of topo IIα would be lethal early in embryogenesis unless topo IIβ is able to substitute its
functions. Further support of this view comes from the investigation of cells with an aberrant
cytosolic expression of topo IIα, which causes aneuploidity and incomplete chromosome
condensation (Grue et al., 1998). The reported differences between topo IIα and IIβ have led
to the model of a division of labour. Whereas topo IIα is believed to be involved in cell
division specific events, such as DNA synthesis, condensation and segregation, the topo IIβ
isoform might maintain a housekeeping function possibly involved in DNA transcription
(Capranico et al., 1992; Prosperi et al., 1992).
The investigation of isoform specific functions is further complicated by data
suggesting that a heterodimeric form of mammalian topo II is formed in addition to the two
homodimeric forms of the enzyme (Biersack et al., 1996; Gromova et al., 1998). Thus, cells
may contain three distinct subclasses of topo II: α/α, β/β homodimers and α/β heterodimers.
However, data about biochemical activity or cellular localization of topo II heterodimers are
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lacking, and a more detailed investigation is required to assign a specific biological role to
these otherwise possibly aberrant forms of the enzyme. Their existence, however, merits
consideration whenever topo II in vivo functions and cell-cycle regulation are investigated.
1.3.2 Domain Organization and Protein Structure of Topoisomerase II
Limited protease-digestion of various topo II polypeptides suggests that the enzyme
can be divided into three subdomains (Austin et al., 1995; Lee and Hsieh, 1994; Lindsley and
Wang, 1991; Reece and Maxwell, 1989; Shiozaki and Yanagida, 1991). As shown in Fig. 1.5,
S.cerevisiae topo II is cleaved by SV8 endoprotease at three sites, designated V8-A (residue
410), V8-B (residue 660) and V8-C (≈ residue 1164). V8-A and V8-C are the predominant
cleavage sites whereas V8-B is only a minor site cleaved less efficient (Lindsley and Wang,
1991). Sites in a globular protein available to limited protease digestion must be accessible to
the protease. The protease pattern therefore indicates that yeast topo II can be divided into
three separate and spatial distinct domains that are termed: ATPase domain (amino acid 1-
410), DNA binding/Cleavage domain (amino acid 410-1164) and C-terminal domain (amino
acid 1164-1428).
Figure 1.5: Sequence comparison among type IIA topoisomerases. The three-domain structure of
the type IIA family is shown based on amino acid sequence homologies with the E.Coli DNA gyrase
(Caron and Wang, 1994). Regions homologous to the Gyr B subunit (excluding the insertion 550-719)
are shown with sequence coordinates and a grey shaded box. Regions homologous to the first 505
amino acids of GyrA are depicted by a box with diagonal striping. V8 protease sensitive sites in
S.Cerevisiae topo II are shown below its respective panel.
The three-domain structure of eukaryotic topo II is further supported by comparison
with bacterial type II topoisomerases. DNA gyrase, the E.coli counterpart of eukaryotic topo
II, is structurally different from its eukaryotic counterparts. DNA gyrase is the product of two
separate genes gyrB and gyrA and the enzyme is a heterotetramer of an A2B2 configuration,
whereas eukaryotic topo II has a dimeric AB configuration. (Austin et al., 1993; Horowitz and
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Figure 1.6: Structure of the 92 kDa
fragment of S.Cerevisiae topo II. A ribbon
representaion of the crystallized dimeric
structure of the 92 kDa yeast topo II fragment
showing an enzyme clamp with two sets of
jaws and a large central hole. The two
crescent-shaped monomers form a pair to
make a heart shaped dimer with a large
central hole. The B’ fragments (residues 410-
680) are coloured red and orange, whereas
the A’ fragments (residues 680-1202) are
shown in purple and blue. The active site
tyrosines (Y*) are situated 25 Å apart and are
indicated by green spheres. The large hole is
55Å wide at its base, 25Å wide at the top and
60Å deep. Figure adapted from (Berger et
al., 1996)
Wang, 1987). The three-domain structure is also in agreement with sequence comparison of
various eukaryotic type II topoisomerases with DNA gyrase (see Fig. 1.5 for details): an N-
terminal region homologous to the B subunit of DNA gyrase (GyrB), a central domain
homologous to the GyrA subunit and a C-terminal region very divergent in nature with no
equivalent in bacterial DNA gyrase (Austin et al., 1993; Caron et al., 1994; Jenkins et al.,
1992; Lynn et al., 1986; Wyckoff et al., 1989).
The three domains described by proteolysis and sequence comparison can be assigned
to different functions. The ATPase region is involved in ATP binding and hydrolysis. The
central core-domain is responsible for DNA binding and cleavage, whereas the divergent C-
terminal domain is dispensable for in vitro catalytic activity (Crenshaw and Hsieh, 1993;
Jensen et al., 1996a). Of these three domains, only the divergent C-terminal domain has not
yet been crystallized and resolved to high resolution. The structure of the central domain is
now known for both DNA gyrase and yeast topo II, whereas the structure of the N-terminal
domain has only been solved for DNA gyrase.
The high-resolution structural studies on topoisomerases over the past years have
highly elevated our knowledge about the mechanism of topo II catalysis and drug interaction
(reviewed in (Berger, 1998; Champoux, 2001)). The crystal structure of a 92 kDa yeast topo
II fragment - spanning amino acids 410-1202 between V8 cleavage sites A and C - has been
solved to 2.7 Å resolution (see Fig. 1.6) (Berger et al., 1996). The 92 kDa fragment contains
the central DNA binding and DNA-breakage/reunion domain (see Fig. 1.5) but lacks the
ATPase domain (residues 1-409) and the C-terminal domain. It can cleave DNA but cannot
execute strand transfer, since it lacks the essential ATPase domain. The 92 kDa polypeptide
fragment folds into two subfragments, denoted B’ (residues 420-630) and A’ (residues 682-
1178) which are connected by a disordered, 50 amino acid linker. Interestingly, the V8-B
protease cleavage site lies in this linker region. The two enzyme subunits form a pair (A’B’)2
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to make a heart shaped dimer of an overall dimension of 120 x 120 x 55 Å with a large central
hole nearly 50 Å in diameter (see Fig. 1.6).
Two dimerization regions can be observed in the structure of yeast topo II: One
between the two B’ fragments and a second between the C-terminal end of the two A’
fragments (Berger et al., 1996). The B’-B’ contact takes place between two small but
conserved hydrophobic patches on each sub fragment. The dimer contact in the B’-B’ region
buries an area of approximately 750 Å2 surface in each fragment. A biochemical study has
supported the existence of a B’-B’ dimer contact (Olland and Wang, 1999). The structure
further shows that part of the A’ domain is involved in formation of the so-called primary
dimer interface. The existence of the A’A’ dimer interface is supported by a number of
genetic and biochemical studies. Three cold-sensitive mutations of topo II have been mapped
to the A’-A’ dimerization region (Thomas et al., 1991) and appear to either increase the
amount of buried hydrophobic surface or to create new salt bridges between monomers thus
stabilizing the dimer. A biochemical approach has identified the primary dimerization region
in human topo IIα (Bjergbaek et al., 1999) which was homologous to the A’-A’ dimer
interface identified in the yeast crystal.
A third dimer interface is formed at the ATPase domains. The crystal structure of
E.coli gyrase together with biochemical data suggests that the ATPase domain forms a dimer
in the presence of a non-hydrolysable ATP analogue (AMPPNP) (Ali et al., 1995; Wigley et
al., 1991). Interestingly, in the presence of AMPPNP the protease pattern of yeast topo II is
changed. The cleavage preference is shifted from site A to site B, which demonstrates that the
binding of AMPPNP changes the structure of topo II (Lindsley and Wang, 1991). This
phenomenon suggests a conformational change induced by the binding of ATP to the enzyme,
which likely leads to the dimerization of the ATPase domain. This process seems to be
important for proper strand passage (Bjergbaek et al., 2000)
When the structure of the 92 kDa yeast topo II fragment (Berger et al., 1996) is
combined with the structure of the GyrB ATPase domain from E.coli DNA gyrase (Wigley et
al., 1991), a three-dimensional picture of catalytic active topo II emerges: The (A’B’)2 yeast
dimer forms a heart shaped structure representing the catalytic core of the enzyme, where the
ATPase domain from DNA gyrase can be modelled to extend from the N-terminus of the
catalytic core. The three-dimensional model is now generally accepted and further supported
by electron microscopy (EM) studies producing the only images of intact type II
topoisomerases obtained so far (Benedetti et al., 1997; Schultz et al., 1996): In the absence of
ATP, both human and yeast topo II appear as multi-lobed structures in which two medium-
sized objects extend from a large globular core. Upon binding of AMPPNP the smaller lobes
will close together and dimerize which is consistent with biochemical and crystal data from
the Gyrase ATPase domain (Ali et al., 1995; Wigley et al., 1991). These observations agree
with the model that the ATPase domain is extending from the B’ region, and that the ATPase
domain will dimerize as a consequence of ATP binding.
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Figure 1.7: The Current Model for the
Catalytic Reaction of Eukaryotic
Topoisomerase II. The ATPase domain,
B’ and A’ subfragments are colored
yellow, red and blue, respectively. The
G-segment DNA (containing the DNA
gate) is grey, and the transported T-
segment is an open cylinder or a green
cylinder. (1) Binding of the G-segment.
(2) Cleavage of the G-segment. (3)
Binding of ATP (represented by
asterisks) and capture of the T-segment
and opening of the G-segment. (4)
Storage of the T-segment in the central
cavity. (5) Religation of the G-segment
and release of the T- and G-segment,
ATP is hydrolysed thereby regenerating
the starting state. For clarity, the DNA
transport step is shown to proceed
through a hypothetical intermediate
(brackets). Presentation reproduced from
(Berger et al., 1996).
1.3.3 Catalytic Cycle of Eukaryotic Topoisomerase II
The catalytic cycle of topo II has been extensively studied in biochemical assays and,
with the aid of the crystal structure, a two-gate model was proposed (Berger et al., 1996;
Cabral et al., 1997; Fass et al., 1999; Roca et al., 1996; Roca and Wang, 1994). This model
(Fig. 1.7) proposes a concerted and complex process, involving several events including
DNA-binding (step 1), DNA cleavage (step 2), ATP binding (step 3), DNA strand passage
(step 3-4), DNA religation (step 4), ATP hydrolysis and enzyme turnover (step 5).
The catalytic cycle is initiated by binding of the DNA segment to be cleaved, the so-
called G-segment (the DNA segment to be cleaved and opened to form a gate) (step 1 in Fig.
1.7). The G-segment is bound to the central DNA breakage/reunion domain. The N-terminal
parts of the two A’ domains create a semicircular groove of 20-25Å which funnels down to a
tunnel leading to the active site of DNA cleavage. Electrostatic calculations show that the
semicircular groove formed by the two A’ regions has a strong positive electrostatic potential,
which might attract the G-segment. Binding of the G-segment to the A’A’ groove is also
found in footprinting, crosslinking and DNase protection assays (Hung et al., 1996; Lee et al.,
1989; Li and Wang, 1997; Thomsen et al., 1990). EM studies of the GyrA-DNA complex
came to a similar conclusion (Kirchhausen et al., 1985). In addition, the active site tyrosines
of topo II reside in this A’A’ grove (Berger et al., 1996). In summary, these data imply that
this grove is responsible for the recognition of the DNA substrate.
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The recognition of DNA is mainly determined by the topological structure of the
DNA, since topo II does not have any preferred cleavage sequence (Osheroff et al., 1991;
Sander et al., 1987). The lack of choice for a specific DNA sequence may have an important
physiological role, since it permits the enzyme to act all over the genome. The recognition of
topological forms of the DNA is exemplified by the preferential binding of the enzyme to
supercoiled over relaxed DNA (Osheroff, 1986; Osheroff et al., 1983) and the enzyme’s
interaction with curved DNA and DNA crossovers (Bechert et al., 1994; Zechiedrich and
Osheroff, 1990). The preferential recognition of certain topological states of DNA is
important for the function of topo II, allowing the enzyme to discriminate between the
substrates and products of its catalytic reaction.
 Following recognition and binding of a G-segment, the enzyme undergoes a range of
conformational changes. These changes include a concerted movement of the A’ and B’
domains which brings the two A’ domains into close proximity and the active site tyrosines
into an attacking position for DNA-cleavage (step 2 in Fig. 1.7). This structural arrangement
of topo II at the beginning of the catalytic cycle is termed T2C. Cleavage of the G-segment
occurs in the T2C conformation (step 2 in Fig. 1.7) (Fass et al., 1999). The cleavage is
mediated by a coordinated nucleophilic attack of the DNA backbone by the active site
tyrosines in the two subunits of the dimeric enzyme (Zechiedrich et al., 1989). The attack by
the two tyrosines generates a double-stranded break 4 base pairs apart in the G-segment, and
the enzyme is covalently linked to the 5’-end of the cleaved substrate through its active site
tyrosines (Rowe et al., 1986). The covalent linkage between the DNA and the enzyme
prevents the release of a DNA double-stand break. The cleavage reaction requires the
presence of a divalent cation, preferentially Mg2+ (Osheroff, 1987; Osheroff and Zechiedrich,
1987), but occurs in the absence of ATP (Lindsley and Wang, 1993; Tingey and Maxwell,
1996).
The protein-operated gate allows the transport of a second DNA strand necessary for
the separation of catenated DNA. The transport of a second DNA strand, named T-segment
(the DNA segment transported through the gate in the G-segment), through the gate is a
complex process and requires the presence of ATP and a dynamic opening and closing of the
three dimerization regions. Following cleavage of the G-segment and binding of ATP at the
ATPase domain, the enzyme binds a T-segment and the complex process is initiated which
transports the T-segment from the “top” of the enzyme through the dimeric interface until the
T-segment finally exits a the “bottom“ of the enzyme (step 3-5 in Fig. 1.7) (Berger et al.,
1996; Fass et al., 1999).
From analysis of crystal structures of the breakage-reunion domain a model for the
transport of the T-segment has been proposed (Berger et al., 1996; Cabral et al., 1997; Fass et
al., 1999). Cleavage of the G-segment and binding of ATP is believed to induce a changed
conformation for both the A’ and the B’ regions and dimerization of the ATPase domains.
The changed conformation includes a rotation of the B’ sub-fragments and a separation of the
A’ sub-fragments allowing for the opening of the DNA gate and the transport of the T-
segment through the DNA gate into the central cavity. The conformation of topo II after
strand passage is called T2O (Berger et al., 1996; Fass et al., 1999). This model is in
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agreement with a range of biochemical data. Binding of ATP induces dimerization of the
ATPase domain (step 3 in Fig. 1.7) (Ali et al., 1995; Roca and Wang, 1994; Wigley et al.,
1991) changing the enzyme from an open clamp to a closed clamp. Interestingly, binding of
AMPPNP changes the sites in the structure accessible to proteases supporting the described
model that binding of ATP induces a changed conformation of topo II. The previously
described preference for cleavage at sites A and C is changed to cleavage at site B and C (V8-
B in Fig. 1.5) (Lindsley and Wang, 1991). Furthermore, the binding of AMPPNP also induces
the formation of a wide hole in the large core. The central hole present in the structure is
interesting because it is of an appropriate electrostatic nature to attract a DNA duplex.
Therefore, transport of the T-segment into the central cavity is believed to be partly due to
electrostatic attraction and partly steric repulsion (Berger et al., 1996). After strand transfer,
the T-segment is stored in the central cavity of the enzyme (step 4 in Fig. 1.7).
Structural data suggest that, after the T-segment has entered the central cavity, the A’
domains move towards each other to allow religation of the cleaved G-segment. The
accompanying constriction of the central hole destabilizes the A’-A’ interface sufficiently to
open and expel the stored duplex (step 5 in Fig. 1.7) (Berger et al., 1996; Fass et al., 1999;
Maxwell, 1996; Roca and Wang, 1992). Indeed, biochemical studies show that the A’-A’
primary dimer interface opens to allow the escape of the T-segment (Roca et al., 1996; Roca
and Wang, 1994).
The final step of one catalytic cycle is the hydrolysis of ATP bound to the ATPase
domains and reformation of the primary dimer interface between the two A’ sub-fragments
(Berger et al., 1996). The hydrolysis of ATP facilitates enzyme turnover and reopening of the
ATPase domain and allows the initiation of a new catalytic cycle (Osheroff, 1986; Osheroff et
al., 1983). The above-described two-gate model emphasizes that the T-segment enters from
one end of the enzyme, passes through the central axis between the two monomers, and exits
at the other end.
1.3.4 Drugs Targeting Topoisomerase II
Topo II is the major cellular target of several anti-tumour drugs. The knowledge of the
catalytic cycle has greatly increased our understanding of how topo II targeting drugs exert
their anticancer effect. According to the mechanistic differences in their mode of action, the
drugs known to target topo II can be divided into two classes: poisons and catalytic inhibitors
(Froelich Ammon and Osheroff, 1995). The topo II poisons function by stabilizing the
transient enzyme-DNA complex formed upon DNA cleavage, thus increasing the number of
topo II molecules bound covalently to DNA (Robinson et al., 1991; Robinson and Osheroff,
1991; Sorensen et al., 1992). It is thought that cellular processes such as replication and
transcription convert the drug-stabilized covalent complex into double stranded DNA breaks,
which ultimately lead to cell death (Chen and Liu, 1994; Pommier et al., 1994). Catalytic
inhibitors, on the other hand, inactivate the enzyme by inhibiting the catalytic activity of the
enzyme without inducing double stranded breaks. These substances probably kill the cells, as
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they induce traverse through mitosis without a functional topo II enzyme (Holm et al., 1989a;
Wang, 1994).
When topo II poisons are used in clinical anticancer treatment, resistant cancer cells
emerge typically during later stages of chemotherapy. Similarly, resistant cells emerge in cell
culture when they are exposed to the drug for an extended period of time. Several
mechanisms are responsible for the development of drug resistance, including mutations in
the enzyme, altered drug transport and attenuated expression of topo II. Development of drug
resistance to poisons is commonly associated with a down-regulation of mRNA and protein
expression of one or both of the mammalian topo isozymes (reviewed in (Beck et al., 1993;
Froelich Ammon and Osheroff, 1995; Pommier, 1993)). The observation that elevated
expression of topo II leads to a hypersensitivity of cell lines to these drugs is consistent with a
correlation between drug sensitivity and the level of topo II (Davies et al., 1988; Fry et al.,
1991). Direct evidence for a role of down-regulation of topo IIα mRNA level in the
generation of drug resistance was provided by expression of anti-sense RNA fragments,
which reduces the level of cellular topo IIα protein, thus leading to higher resistance to
etoposide in mammalian cells (Gudkov et al., 1993).
Drug resistance can as well be due to mutations in the topo IIα gene. A number of
point mutations affecting either the catalytic properties of topo II or the enzyme DNA drug-
interaction have been reported (Bugg et al., 1991; Danks et al., 1993; Lee et al., 1992; Patel
and Fisher, 1993). In addition to point mutations, deletions in TOP2A associated with drug
resistance have also been identified in human cells (Grue et al., 1998; Matsumoto et al., 1997;
Mirski and Cole, 1995; Wessel et al., 1997; Yu et al., 1997). Interestingly, of the deletion
mutants reported, many are not affected in their catalytic cycle. Instead, the resistance is
caused by a changed cellular localization. Several deletions in the divergent C-terminal
domain lead to improper nuclear localization and will be further discussed in the next section.
1.3.5 Function of the C-terminal Domain in Eukaryotic Topoisomerase II
Several studies indicate that the N-terminal and the core domain of topo II are
sufficient for its in vitro catalytic activity. Thus, other functions must be ascribed to the
divergent C-terminal region (Crenshaw and Hsieh, 1993; Jensen et al., 1996a; Shiozaki and
Yanagida, 1991). Of interest in this respect, the overall amino acid sequence identity of 68%
between the two human isoforms is not evenly distributed: While the N-terminal three
quarters are 78% identical, the similarity in the C-terminal quarter is only 34% (Austin et al.,
1993; Lang et al., 1998; Sng et al., 1999). This suggests that the C-terminal domain might
mediate isoform-specific functions.
In higher eukaryotes several nuclear localization sequences (NLS) have been
identified in the C-terminal domain of topo IIα and IIβ. The last 168 amino acids in murine
topo IIα are essential for proper nuclear localization and a similar region is found in the IIβ
isoform (Adachi et al., 1994). In human topo IIα, a sequence spanning amino acids 1454 to
1497 has been shown to be sufficient for nuclear localization, and in the human IIβ isoform,
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the NLS sequences were mapped to amino acids 1522-1573 (Mirski et al., 1999; Mirski et al.,
1997).
A second role for the divergent C-terminal domain is its interaction with other cellular
proteins. Topo II has functions in virtually all aspects of DNA metabolism. In addition, topo
II has a rather broad substrate specificity. Thus, its activity in vivo must be guided or
controlled, probably by the aid of co-factors and/or other proteins. Indeed, several proteins
interacting with the C-terminal region have been identified. Although many roles of such
interactions are postulated, functional assays proving such roles are mostly lacking so far.
Nevertheless, the following listing of putative interacting partners of topo II was sorted
according to their putative function.
Only two studies have revealed a relation between topo II and transcription. Far
western assays suggested that topo II interacts with transcription factors such as CREB, ATF-
2 and c-Jun. In vitro, topo II-decatenation activity furthermore appeared to be slightly
stimulated by CREB and c-Jun (Kroll et al., 1993). It has also been shown that topo II co-
purifies with the chromatin accessibility complex (CHRAC) (Varga-Weisz et al., 1997),
although the same group recently stated that topo II should not be considered as a stable
subunit of CHRAC (Eberharter et al., 2001).
Several other interactions likely play a role during mitosis. The Drosophila barren
protein, which is essential for sister chromatid segregation in mitosis, interacts with topo II
throughout mitosis, as shown by yeast two hybrid and immunoprecipitation. It stimulates topo
II relaxation activity in vitro (Bhat et al., 1996). Since mutations in the barren gene cause a
failure of proper chromosome segregation at anaphase, it has been proposed that the barren -
topo II association facilitates the decatenation of chromatids at anaphase, and thus is required
for proper chromosomal segregation. A similar role has been suggested for the retinoblastoma
protein (Rb). Rb is shown by immunoprecipitaion to interact with topo IIα and to inhibit topo
IIα decatenation activity. Rb is a phosphoprotein and it is the non-phosphorylated form that
seems to interact with human topo IIα and inhibits its activity (Bhat et al., 1999). Since Rb
and topo II are both phosphorylated during G2/M phase, a model could be envisaged, in
which phosphorylation regulates the activity of topo IIα in a cell-cycle specific manner.
Phosphorylation of Rb in G2/M phase would disrupt Rb-topo II interaction thereby activating
topo II during mitosis (Bhat et al., 1999). Thus, both barren and Rb might stimulate topo II
decatenation activity during chromosome condensation and segregation. An interaction
between topo II and pat1 (protein associated with topo II) has also been implicated in
regulating topo II during mitosis. Screening of a yeast library using the C-terminal domain of
yeast topo II revealed that pat1 interacts with this domain. Pat1 has functions in chromosome
segregation and interacts with the highly conserved leucine-rich region in yeast topo II (Wang
et al., 1996). It is possible that similar protein interaction partners in higher eukaryotes
mediate an isoform specific function, since only topo IIα but not topo IIβ contains a leucine
zipper motif (Austin et al., 1993). Yeast two-hybrid experiments and immunoprecipitation
also demonstrated an interaction between topo II and sgs1, an interaction suggested to be
important for faithful segregation of newly replicated chromosomes (Watt et al., 1995). It is
not known if pat 1 and sgs1 affects the catalytic activity of topo II. Interestingly, topo IIα has
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been shown to be part of the purified UB2 complex in mouse, which consists of several
proteins including scaffold protein 2 (sc2). In the UB2 complex topo IIα preferentially binds a
specific sequence, whereas free topo IIα has a low sequence specificity. The higher sequence
stringency of UB2 over that of free topo IIα could be an important factor in limiting the
number of DNA sequences bound by topo IIα (in the form of UB2) in vivo (Ma et al., 1993).
The authors furthermore suggest that UB2 may be involved in mitotic chromosome
condensation.
Topo IIα may also interact with CAD nuclease (Durrieu et al., 2000) connecting topo
IIα to chromatin condensation during apoptosis. Indeed, it has recently been suggested that
topo II is involved in caspase-independent excision of DNA loop domains during apoptosis
(Solovyan et al., 2002). The authors suggest that this cleavage is performed by topo II located
at the nuclear matrix.
Finally, the C-terminus of topo II plays a major role in the regulation of topo II by
phosphorylation. Topo II is phosphorylated on multiple serine and threonine residues, the
majority of which are located in the C-terminal domain (reviewed in (Isaacs et al., 1998)). It
has been proposed that phosphorylation may regulate the activity of the enzyme and its
interaction with other cellular proteins. However, the exact role of phosphorylation in
regulating topo II activity is still under debate. Phosphorylation has been reported to stimulate
the in vitro activity of topo II 2-3 fold (Ackerman et al., 1985; Corbett et al., 1992; Corbett et
al., 1993; DeVore et al., 1992). In agreement with this, soluble mitotic extracts from HeLa
cells, which are known to be hyper-phosphorylated, contain a higher topo II activity than S-
phase extracts (Estey et al., 1987). However, several observations have seriously challenged
any significant role of phosphorylation in regulating topo II catalytic activity. For example,
the enzymatic activity of fission yeast topo II is not affected by phosphorylation or
dephosphorylation in vitro (Shiozaki and Yanagida, 1992). In addition, topo II interacts with
the β subunit of protein kinase casein kinase 2 (PK CK2) in yeast (Bojanowski et al., 1993;
Leroy et al., 1999), but Kimura and co-workers reported that PK CK2 has no effect on the
activity of mouse topo IIα. More importantly, the authors concluded that their previously
reported results (Saijo et al., 1990), showing a stimulation of topo IIα activity by PK CK2,
could not be attributed to the kinase, but to the composition of the incubation buffer (Kimura
et al., 1996b). Instead, a new mechanism by which PK CK2 could regulate human topo IIα
function has been suggested. PK CK2 phosphorylated the enzyme and increased its in vitro
activity, but the cause of the activation was not phosphorylation, but rather stochiometric
stabilization against thermal inactivation of human topo IIα during the incubation (Redwood
et al., 1998). Of possible significance in this regard is the observation that the β subunit of PK
CK2 confers thermal stability upon the PK CK2 α subunit, in which the catalytic activity of
the dimer resides (Meggio et al., 1992). Since the topo II - PK CK2 interaction is also
mediated by the β subunit (Bojanowski et al., 1993; Leroy et al., 1999), it can be speculated
that the β subunit of PK CK2 is involved in stabilizing topo IIα thereby increasing its in vitro
activity. Taking all these findings together, it seems appropriate to conclude that the major
role of topo II phosphorylation does not appear to be the regulation of enzyme activity.
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In vitro studies of topo II have implicated that phosphorylation of the enzyme plays a
role in chromosome condensation. Yeast topo II is able to form multimers in vitro and this
multimerization is dependent on phosphorylation (Cardenas and Gasser, 1993; Vassetzky et
al., 1994). Topo II preferentially binds and aggregates S/MAR containing DNA. The
interaction is highly cooperative and, with increasing concentrations of topo II the enzyme
titrates first S/MAR containing DNA and then non S/MAR DNA (Adachi et al., 1989).
Similar to multimerization, the specific topo II S/MAR interaction is abolished when the
enzyme is dephosphorylated (Dang et al., 1994; Vassetzky et al., 1994). These in vitro studies
lead to a model in which topo II plays a structural role, fastening DNA loops to the scaffold
via specific interactions with S/MAR sequences. Multimerization of topo II binding S/MAR
elements could tether the chromatin fibre together thus facilitating an ordered chromosome
condensation.
The fact that topo II multimerization and its interaction with S/MAR elements require
phosphorylation of the enzyme strongly indicates an important biological function of topo II
phosphorylation in chromosome organization. Indeed, phosphorylation of topo II is cell cycle
specific, reaching a maximal level during G2-/M-phase (Cardenas et al., 1992; Heck et al.,
1989; Kimura et al., 1996a; Kimura et al., 1994a; Saijo et al., 1992; Wells et al., 1995; Wells
and Hickson, 1995). Thus, one function of phosphorylation of topo II in G2-phase could be to
stimulate topo II mediated chromosome condensation.
In summary, it is clear that the N-terminal and central domains of topo II are required
for basic enzymatic activity, whereas the C-terminal domain is most probably mediating the
specific biological roles of the enzyme. It is involved in transport to the nucleus, interaction to
other proteins and phosphorylation which all are important for the biological functions of
topo II.
1.4 Biological Functions of Eukaryotic Topoisomerases I and II
Already from their catalytic properties it is evident that topo I and II must be involved
in most if not all processes of DNA metabolism. Many of the biological roles of
topoisomerases in the cell are possibly shared among the different types. However, the ability
to decatenate interlinked DNA is a unique feature of topo II. Thus, the enzyme must have
unique biological functions. Topoisomerases are required in interphase for processes like
transcription, replication, recombination, and in mitosis for chromosome condensation and
segregation. In addition, it has been suggested that topo II plays an important role in the
architectural organization of the nucleus, because it is part of the nuclear matrix and the
chromosomal scaffold. Emphasis in this section is put on the role of topo I and II in
transcription and replication, and another major focus will be on their role during mitotic cell
division. The role of topo I and II in meiosis, recombination, DNA damage/repair and
apoptosis is less well understood and will not be discussed further.
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1.4.1 Transcription and Replication
According to the twin domain model of Liu and Wang, transcription of a right handed
double DNA helix generates positive supercoils ahead of the moving RNA-polymerase
complex and negative supercoils behind it (Liu and Wang, 1987). Similarly, positive
supercoils are generated during semi-conservative replication in front of the replication
complex as the parental strands come apart behind it (Cook, 1999; Wang, 1991). A swivel
activity, which removes supercoils, is therefore required during these processes (reviewed in
(Andersen et al., 1996; Nitiss, 1998; Wang, 2002)). Recent evidence suggests that supercoils
can diffuse across the replication fork, resulting in intertwined replicated strands called
precatenanes (reviewed in (Postow et al., 1999; Postow et al., 2001)). This implies that not
only relaxation (swivelation) but also decatenation activity is required during replication.
To date, topo I is believed to be the most likely candidate for the swivelase activity
during transcription. Plasmids carrying actively transcribed genes were found to be extremely
negatively supercoiled when isolated from yeast lacking topo I but not topo II (Brill and
Sternglanz, 1988). Consistent with this, injection of the drug VM 26, which inhibits topo II
activity, into human HeLa cells or Xenopus oocytes did not decrease RNA polymerase
transcription rate, indicating that topo II is not essential for efficient transcription (Dunaway,
1990; Schaak et al., 1990). On the other hand, the topo I-specific inhibitor camptothecin
decreased the rate of transcription significantly, further supporting the view that mainly topo I
is responsible for the swivelase activity during transcription (Schaak et al., 1990).
Localization studies showing topo I to colocalize with transcribed regions (Fleischmann et al.,
1984; Gilmour et al., 1986; Shaiu and Hsieh, 1998) are in agreement with the view that topo I
is responsible for resolving topological problems generated during transcription.
Until quite recently it was believed that topo I is also the enzyme responsible for the
removal of supercoils generated during replication. S.cerevisiae mutants lacking both topo I
and topo II, can initiate replication but elongation requires a topo activity. Inactivation of topo
I leads to a temporary delay in DNA chain elongation, whereas inactivation of topo II had
little effect on the rate of chain elongation (Kim and Wang, 1989). Studies on the replication
of Simian Virus 40- DNA confirmed these results and moreover implicated that topo II is only
required during replication of the final 5% of the genome (Sundin and Varshavsky, 1981;
Yang et al., 1987). It is now generally held that topo I removes supercoils, thus driving
elongation, whereas topo II is required to remove catenane crossings persisting after
replication. In addition, the discovery that precatenanes are formed behind the replication
complex (Sogo et al., 1999) suggests that these structures are also resolved by topo II. In
keeping with this, it was recently demonstrated that topo II acts behind the forks at all stages
of elongation (Lucas et al., 2001).
Topo II was previously recognized as the major non-histone protein component of the
chromosome scaffold (Earnshaw et al., 1985; Gasser et al., 1986) and the interphase nuclear
matrix (Berrios et al., 1985), insoluble nuclear structures believed to play an architectural role.
In keeping with this, topo II was detected by immunocytochemistry along the longitudinal
axes of gently expanded chromosomes (Earnshaw and Heck, 1985; Gasser et al., 1986) and
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shown to bind preferentially to AT-rich DNA elements (S/MARs) believed to specify the
bases of chromatin loops (Adachi et al., 1989). Ever since, topo II is considered to play a
structural role in chromosome organization in addition to its enzymatic functions (Adachi et
al., 1991). This view is supported by findings that topo II inhibitors induce cleavage at
S/MARs in vivo (Gromova et al., 1995), and that S/MAR sequences are preferential cleavage
sites for topo II both in vitro and in vivo (Cockerill and Garrard, 1986; Kas and Laemmli,
1992; Miassod et al., 1997). An important biological function of topo II appears thus to be
that it helps organizing the interphase chromatin into constrained topological domains, which
contain genes independently regulated (reviewed in (Laemmli et al., 1992)).
In this context, it is worth mentioning that the presence of flanking S/MARs
consistently stimulated the expression of stably integrated transgenes, as compared to the
same transgenes integrated without flanking S/MAR sequences (Blasquez et al., 1989; Klehr
et al., 1991; Poljak et al., 1994; Stief et al., 1989). S/MAR elements are believed to mediate
their stimulatory effect by altering the chromatin structure in such a way that displacement of
histone H1 is facilitated (Poljak et al., 1994) and/or that spreading of the closed chromatin
structure form adjacent gene domains to the transcribed gene and vice versa is blocked
(Laemmli et al., 1992).
In vitro studies have suggested that, besides being involved in binding of S/MAR
elements to the nuclear matrix, topo II could also play a more direct role in S/MAR-
stimulated expression. As elaborated above, transcription generates supercoils that need to be
removed by the swivelase activity of topo I. S/MARs and topo II could also be involved in
relieving these negative supercoils. S/MAR sequences alone have been proposed to remove
negative supercoils generated during transcription based on their ability to base-unpair under
superhelical strain (Bode et al., 1992). This could release negative supercoils and could be
considered as a storage place or sink for thermodynamic energy in the form of negative
supercoiling. Interestingly, a number of eukaryotic genes are optimally transcribed when
supercoiled (Hirose and Suzuki, 1988). For example, a certain degree of negative supercoiling
enhances the transcription of the fibroin gene (Mizutani et al., 1991a; Mizutani et al., 1991b).
The thermodynamic energy stored at nuclear matrix bound S/MARs could then at other times
be converted into negative supercoiling in order to enhance transcription within the domain
(Bode et al., 1992). Alternatively, the negative supercoiling stored in the S/MARs could be
released by topo II that binds S/MARs at the nuclear matrix.
1.4.2 Chromosome Structure and Condensation
In human interphase cells, chromosomal DNA molecules (having a total length of ≈1.4
m) are packaged into nuclei that are only ≈10 µm in diameter. At mitosis, the chromosomes
become further condensed to an overall 10,000-fold compaction. Compaction of the DNA is
accomplished by a hierarchy of DNA and chromatin packing devices (reviewed in (Earnshaw,
1991; Koshland and Strunnikov, 1996)). At the lowest level, the DNA fibre is compacted six-
to seven-fold by winding around the histone core of the nucleosome, generating fibres of ≈10
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nm in diameter (Kornberg, 1974). At the second level, association of histone H1 causes the
fibre to shorten and thicken to a diameter of ≈30 nm effecting an overall compaction of ≈40-
fold (Finch and Klug, 1976; Horowitz et al., 1994; Thoma et al., 1979). The remaining 250-
fold compaction is achieved by more complex architectural measures. The most widely
accepted model, the so-called loop model, proposes that the 30 nm-fibre is gathered into loops
each containing ≈50-100 kb of DNA. In this model, the chromatin fibre is presumably
organized into domains that are constrained by a residual chromosomal scaffold (Adolph et
al., 1977; Laemmli et al., 1978; Paulson and Laemmli, 1977). The loop domains are further
organized into rosettes, which are compacted into coils that finally form the two chromatids
(Boy de la Tour and Laemmli, 1988; Filipski et al., 1990).
Topo II is the most abundant non-histone protein of isolated metaphase scaffolds
(Earnshaw et al., 1985; Earnshaw and Heck, 1985; Gasser et al., 1986). Roughly three copies
of topo II per DNA loop are present in an average human metaphase chromosome (Gasser et
al., 1986). The architectural role of topo II in chromosome structure is also indicated by its
proposed ability to form multimers and to bind S/MAR fragments in a cooperative manner
(Adachi et al., 1989; Vassetzky et al., 1994). Some localization studies of topo II in
metaphase chromosomes have shown the enzyme at the longitudinal axes of the chromosome
arms, which is consistent with the scaffold model. However, other studies have reported a
uniform distribution of topo II through the entire diameter of the chromosomes, which argues
against the scaffold model. Thus it remains uncertain, whether topo II resides at the base of
the chromosome loops or is dispersed over the entire chromatin. Most importantly, the
observation that topo II is uniformly distributed over the chromosomes does not exclude that
topo II is also present in the chromosomal scaffold.
Lohka and Masui have developed an elegant in vitro assay for studying chromosome
condensation, and have thus studied the role of topo II in chromosome condensation
extensively. They found that incubation of chromatin with extracts from frog eggs induces
condensation (Lohka and Masui, 1983). By using extracts from Xenopus eggs immuno-
depleted of topo II, Adachi and co-workers examined the role of topo II in chromosome
condensation. In chicken erythrocyte nuclei, which contain very low levels of topo II, the
depleted extracts were incompetent in forming condensed chromosomes, whereas addition of
purified topo II restored their ability to support chromosome condensation (Adachi et al.,
1991). Analogous results have been obtained with extracts from mammalian cells (Wood and
Earnshaw, 1990). In summary, these experiments precipitated the conclusion that topo II is
essential for proper chromosome condensation. Hirano and Mitchison further examined the
role of topo II in condensation, and confirmed this notion. Surprisingly, however, they
showed that all detectable topo II could easily be extracted from the chromosomes under mild
salt conditions without dramatically changing their shape. After salt extraction, topo II was no
more detectable in the chromosomes by topo II specific antibody staining, whereas the
chromosome core as delineated by the MPM-2 antibody remained intact. From these
examinations the authors concluded that topo II is essential for mitotic chromosome assembly,
but does not play a scaffolding role in the structural maintenance of chromosomes after their
assembly (Hirano and Mitchison, 1993). Later it was shown that a phosphorylated form of
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topo II is the major target of the MPM-2 antibody in mitotic chromosome scaffolds
(Taagepera et al., 1993). Thus the question arises whether in the study of Hirano and
Mitchison the MPM-2 antibody was after all detecting topo II and, thus, residual enzyme at
the chromosomal axis escaped investigation. If the epitope(s) detected by MPM-2 in the
extracted chromosomes indeed were topo II, this would indicate that a small, salt resistant
fraction remained at the chromosomal scaffold and that this fraction is essential for
maintaining the chromosomal structure. Such an interpretation is consistent with the loop
model and the proposed function of topo II in organizing the chromosomal loops.
Additional evidence for an involvement of topo II in chromosome condensation comes
from genetic data obtained in yeast. Chromosomes of fission yeast are known to undergo
condensation to some degree. In a strain carrying double mutations in the topo II and β-
tubulin genes, however, chromosomes appeared to be less condensed (Uemura et al., 1987).
And finally, when topo II was inhibited by specific drugs in mammalian cells, proper
chromosome condensation was inhibited leading to the same conclusion that topo II is
essential for chromosome condensation (Anderson and Roberge, 1996; Buchenau et al., 1993;
Downes et al., 1991; Ishida et al., 1994; Newport and Spann, 1987; Roberge et al., 1990).
The role of topo I in chromosome condensation is less clear. Direct evidence linking
topo I to condensation is lacking altogether. However, genetic studies in yeast have implicated
an involvement of topo I in condensation. Although, topo I is not essential in yeast (Goto and
Wang, 1985; Thrash et al., 1985), it has been shown that yeast with topo 1 trf4 double mutants
are defective in mitotic chromosome condensation (Castano et al., 1996a; Castano et al.,
1996b). These strains fail to establish and maintain chromosome condensation in the rDNA at
mitosis (Castano et al., 1996a). This may indicate a special role of topo I in the condensation
of rDNA, an interpretation consistent with immunofluorescent findings suggesting that topo I
is concentrated in NOR’s of metaphase chromosomes (Suja et al., 1997). Finally, the
involvement of both topo I and topo II in chromatin condensation during mitosis is indicated
by their physical interaction with the condensins and the SMC-complex (Kimura and Hirano,
1997; Kimura et al., 1999).
1.4.3 Chromosome Segregation
At anaphase, the two sister chromatids are separated and equally distributed between
the two daughter cells. Separation is a complex process and requires the enzymatic function of
topo II to ensure the disentanglement of the two sister chromatids. ∆TOP2 mutants of
S.cerevisiae and S.pombe fail to segregate the replicated sisterchromatids and a substantial
level of chromosome nondisjunction and breakage can be observed, consequently leading to
cell death (Holm et al., 1985; Holm et al., 1989b; Uemura et al., 1987). In addition, the use of
nocodazole, an inhibitor of tubulin polymerization that prevents the formation of the mitotic
spindle, rescued cell viability of ∆TOP2 mutants of S.cerevisiae. Thus, yeast cells lacking the
ability to segregate the chromosomes can survive without a functional topo II which
implicates that topo II is only essential for the segregation of the chromosomes (Holm et al.,
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1985). In yeast cells lacking an active topo II, small chromosomes (with arms less than 380
kb) can segregate most likely simply by unravelling at their ends, whereas larger
chromosomes are inclined to fragmentation (Spell and Holm, 1994). The crucial role of topo
II in segregation has also been observed in Drosophila and mammalian cells, where inhibition
of topo II activity prevents the separation of sister chromatids during anaphase (Buchenau et
al., 1993; Clarke et al., 1993; Downes et al., 1994; Downes et al., 1991; Ishimi et al., 1995).
The segregation of sister chromatids at anaphase instead of during S- or G2-phase lead
to a model proposing that a driving force such as pulling by microtubules is a necessary
requisite for topo II to untangle the chromosomes. This model is supported by the study of
Uemura et al. (1987) where a TOP2 temperature-sensitive and NDA3 cold-sensitive double
mutant was used to separate the functions of topo II in condensation and segregation. By
lowering the temperature to inactivate the NDA3 gene encoding β-tubulin the cells were
arrested at metaphase and it was shown that in this situation chromosomes could be
condensed to completion in the presence of an active topo II. However, when temperature was
subsequently raised, thereby inactivating topo II and activating mitotic spindle formation, the
chromosomes became fragmented (Uemura et al., 1987). This experiment demonstrates that
fully condensed chromosomes remain catenated in the presence of active topo II if a pulling
force such as the mitotic spindle is absent. However, the idea of segregation being dependent
on microtubule forces has been challenged by the observation that sister chromatid separation
can occur in the absence of microtubules (Straight et al., 1996). The lack of a requirement for
microtubules indicates that another kind of directional force than the spindle is responsible for
mediating topo II decatenation of the two sister chromatids. Based on the observation that
many topo II interacting proteins are involved in chromosome condensation and segregation,
it seems reasonable to speculate that topo II interaction partners could mediate such a
function. Indeed, it has been suggested that the Drosophila barren protein may have such a
function in segregation, by regulating the activity of topo II during anaphase (Bhat et al.,
1996). It should also be mentioned that the process of chromosome condensation has also
been proposed as a driving force for chromosome disentanglement (Haglund and Rothblum,
1987; Holm, 1994; Holm et al., 1989b).
In conclusion, the ability of topo II to decatenate the two sister chromatids makes the
enzyme essential during segregation. However, the complete function and regulation of topo
II in chromosome dynamics does most likely involve a complex interaction with other
chromosomal proteins such as the SMC complex and cohesion proteins.
1.5 Subnuclear Distribution of Mammalian Topoisomerases
1.5.1 Topoisomerase I
The subnuclear localization of topo I is not entirely settled but much less
controversially discussed than that of the two topo II isoforms (see below). Therefore, this
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topic will subsequently be discussed in less detail. Indirect immunofluorescence studies have
shown that during interphase topo I is located in the nucleoplasm and in the nucleoli
(Buckwalter et al., 1996; Danks et al., 1996; Kaufmann et al., 1995; Meyer et al., 1997;
Muller et al., 1985). Recently, this notion has been partially confirmed by transient expression
of GFP topo I fusion proteins (Mo et al., 2000b). However, in the latter study, only 15% of
cells displayed nucleolar localization. This may be due to a cell-cycle effect or to the
relatively brief expression period that might not be sufficient for the expressed protein to get
properly allocated in the cell. Interestingly, a number of studies have shown that the
catalytically dispensable N-terminal region of topo I is important for correct cellular targeting
of topo I. The N-terminal region targets topo I to transcriptional active loci in Drosophila
(Shaiu and Hsieh, 1998), and to the nucleoli in human cells (Mao et al., 2002; Mo et al.,
2000a; Mo et al., 2000b). The recruitment to nucleoli was independent from an interaction
with nucleolin (Mao et al., 2002), which previously was believed to be responsible for proper
nucleolar localization of topo I (Edwards et al., 2000). Instead, Mao et. al. (2002) suggested
that ongoing rDNA transcription recruits topo I to the nucleoli.
Topo I is closely associated with mitotic chromosomes throughout mitosis (Meyer et
al., 1997; Mo et al., 2000b) in a manner independent from the enzymes catalytic activity (Mo
et al., 2000b). Furthermore, it has been observed that the enzyme concentrates in NORs of
mitotic cells (Guldner et al., 1986; Suja et al., 1997), which fits its physical interaction with
RNA-polymerase I (Rose et al., 1988).
1.5.2 Topoisomerase II
In an approach to identify possible isoform specific functions, the subcellular
localization of DNA topo IIα and IIβ has been studied in extenso. However, the results
obtained so far are rather equivocal and sometimes contradictory to each other. A clear image
of the localization of topo IIα and IIβ at the subnuclear level is still lacking. Especially for the
IIβ isoform different results have been reported. To fully understand the biological role of
topo IIα and IIβ in the cell, it is essential to determine their precise nuclear distribution. In the
following sections the current knowledge regarding this subject will be summarized and
possible reasons for the apparent contradictions in previous results will be discussed.
The localization of topo IIα in interphase has been thoroughly investigated by indirect
immunofluorescence and the results are in general consistent. During interphase, DNA topo
IIα has a nuclear localization and is found in both the nucleoplasm and the nucleoli (Cowell et
al., 1998; Meyer et al., 1997; Petrov et al., 1993; Rattner et al., 1996). The staining of the
nucleoplasm has been reported to be either homogeneous (Chaly et al., 1996; Cowell et al.,
1998; Sugimoto et al., 1998; Zini et al., 1992; Zini et al., 1994) or homogeneous with some
speckle formation (Chaly and Brown, 1996; Meyer et al., 1997; Petrov et al., 1993). The
presence of topo IIα in the nucleolus is supported by most of the data (Cowell et al., 1998;
Grue et al., 1998; Meyer et al., 1997; Negri et al., 1992; Petrov et al., 1993; Rattner et al.,
1996; Sugimoto et al., 1998; Zini et al., 1994), although some studies claim an exclusion from
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the nucleolus (Cabral et al., 1997; Chaly and Brown, 1996; Chaly et al., 1996; Zini et al.,
1992). Those studies demonstrating a nucleolar localization of topo IIα show different
staining patterns at the subnucleolar level. Intensity of nucleolar staining ranges from less
intense than the nucleoplasm (Negri et al., 1992; Sugimoto et al., 1998; Zini et al., 1994) to a
slight increase in intensity as compared to the nucleoplasm (Meyer et al., 1997), and one
study found nucleoli to be even more intensely stained than the nucleoplasm (Cowell et al.,
1998).
The localization of topo IIβ in the interphase nucleus is even less clear. In one series of
studies, antibodies against topo IIβ were reported to stain only the nucleolus (Negri et al.,
1992; Zini et al., 1992; Zini et al., 1994; Zweyer et al., 1995), whereas other studies using a
different set of antibodies have reported topo IIβ to be present in both the nucleoplasm and
the nucleolus (Chaly and Brown, 1996; Chaly et al., 1996; Cowell et al., 1998; Petrov et al.,
1993; Sugimoto et al., 1998; Turley et al., 1997). However, the extent of nucleolar staining in
these reports is not the same, showing an up-concentration in the nucleolus (Cowell et al.,
1998; Petrov et al., 1993), a similar level in the nucleolus and the nucleoplasm (Sugimoto et
al., 1998) or a very low level in the nucleolus (Chaly and Brown, 1996; Chaly et al., 1996).
Interestingly, a study has even reported an exclusion of topo IIβ from the nucleolus (Meyer et
al., 1997), which further complicated our understanding of the cellular localization of the
enzyme.
As discussed above, topo II has functions at various stages of chromosome formation
and separation. Thus, numerous studies were undertaken to describe its precise chromosomal
localization. One approach used living cells of Drosophila embryos micro-injected with
rhodamine-labeled topo II to investigate the distribution of mitotic topo II (Swedlow et al.,
1993). This study indicated that there are at least three pools of topo II in the chromosome:
one that leaves the chromosome after prophase, one that leaves after metaphase, and a third
that remains associated with the chromosomes throughout the mitotic cycle. Since Drosophila
only expresses a single topo II isoform, it is possible that in higher eukaryotes the role of one
of these pools is conducted by only one of the two isoforms.
All studies on the localization of mammalian topo II isoforms during mitosis have
been performed on dead and fixed cells. Immunohistochemical staining methods revealed that
during mitosis, topo IIα is associated with metaphase chromosomes (Chaly et al., 1996;
Earnshaw et al., 1985; Earnshaw and Heck, 1985; Meyer et al., 1997; Rattner et al., 1996;
Sugimoto et al., 1998; Sumner, 1996) although two reports have shown chromosomes not
stained by topo IIα specific antibodies (Fischer et al., 1993; Petrov et al., 1993). However,
questions still remain on the precise distribution of topo IIα on mitotic chromosomes.
Immunostaining for topo IIα of hypotonically treated chromosomes revealed a more or less
axial distribution through the center of chromosomal arms (Earnshaw and Heck, 1985; Gasser
et al., 1986; Saitoh and Laemmli, 1994; Strick et al., 2001) and a concentration of the enzyme
at centromers (Taagepera et al., 1993). In contrast, histone depleted HeLa and Drosophila
chromosomes showed a more general distribution of topo IIα over the chromosome arms
(Boy de la Tour and Laemmli, 1988; Buchenau et al., 1993; Swedlow et al., 1993). Two
studies have reinvestigated the precise chromosomal localization of topo IIα with particular
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interest to cell-cycle effects (Rattner et al., 1996; Sumner, 1996). In prophase, topo IIα was
present at high concentrations throughout the chromosomes. At metaphase, topo IIα was lost
from the chromosome arms, but still stained the axial cores and concentrated at the
centromers. In anaphase, centromeric staining was lost and only the chromosome core was
stained. The presence of multiple populations of topo IIα and a temporal shift in location of
these populations during mitosis (Rattner et al., 1996; Sumner, 1996) parallels the behaviour
of Drosophila topo II during mitosis (Swedlow et al., 1993). The apparent axial distribution of
topo IIα has been suggested to reflect its location at the base of the chromosomal loop
domains, where topo II attaches to S/MAR sequences. Recently, the transient expression of
EGFP tagged topo IIα has been reported (Mo and Beck, 1999). The authors show that GFP-
topo IIα is closely associated with mitotic chromosomes in living cells. Based on fixed cells
stained with Hoechst dye they furthermore conclude that GFP-topo IIα is distributed in an
axial pattern along chromosome arms.
The precise distribution of topo IIβ in mitotic cells is not satisfactory described.
Several investigations have shown topo IIβ to be excluded from metaphase chromosomes
(Chaly and Brown, 1996; Chaly et al., 1996; Meyer et al., 1997; Petrov et al., 1993; Turley et
al., 1997; Zini et al., 1992). However, after careful examination of the data in two of these
studies (Chaly and Brown, 1996; Chaly et al., 1996) staining of telophase chromosomes
cannot be excluded. In all these studies, topo IIβ  was detected in the cytosol as a
homogeneous staining surrounding the chromosome (Chaly and Brown, 1996; Chaly et al.,
1996; Meyer et al., 1997; Petrov et al., 1993; Turley et al., 1997; Zini et al., 1992).
Contradictory to these studies, topo IIβ has recently been found to colocalize with condensed
chromosomes, although to a lesser extent than the IIα isoform (Sugimoto et al., 1998). The
presence of topo IIβ at the chromosomes is in agreement with a previous analysis showing
that topo IIβ is part of the chromosomal scaffold (Renzi et al., 1997; Taagepera et al., 1993).
When discussing cellular distribution of topo II it seems somehow surprising that so
many different results have been reported. It is now generally held that these localization
results have been subjected to the influence of many marginal factors including differences in
cell lines, different fixation and permeabilization methods and different mono- or poly-clonal
antibodies employed. As discussed below, all these factors have influenced the results
reported in the literature and biased the conclusions drawn from them.
The effects that cell fixation and permeabilization have on immunohistochemical
localization of topo II is very well exemplified by an examination of Sumner (Sumner, 1996).
Even with the method that gave the best and most consistent results, considerable variation
within a single preparation of metaphase chromosomes was observed. The staining of the
chromosomes by a topo IIα specific monoclonal antibody (OM-11-930) ranged from no
staining at all to a general staining of the whole chromosome arms. Chromosomes with a
centromeric up-concentration and axial distribution could be observed in the same sample.
Phase contrast images revealed that unstained chromosomes were surrounded by a significant
amount of cytoplasm, suggesting that the fixation/permeabilization protocol is the most likely
cause for this variation. This notion is also illustrated in a recent study reporting an axial
localization of topo IIα in spread chromosomes. The authors demonstrate that depletion of
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divalent cations during spreading causes a 10-fold reduction of antibody staining for topo IIα
(Strick et al., 2001).
In addition, the immunohistochemical localization of topo II is to a considerable extent
influenced by the antibody used for staining. This is exemplified by comparing two studies
using the same fixation/permeabilization protocol (4% PFA and 0.5% T-X-100), but different
sets of antibodies. One study observed an exclusion of topo IIα from the chromosomes
(Petrov et al., 1993), whereas the second report shows chromosome staining (Chaly et al.,
1996). One possible explanation for such differences could be that some antibodies
preferentially or exclusively recognize a posttranslationally modified form of the enzyme.
Cell line-specific localization differences could as well be the cause of inconsistent results. In
summary, it becomes clear that available immunohistochemical data on the localization of
topo IIα and IIβ are to be interpreted with outmost care and can not be trusted with respect to
the differentiation of nuclear ultrastructures and subnuclear compartments.
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2. Aims of Study
As described above, the precise localization of topo I, IIα, and IIβ, in the cell nucleus
and their association with various defined nuclear substructures is still an unsettled subject.
Since this is most likely due to uncontrollable variations caused by fixation methods and
antibody preparations inherent in classical immunohistochemical methods, the first goal of
this study was to study cellular localization of these enzymes by an alternative approach. I
wanted to investigate localization of the enzymes in living mammalian cells, thereby not only
avoiding the use of permeabilization, fixation and antibody techniques, but also being able to
tackle questions of dynamic reallocation of the enzymes during the cell-cycle. The discovery
of green fluorescent protein (GFP) from the jellyfish Aequorea victoria has provided the tool
for such a study (Chalfie et al., 1994). GFP can be fused to proteins presumably without
influencing their function (reviewed in (Ludin and Matus, 1998; Stearns, 1995)) and such
GFP-linked proteins can be directly traced in cells living under a fluorescent microscope.
Therefore, I set out to investigate the cellular disposition of mammalian topoisomerases by
expressing GFP-chimera of these enzymes in human cells.
A second subject of this thesis was the question, whether topo II plays a role in
building the interphase nuclear matrix and the chromosomal scaffold (Adachi et al., 1991;
Berrios et al., 1985), structures that have been considered to provide an immobile element of
cellular architecture. This subject is highly controversial. If only a fraction of topo II was part
of such immobile structures, it should be immobile in a living cell. Thus, I set out to address
the question of an architectural role of topo II by determining the mobility of topo II-GFP at
various locations in the living cell nucleus by confocal microscopy and photobleaching
techniques.
The third objective of my thesis is one of lesser scientific controversy but a more
pronounced impact on medical praxis. Topo I and II are cellular targets of some of the most
potent and most widely used anti cancer agents. It is well established that most of these
poisons stabilise covalent complexes between DNA and topoisomerases I or II, which are
otherwise quite transient. While this mechanism of drug action has extensively been
characterised in vitro, it is still unclear to what extent it actually applies to the situation
encountered in a living cell. Where in the living cell nucleus are such covalent
DNA•topoisomerase complexes formed; how immobile are they actually; and how long do
they persist? My thesis aimed at addressing these question by treating cells expressing GFP-
chimera of topoisomerases with such drugs and then studying their impact on localization and
mobility of GFP-topoiosmerases in the living cell by confocal microscopy and
photobleaching.
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The aims of this study may be summarized as follows:
1. Generation and characterization of cell lines stably expressing GFP
chimeras of topoisomerases I, IIα and IIβ.
2. Description of the precise localization of topo I, IIα and IIβ  in the
interphase nucleolus and in mitotic chromosomes.
3. Study of the in vivo mobility of topo II with special emphasis on the
question of whether the enzyme participates in the formation of an
immobile nuclear matrix/chromosomal scaffold
4. Study of the effects of topo poisons on the behaviour of topoisomerases
in a living cell.
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Figure 3.1: The pMC vector system. pMC
harbours a CMV promoter element (open box),
EGFP (grey box), an IRES element (black bar),
pac (diagonally striped box), and a SV40 p(A)
site (grey bar). (A) Topo IIα and IIβ (vertically
striped boxes) were inserted in front of EGFP.
(B) Topo I, topo ITyr723Phe, topo I-C, and topo I-N
(vertically striped boxes) were fused to the C-
terminus of EGFP. (C) Expression from the
pMC vector system: After transfection pMC
produces one bicistronic mRNA. Translation of
the first cistron is mediated by the normal CAP-
dependent translation initiation. The IRES
element mediates translation initiation of the
second cistron.
3. Materials and Methods
3.1 Plasmid Construction
For the expression of GFP chimera of human topoisomerases I, IIα, and IIβ,
bicistronic expression vectors for mammalian cells were constructed from the plasmid pMC-
2P (Mielke et al., 2000), in which the puromycin resistance gene (pyromycin-N-acetyl-
transferase, pac) constitutes the second cistron, followed by the simian virus 40 (SV40)
polyadenylation signal. In front, it is linked by an IRES element to a multiple cloning site
(MCS), where the cDNAs of topo-GFP chimera were inserted. GFP was attached to the N-
terminus of topo I (Fig. 3.1.B) and to the C-terminus of topo IIα and IIβ (Fig. 3.1.A), because
previous experiences (Jensen and Svejstrup, 1996; Mo et al., 1998; Mo et al., 2000b)
suggested that at these positions GFP-fusions would less likely disrupt enzymatic functions. A
cytomegalovirus promotor (CMV) fused to the myeloproliferative sarcomvirus (MPSV) LTR-
enhancer repeat ensures a high transcription level of the bicistronic message in various
mammalian cells and the transcriptional linkage ensures a fixed simultaneous expression of
pac and the topoisomerase (Fig. 3.1.C).
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The coding sequence of GFP and for chimera of human topoisomerases and GFP were
inserted in front of the IRES by linker PCR. Thus, topo GFP chimeras were encoded by the
first cistron and the puromycin resistance gene (puromycin-N-actyl-transferase (pac)) by the
second cistron. Sequences of PCR primers used for cloning are listed in section 3.1.1.
pMC-EGFPP and pMC-EGFPP-N: EGFP was PCR-generated from pEGFP (Clontech,
Heidelberg, Germany) using primer sets K/J or F/B respectively and cloned (EcoR I/HindIII)
into pMC-2P. The plasmid pMC-EGFPP (Fig 3.1.A) and pMC-EGFPP-N (Fig. 3.1.B) thus
obtained contain MCS’s for the insertion of various open reading frames in front of, or behind
EGFP, respectively.
The sequence encoding the last 531 amino acids of human topo IIα was PCR
generated from pHT300 (Jensen et al., 1996b), (primer set G/M). pHT300 carries the wild-
type human topo IIα cDNA. The PCR generated fragment was then cloned into pMC-EGFPP
(SpeI/ApaI), thereby generating pMC-TIIα-c531-EGFPP. From this pMC-TIIα-EGFPP was
created by inserting the N-terminal part of topo IIα (MluI/SpeI). The same strategy was used
to clone pMC-TIIβ-EGFPP using primer sets L/N and pTIIβKOZ (carries the wild-type
human topo IIβ cDNA; Larsen MK, unpublished) as template.
For the yeast complementation assay plasmids pHT300 and pHT400 (Jensen et al.,
1996b) carrying cDNAs of human topo IIα and IIβ under the control of the yeast triose
phosphate isomerase (TPI) gene promoter were modified to express human topo II-GFP
fusion proteins by replacing 3’-terminal restriction fragments of topo II reading frames by
PCR-generated fragments containing the respective GFP chimera of the mammalian
expression vectors. Briefly, the sequence encoding a C-terminal fragment of topo IIα and
GFP was generated by PCR amplification using the primer set G/A and pMC-TIIα-EGFPP as
template. The fragment was then inserted (SpeI/NotI) into pHT300, thereby generating
pHT300-EGFP. The sequence encoding a C-terminal fragment of topo IIβ and GFP was
generated by PCR amplification using the primer set E/A and pMC-TIIβ-EGFPP as template.
The fragment was then inserted (BamHI/NotI) into pHT400, thereby generating pHT400-
GFP.
Human topo I was PCR amplified from pHT-100 (Alsner et al., 1992) using the primer
set H/C, and then inserted (MluI/ApaI) into pMC-EGFPP-N, thereby generating pMC-EGFP-
TIP. pHT100 carries the wild-type human topo I cDNA. pMC-EGFP-TITyr723PheP, was cloned
using the same strategy, with the exception that a plasmid encoding the active site tyrosin
mutant of human topo I (Tyr723Phe) (Madden et al., 1995) was used as a template for the PCR
reaction. pMC-EGFP-TINP was PCR cloned, using pHT100 as template and the primer set
H/D. This plasmid encodes the N-terminal domain (amino acids 1-210). The C-terminal
domain of human topo I (amino acids 210-765) supplemented with an SV40 NLS was cloned
into pMC-EGFP-N using pHT100 as template and the primer set I/C, thereby generating
pMC-EGFP-TICP.
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3.1.1 PCR
All PCR fragments intended for subsequent cloning were generated using the
Expand™ high fidelity PCR system (Roche, Basel, Switzerland). The reactions were carried
out on a Perkin Elmer Cetus DNA thermal cycler, programmed as follows:
1x  5   min 96°C
 30  s 94°C
25x  30  s 55°C
 3-5* min 72°C
*: Depending on the length of the substrate
Oligonucleotides used as PCR-primers
(in alphabetic order)
A) 3’G/BFP-Not I
5’ GGG CGC GGC CGC TTA CTT GTA CAG CTC GTC 3’
B) 3’GFP-PL-EcoRI
5’ GGA ATT CGG GCC CAC TAG TCC TCA GGA CGC GTC CAC CGC TTG
TAC AGC TCG TCC ATG 3’
C) 3’TopI-ApaI
5’ GCG TAG GGC CCC TAA AAC TCA TAG TCT TC 3’
D) 3’TopI-210-ApaI
5’ GCG TAG GGC CCC TAC TTG ATG CCT TCA GGA TA 3’
E) 5’BamHI Topo2b
5’ ACG AAT GCT AGA TGG CCT 3’
F) 5’GFP-HindIII
5’ GGC GGG AAG CTT CCA TGG TGA GCA AGG GCG 3’
G) 5’Spe I-h:
5’ GAG AGA GTT GGA CTA CAC 3’
H) 5’TopI-MluI
5’ GGG ACG CGT ATG AGT GGG GAC CAC CTC 3’
I) 5’TopI-MluI-SV40
5’ GGG CGG ACG CGT ATG TGT ACA CCT CT AAG AAG 3’
J) EGFP-3-EcoN:
5’ CGA ATT CTT ACT TGT ACA GCT CGT CC 3’
K) EGFP-5-Pl:
5’ CGC AAG CTT GCG GCC GCA CGC GTC CTA AGG ACT AGT AGG GCC
CAC CGG TCG CCA TGG 3’
L) hTβBsu-f:
5’ CTG GCT GGA ATG TCT GGA AAA G 3’
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M) Top2α-Fus-Apa:
5’ CGC GGG CCC AAC AGA TCA TCT TCA TCT G 3’
N) Top2β-Fus-Apa:
5’CGC GGG CCC TTA AAC ATT GCA AAA TCA AC 3’
Before restriction digestion all PCR products were treated with proteinase K (1mg/ml
proteinase K in 1 x modified bradley solution (10 mM Tris-HCl pH 7.5, 2 mM EDTA, 10 mM
NaCl, 0.5 % SDS)) for 1 h at 37°C. Subsequently, 1 volume of phenol-chloroform-isoamyl
(25:24:1) was added and the phases were separated by centrifugation (14000 x g, 10 min, 20°
C). DNA was precipitated from the water phase by adding 2 volumes of 0.6 M LiCl-EtOH.
PCR-products were finally dissolved in 10 µl TE (10 mM Tris-HCl pH 7.5, 1 mM EDTA).
3.1.2 Gel Electrophoresis and Recovery of DNA from Agarose Gels
The DNA fragments were dissolved in loading buffer (3 % Ficoll, type 400, 8 mM Tris-HCL
pH 8.5, 8 mM Glacial acetic acid, 0.4 mM EDTA, 0.05 % Bromphenol blue) and separated by
electrophoresis through an agarose gel (0.8-1.2% agarose (depending on fragment size) in
TAE buffer (40 mM Tris-HCl pH 8.5, 40 mM Glacial acetic acid, 2 mM EDTA)). After
electrophoresis, DNA in the gels was stained with 1 µg/ml ethidium bromide (EtBr). The
fragments were excised and recovered from the agarose by electroelution. DNA was
precipitated from the eluates with EtOH and redissolved in 10 µl TE.
3.1.3 Ligation
To insert PCR or restriction fragments into vectors, T4 DNA ligase (New England
Biolabs, Beverly, USA) was used. Ligation was carried out at RT for 30 min. Prior to
transformation, the ligation sample was heated (10 min, 65° C) to inactivate the ligase.
3.1.4 Sequencing of Plasmids
Sequencing of the constructs was done using the Dye Terminator Cycle Sequencing
Kit (Perkin Elmer) according to manufacturer’s protocol.
3.2 E.coli Strains, Transformation, and Isolation of Plasmid DNA
3.2.1 E.coli Strain
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DH5α (supE44 ∆lacU169 (Φ80lacZ∆M15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1)
(Hanahan, 1983).
3.2.2 Generation of Electrocompetent E.Coli cells
E.coli were grown in 1 L TB media (1.2 % Tryptone, 2.4 % Yeast extract, 0.4%
Glycerol, 17 mM KH2PO4, 72 mM K2HPO4, pH 7.2) and harvested (4000 x g, 20 min, 4°C),
when the OD600 of the culture reached a value of 0.5-0.8. The cells were gently resuspended ,
washed twice with ice-cold ddH2O (1 L and 0.5 L, respectively), and finally again sedimented
(4000 x g, 20 min, 4°C). Cells were washed with 20 ml ice-cold ddH2O, containing 10%
Glycerol and finally resuspended in a final volume of 2-3 ml the same medium. Such
competent cells were frozen in dry ice, and stored at - 80 °C.
3.2.3 Transformation of E.coli by Electroporation
2µl ligation reaction mixture was mixed with 8µl ddH2O and placed for 30 min on a
0.05 µm filter (Millipore, Bedford, USA) swimming on a reservoir of ddH2O to remove salt.
Subsequently, the ligation reaction was mixed with 40 µl competent DH5α cells, transferred
to a pre-chilled electroporation cuvette (internal width = 2 mm), and subjected to a charge of
2.5 kV. Immediately hereafter 0.7 ml TB-media (RT) was added. After incubation for 1 h at
37°C, the cells were transferred to LB-agar plates containing 50µg/ml ampicillin.
3.2.4 Plasmid Preparation at a Small Scale (vulgo: Minipreps)
The cell pellet of a 2 ml over night culture was resuspended in 400 µl lysis solution
(0.2N NaOH, 1% SDS), neutralized with 300 µl 7.5 M NH4oAC, kept for 10 min on ice, and
then sedimented again (14000 x g, 20 min, 4°C). The DNA was precipitated form the
supernatant with 500 µl 2-Propanol, sedimented (14000 x g, 20 min, 4°C), resuspended in 80
µl TE, and the sequence was finally confirmed by restriction digestions and sequencing.
3.2.5 Plasmid Preparation at a Large Scale (vulgo: Maxipreps)
E.coli cells grown in 1 L TB media over night were harvested (4000 x g, 20 min, 4°C),
resuspended in 18 ml GTE (50 mM Glucose, 25 mM Tris-HCl pH 8.0, 10 mM EDTA), lysed
by adding 2 ml 20mg/ml freshly prepared lysozyme (Sigma Chemie, Deisenhofen, Germany)
in 40 ml lysis solution (0.2 N NaOH, 1%SDS), neutralized with 30 ml 7,5 M NH4oAC, and
incubated (20 min on ice). Subsequently, the lysis solution was cleared by centrifugation
(20000 x g, 30 min, 4°C). Plasmid DNA was precipitated from the supernatant with 0.625 vol
2-propanol, sedimented (20000 x g, 30 min, 4°C), and dissolved in 4 ml TE, 100 µl 2M Tris.
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4 ml of this solution was mixed with 4.75 g CsCl and shaken 1 h at 37°C. 50 µl EtBr
(5mg/ml) was added, the solution was mixed, cleared (2500 x g, 5 min, 20°), and 4 ml of the
supernatant was transfered into a Beckman quick-seal tube. The tube was filled with a CsCl-
TE solution (100 g CsCL + 100 ml TE) and a CsCl-gradient was established (50000 rpm, 18
h, 25°C). The plasmid DNA was extracted from the gradient under optical control in UV
light. Plasmids were transferred to a fresh Beckman quick-seal tube and the procedure was
repeated. EtBr was removed from the plasmids by repeated extraction with NaCl saturated 2-
propanol. Salt was removed by dialyzing 3 times against TE. Finally the DNA was
precipitated with EtOH and resuspended in TE.
Alternatively, plasmid DNA was isolated using Qiagen maxi prep (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol.
3.3 Mammalian Cells
3.3.1  Mammalian Cells
We used the cell line HEK 293 established from human primary embryonal kidney
cells by transformation with adenovirus type 5 (Graham et al., 1977). This cell line was
obtained from DSMZ, Braunschweig, Germany and will subsequently be referred to as 293
cells.
3.3.2 Maintenance of Mammalian Cells
293 cells were maintained as subconfluent monolayer cultures in Duldecco’s Modified
Eagle’s Medium (DMEM with Glutamax-I (GibcoBRL/Life Technologies, Karlsruhe,
Germany)) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100
µg/ml streptomycin at 37°C under a humidified 5% CO2 atmosphere. For passage, cells layers
were washed once with PBS, detached by a short treatment with 0.675 mM EDTA in PBS and
reseeded upon dilution (1:6).
3.3.3 Transfection and Selection of 293 Cells
24 h before transfection a monolayer culture covering 80% of the substratum (i.e. 80%
confluent) was divided 1:3. Cells were transfected using Lipofectamine (GibcoBRL/Life
Technologies, Karlsruhe, Germany) according to the manufacturer's instructions. Transient
expression could be observed after 12-24 hours with a transfection efficiency varying between
20-90 % depending on the construct used (pMC-EGFPP had the highest efficiency). After 36
Materials and Methods 41
hours stable cell lines were selected and maintained thereafter in medium containing 0.35
µg/ml puromycin (Sigma Chemie, Deisenhofen, Germany).
3.4 Western Blotting
To obtain an efficient extraction of proteins we used an extraction/loading buffer
containing 5% SDS and 4 M urea. Cells were harvested at 80 % confluency, sedimented (600
x g, 5 min, 4°C), resuspended in 100 µl ice-cold PBS, mixed with 100 µl 2 X lysis buffer (25
mM Tris-HCl pH 6.8, 10 % SDS, 8 M urea, 20 % glycerol, 0.04 % bromophenol blue, 10 mM
4-(2-aminoethyl)-benzenesulfonyl fluoride, 1 mM PMSF, 20 µg/ml aprotinin, 10 µg/ml
pepstatin A), and homogenised by exposure to ultrasound for 10 s. Subsequently, samples
were boiled (95°C, 5 min), aliquots equivalent to 5 x 105 cells were then loaded into the slots
of SDS-polyacrylamide gels while still hot, and electrophoresis was started immediately.
For topo II, were the proteins in the sample separated in 1 mm gradient gels containing
3-8% polyacrylamide and Tris-acetate running buffer or 4-20% polyacrylamide and Tris-
glycine running buffer (both obtained from Life Technologies, Karlsruhe, Germany). A mix
of prestained recombinant proteins (Life Technologies, Karlsruhe, Germany) was used as a
size marker. Electrophoresis was at 120 V for approx 1 h, or until the bromo phenol blue of
the samples reached the bottom of the gel. For experiments involving subsequent silver
staining, a homogeneous gel containing 6% polyacrylamide and Tris-glycine running buffer
was used. For topo I the same procedure was used as for Topo II, except that homogeneous
gels (1 mm thick) were used containing 9% polyacrylamide and Tris-glycine running buffer.
Proteins were electrophoretically transferred from the gel to a PVDF membrane
(Immobilon P; Millipore, Bedford, Maryland) by the semi-dry method. Briefly, four 3MM
paper filters soaked in K-buffer (70 mM CAPS-NaOH pH 10.5, 10% MeOH) were stacked on
the anode side of the gel, whereas the PVDF membrane soaked in MeOH, one 3 MM paper
filter soaked in A2-buffer (25 mM Tris-HCl pH 10.4, 20% MeOH), and two paper filters
soaked in A1-buffer (300 mM Tris-HCl pH 10.4, 20 % MeOH) were stacked on the catode
side of the gel. Subsequently, the stack was placed between two graphite plates (NovaBlot,
Amersham Pharmacia Biotech, Freiburg, Germany) and 0.8 mA/cm2 were applied for 2 h.
Finally the PVDF membrane was detached from the stack and left over night to dry.
3.4.1 Western Blot
The PVDF membrane was soaked in MeOH for 5 s, washed for 5 min with CMF-PBS
(167 mM NaCl, 25.5 mM Na2HPO4, 2 mM KH2PO4, pH 7.5), containing 0.05 % Tween 20,
and blocked for 1-2 h with CMF-PBS, containing 0.05% Tween 20 and 2% BSA. The
membrane was then incubated for 1 h with the primary antibody diluted in CMF-PBS, 0.05%
Tween 20, 2% BSA. This was followed by rinsing and 4 washes (1 x 15 min, 3 x 5 min) with
CMF-PBS, containing 0.05% Tween 20. The membrane was then incubated for 45 min with
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the secondary antibody conjugated to the horseradish peroxidase and diluted in CMF-PBS,
containing also 0.1% Tween 20, 2% BSA. This was again followed by rinsing and 4 washes
as above. Protein bands labelled by the secondary antibody were visualized by
chemiluminescence using the ECL Plus system (Amersham Pharmacia Biotech, Freiburg,
Germany).
Human topo IIα was detected with a rabbit peptide-antibody specific for the last 18
amino acid residues of the enzyme  (Genosys, Cambridge, UK), which was diluted 1:10000.
Human topo IIβ was detected with a rabbit peptide-antibody specific for the last 12 amino
acid residues of the enzyme (Boege et al., 1995), which was diluted 1:2000. GFP and GFP-
fusion proteins were detected with a mouse monoclonal antibody (clone JL8, Clontech,
Heidelberg, Germany), which was diluted 1:5000. α-tubulin serving as a loading control was
detected with a mouse monoclonal antibody (Sigma Chemie, Deisenhofen, Germany), diluted
1:1000. Human Topo I was detected with a rabbit peptide antibody specific for the last 14
amino acid residues of the enzyme (OA-11-754, Genosys, Cambridge, UK), which was
diluted 1:10000.
Secondary antibodies were goat anti-rabbit (diluted 1:10000) or goat anti-mouse IgG
(diluted 1:50000) coupled to horseradish peroxidase (Amersham Pharmacia Biotech,
Freiburg, Germany).
3.5 Banddepletion Assay
Band-depletion was performed as described in (Meyer et al., 1997) with minor
modifications. Briefly, cells were harvested (600 x g, 37°C, 5 min), gently resuspended in
medium (37°C) containing topo poisons and 1% DMSO as a solvent aid, and incubated at
37°C. Subsequently, cells were lysed by adding 1 vol of 2 X lysis solution, also containing
topo poisons and 1% DMSO as a solvent aid. From this point on, samples were treated as
described in section 3.4. For depletion of topo II cells were exposed to 200 µM VM 26 for 1
hour. For depletion of topo I cells were exposed to various concentrations of CpT for 20 min.
Controls were treated similarly with medium just containing 1% DMSO.
3.6 Complementation Assay
Yeast complementation was carried out as described in (Jensen et al., 1996b). Briefly,
LEU2 expression plasmids for human topo II isoforms and the respective GFP chimera were
transformed into the haploid ∆top2 strain BJ201 (pHT173 (S.pombe TOP2/URA-ARS/CEN)
MATα ura3 trp1 leu2 his3 pep4::HIS3 prb1Dcan1 top2::TRP1 GAL) which contains a URA3
plasmid carrying the S. pombe TOP2 gene to substitute for the essential topo II activity.
Colonies from selection plates (without Leu) were then streaked onto media containing 1
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mg/ml 5-fluoro acetic acid (5-FOA) to counterselect against the plasmid carrying the S.
pombe TOP2 gene.
3.7 Extraction and Immunoprecipitation of Active Topoisomerase II
from Mammalian Cell Nuclei
Exponentially growing cells were harvested, sedimented (600 x g, 3 min), carefully
resuspended (5x109 cells/3 ml) in lysis-buffer (15 mM Hepes pH 7.5, 1 mM EGTA, 60 mM
KCl, 15 mM NaCl, 30 µg/ml Spermine, 7.5 µg/ml Spermidine, 5 µg/ml Leupeptin, 5 µg/ml
Pepstatin A, 1 mM Benzamidine, 10 µg/ml Aprotinin, 1 mM DTT, 1 mM 4-(2-Aminoethyl)-
benzenesulfonyl fluoride, 1 mM PMSF), and incubated for 5 min on ice to allow for cell
swelling. Cells were then lysed by addition of Triton-X-100 to a final concentration of 0,5%,
followed by a brief incubation (2 min in ice). Nuclei were then sedimented (1000 x g, 5 min,
4°C), washed once with lysis buffer, and finally resuspended (5x109 nuclei/200 µl) in
extraction buffer (50mM Hepes pH 7.5, 0.5 mM EDTA, 100mM NaCl, 50µg/ml Leupeptin, 5
µg/ml, Pepstatin A, 1 mM Benzamidine, 10µg/ml Aprotinin, 1 mM DTT, 1 mM 4-(2-
Aminoethyl)-benzenesulfonyl fluoride, 1 mM PMSF, 10 % Glycerol). Subsequently, NaCl
was added until a final concentration of 500 mM followed by incubation (10 min on ice). The
salt-insoluble fraction was sedimented (20000 x g, 30 min, 4°C) and the supernatant (i.e. the
nuclear extract) was mixed with 1vol of water free glycerol, frozen in liquid N2, and stored at
–80°C until further use.
Magnetic particles (Dynabeads M-500 “Subcellular”, Dynal, Oslo, Norway) were
covalently coated with anti-antibodies according to the producer’s manual. Briefly, 8µg of
goat anti mouse- or goat anti rabbit-IgG (Dianova, Hamburg, Germany) were mixed with
1x107 beads (resuspended in 0.1 M borate buffer pH 9.5) and incubated under slow top over
bottom rotation for 48 h at 20°C. Subsequently, the beads were collected with a magnet,
washed (2 x 15 min with PBS pH 7.4 with 0.1% BSA), and remaining free tosyl-groups were
blocked (24 h at 20°C with 0.2 M Tris-HCl pH 8.5 and 0.1 %BSA). Beads were then washed
and incubated with primary antibodies (5 µg IgG/1x107 beads, 60 min at 4°C, slow top over
bottom rotation). After washing again, the beads were ready to use. They were stored at 4°C
in PBS pH 7.4 with 0.1% BSA until the actual experiment. Primary antibodies were: rabbit
antibodies against topo IIα (Genosys, Cambridge, UK), mouse monoclonal antibodies against
topo IIβ (clone 3H10, (Meyer et al., 1997)), and mouse monoclonal antibodies against GFP
(Roche, Indianapolis, USA).
For immuneprecipitation of topo II, 2x107 beads were incubated for 2h at 4°C with
nuclear extracts obtained from 109 cells in binding buffer (175 mM NaCl, 6 mM HEPES, pH
7.5, 2 mM EDTA, 14 % glycerol, 0.2 mM DTT, 0.5 mM 4-(2-Aminoethyl)-benzenesulfonyl
fluoride, 10 µg/ml aprotinin, 5 % FBS). This amount of extract was sufficient to ligand all
specific binding sites of the beads. Subsequently, the beads were collected with a magnet and
washed with binding buffer (4 x 15min) and assay buffer (1 x 15 min) (120 mM KCl, 50 mM
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Tris-HCl, pH 7.9, 10 mM MgCl2, 1mM ATP, 0.5 mM DTT, 0.5 mM EDTA, 30µg/ml BSA).
Topo II bound to the beads was subsequently assessed for topo II – specific DNA
decatenation activity as described in section 3.8. It should be noted that Dynabeads M-500
Subcellular were found optimal for these experiments, whereas smaller variants of magnetic
beads or sepharose gave less good separations.
3.8 Assessment of Topo II Activity
Immunoprecipitates were subjected to serial dilution and assessed for decatenation of
Crithidia fasciculata kinetoplast DNA (kDNA, TopoGen Inc., Columbus, Ohio, USA). Beads
were incubated for 2 h at 37°C with 1 µg kDNA in a final volume of 40 µl assay buffer (120
mM KCl, 50 mM Tris-HCl, pH 7.9, 10 mM MgCl2, 1mM ATP, 0.5 mM DTT, 0.5 mM
EDTA, 30µg/ml BSA). Negative controls included addition of 300 µM Na3VO4 (inhibiting
topo II activity via poisoning the ATPase activity) and beads not incubated with nuclear
extracts. The reactions were terminated by addition of SDS (0,5%) and subsequently digested
with Proteinase K (60 min, 37°C). Finally samples were subjected to agarose
gelelectrophoresis.
For a quantitative determination and comparison of the amounts of
immunoprecipitated enzyme, 3x106 beads were loaded with extract and eluted with 100 mM
Na3PO4, 100 mM NaCitrate (pH 3) and 3 M urea. The eluted material was subjected to SDS-
PAGE (6% homogeneous gels) and visualized by silver staining (Heukeshoven et al., 1986).
3.9 Microscopy
In all cases cells were grown on glass coated with poly-L-lysine (Sigma Chemie,
Deisenhofen, Germany) until 40-60% of the substratum was covered.
3.9.1 Immunocytochemistry
Cells were grown on microscopic coverslips, washed in PBS, fixed in 2 %
paraformaldehyde in PBS (15 min, 37°C), and permeabilized with 0.25 % Triton X-100 in the
presence of 1% paraformaldehyde in PBS (10 min, RT). All subsequent steps were carried out
at ambient temperature. After washing with PBS, cells were first blocked for 1 h in PBS, 2 %
BSA, 5 % goat serum and then incubated for 1 h with topo IIα antibody KiS1 (mouse), topo
IIβ antibody 3H10 (mouse), topo I antibody Scl70 (human) (Dunn laboratories, Asbach,
Germany) or RNA polymerase I antibody S18 (human autoimmune serum, (Reimer et al.,
1987)). All antibodies were diluted 1:500 in blocking solution (S18, was diluted 1:100). After
washing, bound antibodies were counterstained by incubation for 1 h with Cy3™-conjugated
goat anti-mouse or anti-human F(ab’)2 fragments (Dianova, Hamburg, Germany) diluted
1:1000. Coverslips were then washed three times for 5 min in PBS, the first washing cycle
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including 80 ng/ml of 4,6-Diamidino-2-phenylindole (DAPI) to counter stain the genomic
DNA. Slides were finally mounted in antifade solution (PBS containing 1.5% N-propyl-galate
and 60% glycerol), and immediately inspected (see section 3.9.3).
3.9.2 Spreading of Native Chromosomes
107 exponentially growing cells were harvested, collected by centrifugation for 5 min
at 160 x g, carefully resuspended in 6 ml hypotonic solution (0.075 M KCl), sedimented
again, and resuspended in 400 µl hypotonic solution. Drops of about 50 µl were then spotted
on a slightly tilted glass slide. Prior to this, slides were carefully cleaned in methanol and then
soaked in double distilled water. After spreading, unattached cells were removed by letting
200 µl freshly prepared isotonic CSK buffer (100 mM KCl, 300 mM Sucrose, 10 mM Pipes
pH 6.8, 3 mM MgCl2, 1 mM EGTA, 10 mM 4-(2-Aminoethyl)-benzenesulfonyl fluoride, 1
mM PMSF, 20 µg/ml Aprotinin, 10 µg/ml Pepstatin A) containing 80 ng/ml DAPI run down
the slightly tilted slide. Spread chromosomes were then carefully mounted in the same buffer
and imaged immediately (see section 3.9.3).
3.9.3 Fluorescence Microscopy
Epifluorescent images were acquired with appropriate filter sets (AHF
Analysentechnik, Tübingen, Germany) at 630X magnification using an inverted microscope
(Axiovert 100; Carl Zeiss, Göttingen, Germany) equipped with a cooled charge-coupled
device camera (Sensys, Photometrics Ltd., München, Germany) and an additional 4X
magnification lens.
For observation of living cells, they were grown and inspected in CO2-independent
medium (GibcoBRL/Life Technologies, Karlsruhe, Germany) using live-cell chambers
(Bioptechs Inc., Butler, Pennsylvania) to keep the cells under microscope at 37 ˚C. It should
be emphasized that strict temperature control was crucial for localization and mobility of topo
II especially.
3.9.4 Confocal Laser Scanning Microscopy
Confocal imaging, FRAP and FLIP analyses of living cells were performed at 37 °C
with a Zeiss LSM 510 inverted confocal laser scanning microscope equipped with a CO2-
controlled on-stage heating chamber using a heated 63x/1.4 NA oil-immersion objective and
the FITC filter setting (488 nm / 515 nm) (Carl Zeiss, Göttingen, Germany).
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3.9.5 Photobleaching
For fluorescence recovery after photobleaching (FRAP) experiments, a single optical
section was acquired with 5.6 x zoom. Images were taken before and at 1.577 s time intervals
after bleaching of a circular area at 20 mW nominal laser power with 3 iterations. The
imaging scans were acquired with a laser power attenuated to 0.1 – 1 % of the bleach
intensity. For quantitative FRAP analysis, fluorescence intensities of the bleached region, the
entire cell nucleus and background were measured at each time point. Data were corrected for
extracellular background intensity and for the overall loss in total intensity as a result of the
bleach pulse itself and the imaging scans. Unless stated otherwise, FRAP recovery curves
were generated by calculating the relative intensity of the bleached area Irel as described (Phair
and Misteli, 2000):
Irel = (I bleached spot X I entire cell nucleus at time 0)/(I bleached spot at time 0 X I entire cell nucleus )
The same laser settings were used for FLIP experiments where cells were repeatedly bleached
and imaged at intervals of 15 s. FLIP depletion curves of selected areas outside the bleach
spot were just corrected for the loss of fluorescence intensity caused by the imaging scans by
comparison with the fluorescence intensity of a neighbouring cell nucleus.
FRAP and FLIP of mitotic cells was performed in the presence of 0.1 µM paclitaxel to reduce
movements of the chromosomes.
3.9.6 Kinetic Modelling-Topo I
The computer software Prism (GraphPad Software Inc., San Diegeo, CA) was used for
nonlinear regression analysis and plotting of FRAP-kinetics. Kinetic models assuming the
coexistence of one, two, or three individual enzyme fractions with different mobility were
tested. In all cases, best fits (according to R2-value and F-test significance) were obtained
when assuming the coexistence of two enzyme fractions with different mobility. Values of
maximal recovery derived from nonlinear regression were used to calculate the proportion of
the two enzyme fractions with different mobility, whereas a third, immobile enzyme fraction
was calculated by adding up the two fractions to 100%.
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4. Results
First I will describe in some detail our strategy of expressing bio-fluorescent chimera
of topo I, IIα, and IIβ in a constitutive manner. I believe this to be important, because other
groups trying to do the same experiment with different vector systems have encountered
insurmountable problems. Subsequently, I will present data of the localization of topo IIα and
IIβ in living cell nuclei at interphase, the relocation of the enzymes during cell division, the in
vivo- mobility of the enzymes as determined by various photobleaching approaches, and the
changes of these parameters, induced by specific topo II poisons. Finally I will present similar
data obtained for GFP-chimera of topo I and various truncated versions of the enzyme that are
suited to highlight the biological role of the non-conserved N-terminus of the enzyme. Most
of these results have been published (Christensen et al., 2002a; Christensen et al., 2002b).
Whenever published data are presented, a reference is included in the Figure legends.
4.1 Construction of Bicistronic Expression Constructs
The generation of stable cell lines demands the simultaneous expression of a selectable
marker and the gene of interest, classically achieved with two independent sets of regulatory
elements. Thus, the physical and functional independence of the selection marker from the
gene of interest allows the cell to express the one but not the other.
In the case of topo II this problem has been encountered in a particularly severe
manner. Attempts at stable heterologuous expression of topo II in mammalian cells have
produced cells that either expressed topo II in a transient manner or at levels to low for
observation (Asano et al., 1996; Eder et al., 1993; McPherson et al., 1997). The apparent
counterselection against stably transfected cells was explained with a pronounced sensitivity
of the cells to alterations in the total amount of active topo II in the cell nucleus. Current
belief holds that cell-cycle-related regulation of topo II expression is essential for the enzyme
to function properly in the context of the living cell nucleus. Override of cell-cycle-related
modulations of topo II levels by an unregulated source of expression is therefore likely to
harm the cells. Not unexpectedly, deregulation of topo IIα expression has indeed been found
to induce apoptotic cell death, most probably by disrupting the temporal order of events
mediated by the enzyme during cell division (McPherson and Goldenberg, 1998). Taking all
this into account, it seemed an essential prerequisite of this study first to devise an expression
system that would overcome these problems.
In order to do so, I used a vector system that provides a fixed linkage between the
expression of the selection marker and the expression of the gene of interest. The discovery of
the function of the 5’-untranslated regions of transcripts made by picornaviruses provided the
tool for this purpose. This region triggers translational initiation of the uncapped viral
transcript by directing initiating ribosome’s to a defined start codon about 600-1200
nucleotides downstream and was consequently termed internal ribosome entry site (IRES).
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The IRES element has been shown to function in artificial bicistronic mRNAs. When placed
between two open reading frames, it mediates the translational initiation of the distal cistron
(Molla et al., 1992; Pelletier and Sonenberg, 1988). Using this property of the IRES element, I
constructed a vector system where expression of topoisomerases is physically linked to
expression of the selection marker via the translation of a single bicistronic mRNA. This
linkage ascertains that cells have to maintain heterologous coexpression of the selection
marker and a topoisomerase. Thus, they are forced to compromise between expressing enough
of the one and not too much of the other, when put under selection pressure.
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4.2 Dynamics of Human DNA Topoisomerases IIα and IIβ in Living
Cells
Human embryonal 293 kidney cells were transfected with pMC-EGFPP, pMC-TIIα-
EGFPP and pMC-TIIβ-EGFPP, bearing in the first cistron GFP alone or hybrid genes of topo
IIα or topo IIβ fused at their C-termini to GFP, and in the second cistron the selection marker
pac. Stable cell lines expressing either GFP alone, topo IIα/GFP, or topo IIβ/GFP were then
generated by selection of the transfected cells in the presence of 0.35 µg/ml puromycin. These
three cell lines were maintained as mixed populations and not separated into individual
clones. Significantly less puromycin-resistant cells emerged from transfection with topo II-
GFP than from transfection with the GFP gene alone, attesting to a narrow tolerance margin
for transgenic expression of topo II. This observation might reflect that the cells are unharmed
by a high expression of GFP, whereas cells expressing a high level of topo II-GFP undergo
cell-death, and only cells with a low expression survive. However, cell lines supporting
constitutive expression of topo IIα-GFP or topo IIβ-GFP had growth rates and morphologies
similar to untransfected cells or cells expressing GFP alone. This suggested a quasi
physiological expression of the GFP-tagged topo II species suitable for fluorescence studies in
living cells, provided that the fusion proteins were active, not over expressed, and colocalized
with their endogenous counterparts. Control experiments addressing these issues are
addressed in the following 3 sections.
4.2.1 Expression of Full-length Topoisomerase IIα and IIβ-GFP Chimeras
We performed immunoblotting of the cell lines expressing topo IIα-GFP (Fig. 4.1,
lane 3) and topo IIβ-GFP (Fig. 4.1, lane 4). Untransfected cells (Fig. 4.1, lane 1) and GFP-
expressing cells (Fig. 4.1, lane 2) served as controls. To assess the integrity of the fusion
proteins and to compare their relative expression levels, the blots were probed with GFP-
antibodies (Fig. 4.1, top panel). In transfected cells (lanes 3 and 4), chimeric topo IIα and IIβ
were detected as single protein bands of the expected size (arrow), but were absent in
untransfected cells (lane 1) and in cells expressing GFP alone (lane 2). Thus, we could
exclude rearrangements of the chimeric genes, and ascertain that green fluorescence of the
cells was due to full-length topo II-GFP chimera. Topo IIα-GFP and topo IIβ-GFP appeared
to be expressed in similar amounts (compare lanes 3 and 4), allowing a comparison of data
between these cell lines.
To compare expression levels of GFP-fused topo II isozymes with the endogenous
enzymes, blots were probed with isoform-specific antibodies against topo IIα (Fig. 4.1,
second panel) or topo IIβ (third panel). The GFP chimera could clearly be discriminated from
the corresponding endogenous enzymes as additional bands of slower migration (arrows).
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Figure 4.1: Expression of topo II-GFP in HEK 293
cells. Western analysis of untransfected 293 cells
and cells expressing GFP, topo IIα-GFP, or topo
IIβ–GFP. Blots were probed with GFP antibodies
(upper panel), or antibodies against human topo IIα
or topoIIβ (middle panels), or antibodies against
α–tubulin serving as loading control (lower panel).
Arrowheads on the right margin indicate positions of
topo II-GFP chimera. Figure adapted from
(Christensen et al., 2002b).
From comparison within each lane, it became evident that they were expressed at much lower
levels than the endogenous proteins. Noteworthy, the amount of endogenous topo IIα and IIβ
were the same in transfected and untransfected cells (compare lane 1 with lanes 3 and 4)
demonstrating that a normal regulation of endogenous topo II expression is maintained in all
stable cell lines.
In conclusion, the expression system is suitable for the stable expression of moderate
levels of GFP-tagged topo II isoforms without affecting the normal cell morphology or cell-
cycle-progression. In this context, it is of interest that heterologeous expression of topo IIα-
GFP from a conventional vector (Mo et al., 1998; Mo and Beck, 1999) resulted in a transient
doubling of the total amount of topo II in cell, but did not allow for establishing stable cell
lines. In contrast, we achieved here by way of the bicistronic vector a balance between the
expression of topo II (sufficiently low to not induce apoptosis) and the selection marker (high
enough to allow growth in the presence of selection pressure).
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Figure 4.2: DNA-decatenation activity
of GFP-fused and endogenous topo
II. GFP-directed immunoprecipitates
from cells expressing topo IIα-GFP or
topo IIβ-GFP and immuno-precipitates
from untransfected cells directed at
topo IIa or IIb were subjected to serial
dilution and assessed for kDNA-
decatenation. SDS-PAGE of the
immuno-precipitates is shown four
times in the inserts with arrowheads
identifying those lanes that correspond
to the respective decatenation assay.
Figure adapted from (Christensen et
al., 2002b).
4.2.2 Topoisomerase IIα- and IIβ-GFP Chimera Have The Same Enzymatic
Activity as Their Endogenous Counterparts.
Since protein functions could be disrupted by fusion to GFP, we wanted to ascertain
that the topo II-GFP chimera had the same activity as the endogenous enzymes.
A major role of topo II in vivo is to catalyse the double-stranded cleavage of DNA,
allowing passage of a second DNA duplex through the break. This activity requires ATP and
is necessary for separating catenated DNA dublexes found at the end of replication. The
decatenation of DNA molecules is a topo II-specific reaction which can be used to assay topo
II activity in vitro (Marini et al., 1980).
We separated endogenous and GFP-fused enzyme by immunoprecipitation in order to
compare their in vitro DNA-decatenation activities in quantitative terms. GFP-directed
immunoprecipitates  contained GFP-fused and unfused topo II in equal proportions (Fig. 4.2,
inserts, lanes 2 and 4), suggesting heterodimers of GFP-fused and endogenous topo II. That
topo IIα-GFP and IIβ-GFP form dimers with their respective endogenous counterpart suggest
that GFP does not disturb the formation of the topo II dimer. A quantitative determination of
topo II-specific DNA decatenation activity in the immunopricipitates was achieved by serial
dilution and subsequent assessment of kDNA-decatenation (Fig. 4.2). In the catenated form
kDNA cannot enter an agarose gel, whereas single circles released by topo II from the
catenated network will migrate into the gel. The specific decatenation activity is characterized
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Figure 4.3: Topo II immuno-band depletion assay.
The same cell lines as in Fig. 4.2 were cultured 1 h in
medium containing 200 µM teniposide (+ VM 26) or in
plain medium (- VM 26). Cells were then lysed,
subjected to Western blotting and the blots were
probed with GFP-antibodies (upper panel) or α-tubulin
(lower panel). The position of topo II-GFP is indicated
on the right margin by an arrow. Figure adapted from
(Christensen et al., 2002b).
by the limiting dilution at which free circles are still to be seen. Upon comparing the DNA-
decatenation activity of these mostly heterodimeric immunoprecipitates with similar amounts
of endogenous enzymes obtained from untransfected 293 cells by topo II-directed
immunoprecipitation (Fig. 4.2, inserts, lane 1 and 2, resp.), it appeared that topo IIα (Fig. 4.2,
middle-top) and IIβ (Fig. 4.2, bottom) containing transgenic, GFP-fused subunits had the
same activity as those composed entirely of unfused subunits encoded by the endogenous
genes (Fig. 4.2, top and middle-bottom, resp.). Decatenation activity could in all cases be
inhibited by the ATPase-inhibitor orthovanadate (outmost lanes on the right). Thus, fusion to
GFP did not alter the catalytic properties of the enzymes.
To ascertain in addition that the GFP-fused enzymes were also active in the cells, we
employed immuno-band depletion (Fig. 4.3), which is based on the fact that the transient,
covalent complex between topo II and genomic DNA is stabilized by specific topo II poisons
(Liu, 1989). As a consequence, topo II-specific signals are depleted in western analyses due to
retention of covalent topo II·DNA complexes in the gel slots. Untransfected and transfected
293 cells were treated with the topo II-poison teniposide (VM 26), and subjected to
immunoblotting using GFP-antibodies (Fig. 4.3, top). Obviously, the treatment depleted topo
II-fused GFP bands from the blots (compare lanes 5 to 6 and 7 to 8). The extent of depletion
was similar to that of endogenous topo II (data not shown). GFP alone (compare lanes 3 and 4
in top panel), or α-tubulin (bottom) was not depleted by VM 26, attesting to the specificity of
the assay. These results confirmed that topo II-GFP chimera were as active as endogenous
topo II because they formed the same amount of catalytic intermediates in the genome of the
transfected cells.
Transient expression has shown that fusion to GFP at the C-terminus does not abolish
the ability of topo IIα to bind and cleave genomic DNA in vivo (Mo and Beck, 1999).
However, such findings do not necessarily imply that biofluorescent topo II chimera are also
able to provide all enzymatic functions required for regulated and complex processes like
chromosome segregation. To judge the global functionality of topo II-GFP in mitosis, we
tested complementation of topo II function in S. cerevisiae topo II-deletion strains. It has been
shown that human topo IIα and IIβ are able to complement mitotic growth in S. cerevisiae
(Jensen et al., 1996b), and that such an assay can be used to test for functionality of mutant
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Fig 4.4: Yeast complementation assay: The S.
cerevisiae strain BJ201 carrying a disrupted
endogenous TOP2 gene which is substituted by
the S.pombe  Top2 gene on a URA3-based
plasmid, was transformed with LEU2 plasmids
carrying either the TPI-promoter alone (-) or TPI-
promoted topo II cDNAs encoding topo IIα, topo
IIα-GFP, topo IIβ, and topo IIβ-GFP, respectively.
After growth on selective plates  (without  Leu),
single clones were streaked on plates with 5-FOA
(right) to select for clones that had lost the S.pombe topo II-expressing plasmid. Plates without 5-
FOA served as a control (left). Mitotic growth of cells transformed with the topo II-expression
plasmids on 5-FOA plates indicates that the essential topo II activity is likewise provided by GFP-
tagged and untagged versions of human topo II isoforms. Figure adapted from (Christensen et al.,
2002b).
topo II versions in yeast (Jensen et al., 1996a). We have tested whether human topo IIα-GFP
and IIβ-GFP rescue a yeast topo II deletion (Fig. 4.4). This assay demonstrated that GFP
chimera of human topo IIα and topo IIβ were fully capable of supporting the mitotic growth
of ∆top2 yeast upon eradication of the endogenous salvage plasmid encoding S.pombe topo II
(+5-FOA), whereas cell growth was abolished in the absence of an additional topo II
construct. Apparently, complementation by GFP chimera was as good as by untagged topo II.
Thus, the functionality of human topo II is fully preserved in the corresponding GFP chimera.
4.2.3 Colocalization of GFP-Chimera with Endogenous Topoisomerase II
Although we show that the catalytic activity of topo II (Figs. 4.2 and 4.3) and the
functionality of the enzyme in the cell (Fig. 4.4) is not compromised by a fusion to GFP, we
cannot exclude that cellular targeting of the enzymes is affected. Therefore, we compared the
distribution patterns of GFP-tagged topo II and the endogenous enzyme by indirect
immunofluorescence.
The rational of this experiment is that the antibodies detect both endogenous and GFP
fused topo II. By comparing the antibody- and the GFP-derived fluorescence we should be
able to determine whether the GFP-tagged topo II colocalizes with the pattern of endogenous
enzyme. Fig. 4.5 shows a typical outcome of such an experiment with examples of mitotic
and of interphase cells labelled with isozyme specific topo II antibodies. Untransfected cells
(Fig. 4.5, both panels, top) gave rise to antibody-derived signals only, whereas cells
expressing topo IIα-GFP (Fig. 4.5, left, bottom) or topo IIβ-GFP (Fig. 4.5, right, bottom) also
emitted GFP fluorescence. The distribution patterns of GFP fluorescence (specific for GFP
fusion proteins only) and immunofluorescence (specific for fused and endogenous enzymes)
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Figure 4.5: Colocalization of GFP fusion proteins with endogenous topo IIα and IIβ by indirect
immunofluorescence microscopy. Untransfected 293 cells (top) and topo IIα- (bottom, left) or topo
IIβ-GFP-expressing cells (bottom right) were grown on microscopic slides, PFA-fixed, permeabilized,
and doublestained with isoform-specific topoII-antibodies (columns IIα and IIβ, resp.) and DAPI.
Corresponding images of phase contrast (Phase) and green fluorescence (GFP) are shown. From
each staining combination one representative cell in interphase (upper image) and pro-/metaphase
(lower image) is shown. Figure adapted from (Christensen et al., 2002b).
were virtually identical, attesting to the fact that the GFP chimera colocalized with their
endogenous counterparts. In addition, distribution patterns of topo II in non-transfected and in
topo II-GFP-expressing cells were identical (Fig. 4.5, compare top and bottom portion),
making it unlikely that the GFP chimera disrupted localization of the endogenous enzymes.
It should be noted that the patterns shown in Fig. 4.5 do not represent the true
localization of topo IIα or topo IIβ in living cells, because these cells were fixed and
permeabilized which is known to alter the cellular distribution of topo II in an unpredictable
fashion (Chaly and Brown, 1996). In fact, when we applied different protocols for
permeabilization and/or fixation, we also obtained patterns different from those shown in Fig.
4.5, but in each case antibody staining and GFP fluorescence were identical. The
colocalization of topo II- and GFP-epitopes in fixed cells shows that the cellular targeting of
topo II-GFP chimera is identical to that of the endogenous enzymes. Thus, the GFP-tagged
enzymes should also reflect faithfully the localization of topo II in living cells.
4.2.4 Distribution of Topoisomerase IIα and IIβ in the Interphase Nucleus
Monitoring of topo IIα-GFP and topo IIβ-GFP in living cells by GFP-fluorescence
revealed a very similar distribution of the isozymes in interphase nuclei (Fig. 4.6): Both were
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Figure 4.6: Distribution of topo II-GFP in
interphase nuclei. Phase-contrast images
(top)  and corresponding green
fluorescence (bottom) of living 293 cells
expressing topo IIα-GFP (left) and topo IIβ-
GFP (right). The insert shows images of
selected nucleoli subjected to 2-fold
magnification and contrast enhancement.
Arrowheads indicate areas of decreased
fluorescence intensity within the nucleoli.
Figure adapted from (Christensen et al.,
2002b).
exclusively in the nucleus, where they resided in the nucleoplasm and the nucleoli. The proper
nuclear localization demonstrates that both topo II-GFP isoforms have a functional NLS,
which indicates a proper folding of the two fusion proteins. The minor, nucleoplasmic
subpopulation had a slightly uneven distribution. The major fraction of both isoforms
accumulated in the nucleoli. It had a cloudy but otherwise unstructured distribution in the
entire nucleolar space, which distinctively excluded small globular compartments, imposing
as dark holes within the brightly fluorescent nucleolus (Fig. 4.6, insert, arrows). These
globular compartments have not yet been unambiguously identified. It is, however, likely that
they reflect an exclusion of topo II from the fibrillar centers.
The obvious discrepancy between the true cellular localization of topo II in interphase
shown in Fig. 4.6 and the localization patterns obtained by indirect immunofluorescence in
Fig 4.5 clearly supports my hesitations stated earlier with respect to immunofluorescent
localization studies of topo II.
4.2.5 Isoform Specific Localization of Topoisomerase II in Mitosis
Fig. 4.7 shows time lapsed images of topo IIα-GFP (left) and topo IIβ-GFP (right) in
cells proceeding from metaphase (0’) to early G1-phase (90’). Topo IIα-GFP was mostly
chromosome-associated from metaphase until telophase (0-10 min). The enzyme distinctively
labelled chromosomal structures, whereas the mitotic cytosol contained only a minor fraction.
In contrast, association of topo IIβ-GFP with chromosomes varied during mitosis. In
metaphase (0 min) the enzyme was mostly in the cytosol. It started to associate with the
chromosomes as soon as they were segregated (4 min) and continued to accumulate there
until cytokinesis (18 min). From then on and throughout interphase the two isoforms behaved
similarly. During nuclear reorganization in early G1-phase (18 – 90 min), they concentrated in
small, light-dense structures (18 and 28 min), which later on (45 and 90 min) gradually
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Fig 4.7: Time-lapse imaging of topo II isoforms during mitosis. Cells expressing either topo IIα-
GFP (left) or topo IIβ-GFP (right) were grown on the microscope stage at 37 °C and imaged at
subsequent time points as indicated. Phase-contrast images and corresponding green fluorescence of
representative cells are shown during progression from metaphase to early G1-phase. Figure adapted
from (Christensen et al., 2002b).
assembled into nucleoli. Numerous structures stained by topo II-GFP in the reforming
nucleolus at late telophase are most likely connected to reforming nucleoli. Reformation of
the nucleolus, often termed nucleologenesis, takes place in two stages. First, small
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Fig 4.8: Centromeric accumulation of
topo IIα  at metaphase is lost upon
transition to anaphase. Topo IIα -GFP-
expressing cells were grown on cover
slides, then flattened by placing the slide
with adherent cells directly onto a glass
slide, and imaged directly thereafter.
Representative examples of cells at
metaphase (left) and anaphase (right) are
presented by phase contrast (top) and
corresponding green fluorescence of GFP
(bottom). Arrowheads indicate an example
of centromeric accumulation of topo IIα, as
characterized by two pairs of dots per
chromosome. Figure adapted from
(Christensen et al., 2002b).
prenucleolar bodies (PNBs) are formed that contain various nucleolar proteins including
fibrillarin, B23 and nucleolin (Bell et al., 1992; Jimenez-Garcia et al., 1994). When
transcription is initiated, the PNBs associate with the other nucleolar components to form the
complete nucleolus (Benavente et al., 1987). It is interesting to note that the structures stained
by topo II at early G1-phase (e.g. 28 min) resemble those of established marker proteins of
prenucleolar bodies (e.g. B23; (Olson et al., 2000)), suggesting that both topo II isozymes are
present at PNBs and participate in postmitotic reassembly of nucleoli.
4.2.6 Accumulation of Topoisomerase IIα at the Centromeres is Lost Upon
Sister Chromatid Separation
Previous studies have shown an upconcentration of topo IIα at the centromers during
pro- and metaphase (Rattner et al., 1996; Sumner, 1996; Taagepera et al., 1993). However,
due to the dense chromosome packing, we could not resolve the sub-chromosomal
localization of topo IIα in metaphase plates of living cells (Fig. 4.7). To overcome this
problem, metaphase chromosomes were spread out by gentle mechanical compression of the
cells (Fig. 4.8), which revealed a centromeric accumulation of topo IIα-GFP in pro/metaphase
(Fig. 4 8, left, arrowheads) in the still living cells. In anaphase, however, the enzyme appeared
to be evenly distributed over the whole chromosome (Fig. 4.8, right). Taken together, these
observations demonstrate that topo IIα is located at centromers during condensation but is
released when the centromeric DNA is segregated at anaphase, which is in good agreement
with the immunohistochemical findings described above and supports the idea that in
metaphase (at the onset of chromatid segregation) topo IIα has its major role in separating the
last catenates of centromeric DNA. The upconcentration of topo II at the centromere could be
due to a requirement of a high enzymatic activity during the segregation of the centromeric
heterochromatin. This could ensure that separation of the centromeric regions occurs
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Figure 4.9: Topo IIβ is not completely
excluded from mitotic chromosomes.
A single high-resolution, confocal section
of metaphase cells expressing either
GFP alone (left) or topo IIβ-GFP (right) is
shown (inserts: images of transmitted
light of the same cells). Figure adapted
from (Christensen et al., 2002b).
simultaneously and fast in all chromosomes. In this context, it is also of interest to see here
how fast the enzyme is lost from the centromere, considering the rapid progression of cells
from metaphase to anaphase (comp. Fig. 4.7).
4.2.7 Topoisomerase IIβ Interacts with Metaphase Chromosomes, Too.
The data in Fig. 4.7 show that topo IIβ does not accumulate on chromosomes before
the onset of anaphase. This could either mean that the enzyme is altogether excluded from the
condensed chromatin in metaphase, or that a large cytoplasmic pool of topo IIβ obscures a
smaller, chromosome-associated fraction. It is established that GFP alone is excluded from
dense cellular structures such as the condensed chromosomes. To find out if this is also the
case for topo IIβ, we compared by high-resolution confocal microscopy metaphases of cells
expressing GFP alone and cells expressing topo IIβ-GFP (Fig. 4.9). The untagged, freely
diffusible protein GFP was clearly excluded from densely packed metaphase chromosomes
(Fig. 4.9, left), whereas this was not the case for topo IIβ-GFP (Fig. 4.9, right). Here, the
metaphase plate exhibited the same fluorescence intensity as the surrounding cytosol and was
even highlighted by more intense speckles. It is likely that this represents an upconcentration
of topo IIβ-GFP at centromers. As that may be, the pattern clearly argues against an exclusion
of topo IIβ from metaphase chromosomes. It rather suggests that a minor fraction of the
enzyme is chromosome-associated at this stage of mitosis.
However, it still remained unclear if the subfraction of topo IIβ at the metaphase
chromosomes is a static fraction. Alternatively, the weak topo IIβ signal in metaphase plates
could represent a dynamic equilibrium between a cytoplasmic and chromosomal population.
Evidence for the latter assumption came from metaphase cells treated with the topo II-specific
drug VM 26 (Fig. 4.10). VM 26 caused a rapid redistribution of both topo IIα-GFP (Fig. 4.10,
top) and topo IIβ-GFP (bottom) from the cytosol to the chromosomes, indicating that the drug
efficiently trapped both isozymes on chromosomal DNA. It is of interest that chromosomal
accumulation induced by VM 26 was faster and more complete for topo IIα than for topo IIβ.
In summary, these data indicate that during mitosis topo IIβ is able to engage in DNA-
turnover, but the enzyme is clearly biased to the cytosolic state. In addition, the rapid
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Figure 4.10: Topo IIα and topo IIβ
a c c u m u l a t e  o n  m i t o t i c
chromosomes upon treatment
with VM 26. Cells expressing topo
IIα-GFP (top) and IIβ-GFP (bottom)
were imaged by confocal microscopy
before (0 min) and at the indicated
time points after the addition of 100
µM VM 26. Figure adapted from
(Christensen et al., 2002b).
redistribution of both isoforms from the cytosol to the chromosomes after treatment with VM
26 suggests a dynamic interchange between the two populations thus identifying these
enzymes as highly mobile constituents of the mitotic cell.
4.2.8 Mobility of Topo IIα and IIβ in Interphase Cells and the Effect of Topo II
Poisons.
The dramatic changes in localization induced by VM 26 clearly demonstrated that
topo IIα and IIβ are dynamic and highly mobile enzymes. To follow up on the mobility of
topo IIα and topo IIβ in living cells, we employed photobleaching techniques. Fig. 4.11
summarizes a series of experiments, determining the mobility of topo IIα and IIβ  in
interphase nuclei via kinetics of fluorescence recovery after photobleaching (FRAP) (White
and Stelzer, 1999). Topo II-linked GFP-fluorescence was bleached irreversibly in circular
areas (Ø = 1 µm) by high-powered laser pulses and fluorescence recovery in the bleached
spots as a consequence of topo II-GFP molecules moving in from unbleached areas was
recorded over time. It is readily apparent from time-lapsed fluorescent images (Fig. 4.11, top)
and quantitative plots of recovery kinetics (Fig. 4.11, bottom) that fluorescence recovery after
photobleaching of a nucleoplasmic or a nucleolar area was in each compartment fast and
complete for both topo II isoforms. This suggests that immobile molecules are virtually
absent. Recovery kinetics of topo II-GFP were much faster than those of GFP-histone H3, a
member of nucleosomal core proteins (Fig. 4.11, bottom, Ctrls.) known to be firmly
immobilized on chromatin (Phair and Misteli, 2000). On the other hand, both topo II isozymes
were by no means as freely diffusible as unfused GFP, which exhibited recovery kinetics even
too fast to be recorded with our experimental settings (Fig. 4.11, bottom, Ctrls.). Moreover,
recovery of topo IIα-GFP and topo IIβ-GFP was notably slower in the nucleoli (t1/2 = 6.2 s and
10 s, respectively) than in the nucleoplasm (t1/2 = 1.8 s and 3 s, respectively), suggesting less
mobile enzyme subpopulations in the nucleoli. This and the slight difference in mobility
between the isozymes (topo IIβ was somewhat slower) raised the question of what controls
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Figure 4.11: FRAP analysis of
topo II-GFP. Cells expressing
GFP chimera of topo IIα  and
topo IIβ were bleached for 1.8 s.
Images were taken before
bleaching and at the indicated
time points after the end of the
bleach pulse. The area to be
bleached is indicated by a circle
in the pre-bleach panels. In VM
26-treated cells a nucleolar or a
nucleoplasmic region was
bleached simultaneously in the
same cell, whereas in untreated
cells each compartment was
bleached in separate cells.
Corresponding quantitative data
of fluorescence recovery kinetics
are plotted below. Fluorescence
intensities in the bleached region
were measured and expressed
as the relative recovery over
time. Values represent means
from at least 6 individual cells
and 3 independent experiments.
Standard deviations were in
each case less than 5 % of the
mean values (not displayed).
FRAP kinetics of freely diffusible
GFP, chromatin-bound histone
H3-GFP and formaldehyde-fixed
topo IIβ-GFP served as controls.
F i g u r e  a d a p t e d  f r o m
(Christensen et al., 2002b).
topo II mobility and which role DNA interactions play in this respect. We could address this
issue experimentally, since covalent topo II·DNA intermediates are stabilized by specific
agents such as VM 26 (compare Figs. 4.3 and 4.10). VM 26-treatment induced a profound
redistribution of topo II in the nucleus, which was similar for both isoforms (Fig. 4.11, top
panels, bottom rows). Nucleoli became largely depleted, and almost the entire enzyme pool
concentrated at distinct sites in the nucleoplasm, forming there a granular pattern. FRAP-
analysis revealed that topo II was clearly much less mobile at these granular nucleoplasmic
sites. Notably, immobilization was less pronounced for topo IIβ, which still exhibited a slight
ascension of the recovery curve, whereas topo IIα did not. This is in good agreement with
previous pharmacological studies, showing that topo IIβ is less sensitive to VM 26 (Drake et
al., 1989). In comparison, the small amount of topo IIα and IIβ remaining inside the nucleoli
Results 61
after VM 26 treatment retained a much higher mobility and, here again, topo IIβ was more
mobile (less affected by VM 26) than topo IIα. These data demonstrate for the first time
directly that the vast majority of topo IIα and topo IIβ molecules present in a living cell
becomes indeed trapped by VM 26 in its covalently DNA-bound intermediate state, which
must be relieving for oncologists, relying on this mechanism of action for tumour therapy.
These findings also suggest that nuclear sites where topo II normally accumulates (Fig. 4.6)
do not necessarily represent sites where the enzymes are most actively engaged in DNA-
catalysis. This is most evident in nucleoli where topo II concentration is highest (Fig. 4.6),
enzyme mobility is lowest (Fig. 4.11, untreated cells), but entrapment by VM 26 is least
efficient (Fig. 4.11, VM 26-treated cells).
It should be mentioned that we do not know if VM 26 gains equal access to nucleolar
DNA and to nucleoplasmic DNA. However, it is known that VM 26 induces double stranded
cleavage of rDNA inside the nucleoli (Govoni et al., 1995). Based on the assumption that VM
26 indeed has equal access to both compartments, we conclude that interactions with genomic
DNA do not constitute the major determinant of topo II localization or mobility in interphase
cells.
4.2.9 Topoisomerase II is Freely Moving Between Interphase Compartments.
Although the results in Fig 4.11 clearly demonstrate that topo II is highly mobile
within each nuclear compartment (full recovery in nucleoli and nucleoplasm), they do not
directly prove that topo II is moving between nuclear compartments in an unrestricted
manner. The way to address this question is to bleach an area inside one nuclear compartment
and to measure the fluorescence recovery in the bleached compartment (FRAP) and the loss
of fluorescence in a second nuclear compartment (fluorescence loss in photobleaching,
(FLIP)). In the case of free traffic between compartments the relative loss in intensity should
be the same for the bleached and unbleached compartment after full recovery of the bleached
compartment. The results of such a combined FRAP/FLIP analysis are shown in Fig. 4.12.
First, an entire nucleolus was bleached in a circular area (Ø = 3 µm). Subsequently, we
recorded by sequential imaging scans the fluorescence recovery of the bleached nucleolus and
the loss of signal intensity in an unbleached nucleolus and in a nucleoplasmic area of the same
cell. To enable a comparison of fluorescence recovery in the bleached nucleolus (FRAP) and
of fluorescence loss in the selected reference areas (FLIP), quantitative data were plotted
without the usual correction for overall loss of fluorescence due to the bleach pulse, giving
rise to the slightly unusual drawings shown in Fig. 4.12. The plots for topo IIα-GFP (Fig.
4.12, top) and topo IIβ-GFP (Fig. 4.12, middle) show that in both cases the fluorescence of
the bleached nucleolus recovered at the expense of the two neighbouring areas, which
decreased by the same rate. The three curves rapidly reached equilibrium, and the equilibrium
values were virtually the same, indicating that the mean fluorescence intensity of nucleoli,
having completely recovered from bleaching, was identical to unbleached ones, having lost a
corresponding amount of fluorescence over time. Moreover, unbleached nucleoli were
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F i g u r e  4 . 1 2 :  Exchange between
nucleoplasmic and nucleolar topo II-GFP.
Cells expressing GFP chimera of topo IIα, IIβ,
and histone H3, respectively, were bleached
and analyzed as in Fig. 5 with two exceptions:
(i) A larger area (3 µm diameter; white circle)
was bleached to achieve a substantial loss of
total cellular fluorescence. (ii) The relative
recovery over time in the bleach spot and the
relative loss of fluorescence intensity in
unbleached areas (black and white circles) is
plotted below each image panel. Plotted data
were not corrected for the overall loss of
fluorescence induced by the bleach pulse (~20
%), to allow a quantitative comparison of signal
loss in unbleached areas with signal gain in the
bleached area. For greater clarity, only every
tenth data point is marked by a symbol. Figure
adapted from (Christensen et al., 2002b).
subjected to the same percentage loss of fluorescence intensity as the nucleoplasm. These data
are in striking contrast to those obtained with the largely immobile GFP-histone H3 (Fig.
4.12, bottom), where fluorescence recovery in the bleach spot and fluorescence loss in the
neighbourhood did not converge.
Thus, bleached topo II molecules (from the bleach spot) and unbleached ones (from
the selected neighbouring areas) mixed completely within the time frame of the experiment,
indicating that all of them could freely move between their respective nuclear compartments.
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Figure 4.13: FLIP analysis of interphase topo II-
GFP. Nucleoli of cells expressing topo IIα-GFP or
topo IIβ-GFP were repeatedly bleached in a circular
area (3 µm diameter; white circles). Cells were
imaged before each new bleach pulse, and
fluorescence intensities of neighboring nucleoli and
nucleoplasmic areas (black and white circles) were
determined. Almost all fluorescence was lost from
both compartments after 50 bleach cycles, indicating
an absence of an immobile fraction. Figure adapted
from (Christensen et al., 2002b).
4.2.10 Immobile Fractions of Topoisomerase II do not Exist in Interphase Cells
Topo II has been suggested to be involved in building the so-called interphase nuclear
matrix, an insoluble nuclear structure believed to play an architectural role in the interphase
cell nucleus (Berrios et al., 1985). If topo II indeed is a component of such an immobile
structure, at least a subfraction of the enzyme should be immobile, too. We have shown by
FRAP that topo II is highly mobile. However on the basis of these data, we could not exclude
the existence of an immobile fraction of topo II, since a small, immobile fraction could have
been obscured by a much larger, mobile fraction. To exclude this possibility, we carried out
conventional FLIP analysis (White and Stelzer, 1999).
Nucleoli labelled by topo IIα-GFP (top) or topo IIβ-GFP (bottom) were repeatedly
bleached. It is readily apparent from time lapsed images (Fig. 4.13, top panels) and
quantitative plots of loss of fluorescence (Fig. 4.13, bottom panels) that all topo II-GFP
fluorescence was lost from the nucleoplasm as well as from other nucleoli, indicating that all
fluorescent topo II molecules were eventually hit by a bleach pulse and therefore must be
mobile.
In summary, all these data (Fig 4.11-13) support the conclusion of a rapid and
unrestricted exchange of fluorescent topo II molecules between individual nucleoli, and
between the nucleoplasm and nucleoli. This interpretation is more in agreement with a recent
concept proposing rapid and continuous diffusional movement of proteins between
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Figure 4.14: F R A P experiments on mitotic
chromosomes FRAP (as described in Fig. 5) of
metaphase chromosomes in cells expressing GFP
chimera of topo IIα (with and without 100 µM VM 26),
topo IIβ (VM 26-treated) or histone H3 after bleaching
a circular area of 3 µm diameter. Bleaching of topo
IIβ-GFP-labeled chromosomes not treated with VM
26 was not possible since they were obscured by
large amounts of cytosolic topo IIβ-GFP (see Figs. 3
and 4 B). Figure adapted from (Christensen et al.,
2002b).
nucleoplasm and nuclear compartments (Misteli, 2001) than with the older idea of topo II
existing in separate cellular pools (Swedlow et al., 1993).
4.2.11 Mobility of Topo IIα at Mitosis
The unrestricted mobility of topo IIα and IIβ observed in interphase nuclei makes it
unlikely that the enzymes play a structural role in building an interphase karyoskeleton.
However, it is still possible that they participate in building the mitotic chromosome scaffold,
which is the major structural role proposed for these enzymes (Adachi et al., 1991). To
address this issue, we determined the mobility of topo IIα in chromosomes, using the same
experimental strategy as in interphase cells (Fig. 4.14). These experiments were restricted to
the α-isozyme, because chromosomal and cytosolic locations of topo IIβ-GFP could not be
reliably discriminated (comp. Fig. 4.9) making mobility studies impossible.
Unexpectedly, fluorescence recovery of topo IIα-GFP (Fig. 4.14, upper panel) after
photobleaching of a chromosomal area in a metaphase plate was fast (t1/2 = 3.5 s) and
complete. We obtained similar recovery kinetics with chromosomes of cells in pro-, ana- or
telophase (data not shown). Moreover, the FLIP experiment shown in Fig. 4.15 demonstrates
that all topo IIα-GFP fluorescence was lost from chromosomes and the cytoplasm of a given
cell, when repeated bleach pulses were applied to a distinct chromosomal area. Comparable
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Figure 4.15: FLIP analysis of mitotic topo IIα-GFP.
FLIP as described in Fig. 4.13 of a chromosomal and a
cytoplasmic region (black and white circles) after
bleaching of another chromosomal area (white circle) in
a metaphase cell expressing topo IIα-GFP. Figure
adapted from (Christensen et al., 2002b).
results were obtained when the cytosol was repeatedly bleached (not shown). In summary,
these data indicate that topo IIα is mobile within the chromosome. An immobile fraction is
virtually absent. The FLIP experiment (Fig. 4.15) also demonstrates unrestricted movements
of the enzyme between chromosomes and the cytoplasm. To corroborate these controversial
findings, we needed to prove that we would have detected an immobile fraction, if present.
This was achieved in two ways. Firstly, we demonstrated immobility of GFP-histone H3 in
mitotic chromosomes (Fig. 4.14, bottom panel). Secondly, we demonstrated immobility of
topo IIα-GFP and topo IIβ-GFP trapped on chromosomal DNA by VM 26 (Fig. 4.14, middle
panels). Both control experiments attest to the validity of our data regarding the unexpected
degree of mobility of chromosomal topo IIα in the absence of VM 26.
 In summary, we show that topo II α is as mobile in mitotic cells as at interphase, thus
excluding that it could be part of an immobile chromosomal scaffold.
4.2.12 Axial Localization of Topoisomerase II in Chromosomes?
Our data obviously conflict with the established view that topo IIα plays a structural
role in building a static chromosome scaffold. This view stems in part from observations
made by indirect immunofluorescence microscopy, demonstrating topo II along the
longitudinal axes of chromosome arms (e.g. (Meyer et al., 1997; Sumner, 1996; Taagepera et
al., 1993)). However, such axial patterns were not seen when rhodamine-labeled topo II was
injected into living insect cells (Swedlow et al., 1993), and were not consistently seen with
immunofluorescence microscopy (summarized in (Warburton and Earnshaw, 1997)). In the
immunohistochemical experiments, a variety of reagents were used to swell the chromosomes
and/or extract chromosomal proteins prior to fixation and immunostaining. It is quite possible
that the extraction and swelling methods had numerous side effects both on chromosome
structure and the protein composition as compared to native cellular chromosomes. The
experimental system presented here, allows to monitor what actually happens to topo II
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Figure 4.16: Chromosomal distribution of topo IIα.
Single chromosomes in living metaphase cells
expressing topo IIα-GFP or GFP-histone H3 were
imaged by high resolution confocal microscopy (left).
Distribution of fluorescence intensity was quantified in
the boxed cross sections of the chromosomes. Mean
fluorescence intensity of pixel columns across the
short diameter of the boxes was normalized to
maximal values, and plotted against corresponding
distances measured across the long diameter of the
boxes (right). Figure adapted from (Christensen et
al., 2002b).
during chromosome spreading. Thus we were able to address the long-standing and
controversial question about the axial localization of topo II in a finite manner.
The first objective was to determine the subchromosomal distribution of GFP-tagged
topo IIα in living cells. Histone H3 is an integral part of the chromatin and can hence be
assumed to cover the entire chromosome. It is therefore possible to determine the width of a
chromosome by highly resolved confocal images of histone H3-GFP, instead of staining the
DNA (e.g. with DAPI), as normally done in fixed specimen. Fig. 4.16 shows comparable
images of topo IIα-GFP and GFP-histone H3 in single chromosomes of living cells (left).
Topo IIα and histone H3 appeared to have a similar distribution, without any apparent axial
enhancement. This was confirmed by a quantitative analysis of the distribution of
fluorescence intensity in representative cross sections of the chromosomes (boxes). It shows
that both proteins covered a similar chromosome diameter of 0,8 – 1 µm, and had a similar
distribution (right). These data suggest that, in living cells, topo IIα is not confined to
chromosome axes.
Our next step was to investigate how topo II-GFP responds to hypotonic treatment,
usually the first step in preparation of chromosomes. We exposed cells at metaphase to
hypotonic swelling, while they were under the microscope. Thus, we could monitor the
effects of the procedure on topo in the cell. Swelling was performed with 75 mM KCl for 2
min, which is a standard procedure for preparing chromosomal spreads. Fig. 4.17 A shows the
result of such an experiment with cells expressing topo IIα-GFP (left) or topo IIβ-GFP (right).
As expected the cells increased in volume (Fig. 4.17 A, top, compare 0 and 2 min).
Unexpectedly, the metaphase plate was completely disrupted by the treatment and, most
notably, the entire cellular complement of topo IIα and IIβ became associated with the
chromosomes (Fig. 4.17 A, bottom, compare 0 and 2 min). This redistribution closely
resembles the effect of VM 26 (comp. Fig. 4.10), suggesting that hypotonic treatment disrupts
the catalytic cycle of topo II in such a way that all enzyme molecules are rapidly (within 2
min) trapped in the DNA-bound state. In this context it is worth mentioning that in vitro DNA
binding of topo II is also favoured by lowering the salt concentration.
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Figure 4.17: (A) Effect of hypotonic treatment on
topo II distribution in metaphase. Two cells
expressing topo IIα-GFP or topo IIβ -GFP were
imaged by confocal microscopy before (0 min) and 2
min after exchanging the medium for KCl solution (75
mM). Images of transmitted light are shown above a
corresponding confocal section showing green
fluorescence of the same cell. Note the substantial
increase in size of KCl-treated cel ls.
(B) Subchromosomal distribution and stability of
topo II isoforms in unfixed, spread chromosomes.
Cells expressing topo IIα-GFP or topo IIβ-GFP were
harvested, collected by centrifugation, swollen in
hypotonic solution, and spotted on glass slides
without fixation. Spread chromosomes were mounted
in DAPI-containing CSK-buffer and imaged either
immediately (upper panel) or 2 h later (lower panel).
Arrowheads mark the position of centromer pairs.
Figure adapted from (Christensen et al., 2002b).
To investigate the distribution of topo II in spread chromosomes, we employed a
method to generate spreads of minimally processed, native chromosomes, omitting fixation
methods. Cells were swollen in hypotonic solution, spotted on microscope glass slides, and
spread chromosomes were then washed and mounted in an isotonic “cytoskeleton” buffer.
When such native chromosomes were inspected immediately after spreading (Fig. 4.17 B, top
panel), both GFP-tagged topo II isoforms (GFP) appeared to be distributed over the whole
length and width of the chromosome arms as defined by the DNA stain (DAPI). However,
distribution was not homogeneous any more. Topo IIα-GFP and IIβ-GFP were now
concentrated in a central part of the chromosomes (most evident for topo IIα-GFP), although
they were not altogether excluded from the chromosomal periphery. This demonstrates that
spreading of chromosomes in some cases may induce an apparent axial localization of topo II.
It should also be noted, that chromosome spreading enhanced accumulation of topo IIα at the
centromers (arrows), whereas this was less evident for topo IIβ-GFP.
When the same specimen were inspected after incubation at ambient temperature for 2
h (Fig. 4.17 B, bottom), the overall intensity of topo II-GFP-specific signals decreased and the
pattern changed. Both isoforms were now clearly confined to the central axis of chromosome
arms, delineating a structured helical pattern that closely resembled numerous published
immunohistochemical images. In addition, centromeric accumulation became also evident
with topo IIβ-GFP.
In summary, these observations demonstrate that the localization of topo II in
chromosome spreads differs notably from the situation in living cells. Apparently, hypotonic
treatment of cells and spreading of chromosomes triggers a series of events eventually
generating an axial pattern of topo II: First, the whole complement of the enzymes relocates
Results 68
rapidly from the cytosol to the chromosomes. Then, a loosely bound fraction of topo II is
gradually lost over time from the outer region of the chromosome arms. This unveils another
fraction bound to the centromer and the chromosomal core in a more stable manner. We
envisage that during immunohistochemical staining procedures topo II can easily be lost from
the chromosomal periphery, thus leading to the impression that it is confined to the
chromosome axis. This would also explain why in some cases both patterns – accumulation in
the axes and homogeneous distribution over the whole chromosome arms – have been
detected within the same sample (Sumner, 1996).
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Figure 4.18: Expression and immuno-band
depletion of GFP-topo I and GFP-topo I723Phe in
HEK 293 cells. Immunoblotting of 293 cells not
transfected (lanes 1 and 2), expressing GFP-
topo I (lanes 3 and 4), or expressing GFP-
topo IPhe723 (lanes 5 and 6). Blots were probed
with antibodies against GFP (top) or human topo
I (bottom). The positions of GFP-linked and
endogenous topo I are indicated on the right
margin. Cells in lanes 2, 4, and 6 were cultured
with CpT (20 mM, 20 min) prior to analysis.
Figure adapted from (Christensen et al., 2002a).
4.3 Cellular Localization and Mobility of Human DNA
Topoisomerase I
We transfected 293 cells with pMC-EGFPP-N, pMC-EGFP-TIP and pMC-EGFP-
TITyr723PheP, bearing in the first cistron GFP alone or hybrid genes of topo I or topo I723Phe fused
at their N-termini to GFP, and in the second cistron the selection marker pac. Stable cell lines
expressing either GFP alone, GFP-topo I or GFP-topo I723Phe were then generated by selection
of the transfected cells in the presence of 0.35 µg/ml puromycin. The three cell lines were
maintained as mixed populations and not separated into individual clones. Less puromycin-
resistant cell clones emerged from transfection with GFP-topo I than from transfection with
the GFP gene alone, although the difference was smaller than for topo II. Cell lines supporting
constitutive expression of GFP-topo I or GFP-topo I723Phe had growth rates and morphologies
identical to untransfected cells or cells expressing GFP alone. This suggested a quasi
physiological expression of the GFP-tagged topo I suitable for fluorescence studies in living
cells, provided that the fusion proteins were active and colocalized with their endogenous
counterparts. Control experiments addressing these issues are addressed in the two following
sections.
4.3.1 Expression of Active GFP-Topoisomerase I in 293 Cell
To determine expression levels, we performed western blots of cell lines expressing
GFP-topo I (Fig. 4.18, lane 3) or GFP-topo I723Phe (Fig. 4.18, lane 5). Untransfected cells (Fig.
4.18, lane 1) served as control. When these western blots were probed with GFP-antibodies
(Fig. 4.18, top), GFP-topo I, and GFP-topo I723Phe were readily detected in transfected cells as
single protein bands (lanes 3 and 5, respectively) not apparent in untransfected cells (lane 1),
or cells expressing GFP alone (data not shown). Thus, rearrangements of the chimeric gene
could be excluded and green fluorescence in the cell lines could be unambiguously assigned
to full-length GFP-topo I, or GFP-topo I723Phe. The expression level of GFP-topo I was
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Fig 4.19: Camptothecin dose response. Cells
expressing GFP-topo I were cultured for 20 min
with various concentrations of camptothecin and
subjected to immunoblotting with antibodies
against topo I. Figure adapted from (Christensen
et al., 2002a).
approximately 2 fold higher than that of GFP-topo I723Phe.
When western blots were probed with topo I antibodies (Fig. 4.18, bottom), topo I
chimeras appeared as additional bands of slower migration (lanes 3 and 5). In untransfected
293 cells the additional band was absent (lane 1). In transfected cells, GFP-topo I had a
similar intensity as endogenous topo I (lane 3), whereas the GFP-topo I723Phe were less
expressed than endogenous topo I (lane 5). It is interesting to note that expression of GFP-
topo I was accommodated by a slight reduction in expression of endogenous topo I (Fig. 4.18
A, bottom, lane 3). Thus, the GFP-tagged species was not overexpressed and the overall
expression of topo I was apparently the same as in untransfected cells.
The activity of GFP-topo I was tested by immuno-band depletion (Liu, 1989). Before
immunoblotting, cells were treated with camptothecin (CpT) which stabilizes covalent
DNA·topo I intermediates inherent in the enzyme’s catalytic cycle. Since these intermediates
are too large to enter the gel, the active fraction of the enzyme becomes depleted from the
blots. Apparently, CpT caused an effective depletion of both endogenous and GFP-linked
topo I within the same cell sample (Fig. 4.18, lower panel, compare lanes 3 and 4). In the case
of cells expressing the active site mutant GFP-topo Iphe723 only endogenous topo I was
depleted, whereas GFP-topo Iphe723 was unaffected (compare lanes 5 and 6). Finally, to
ascertain that GFP-topo I possessed the same specific activity as its endogenous counterpart,
we investigated the dose response to camptothecin. Fig. 4.19 shows that it was similar for
GFP-tagged and endogenous topo I.
In summary these data demonstrate that we achieved expression of full length GFP-
topo I and GFP-topo Iphe723. GFP-topo I has the same activity as endogenous topo I whereas
the active site mutant GFP-topo Iphe723 is catalytically inactive.
4.3.2 Colocalization of Biofluorescent and Endogenous Topoisomerase I
Considering finally that fusion to GFP might disrupt the cellular targeting of topo I,
we performed indirect immunofluorescence (same rational as for topo II, see section 4.2.3).
Fig. 4.20 shows a typical outcome of such an experiment, where untransfected cells (left
double column) and cells expressing GFP-topo I (right double column) were stained with topo
I specific antibodies, and the fluorescent patterns obtained with GFP-antibodies (top), topo I-
antibodies (middle), and DAPI (bottom) are compared within individual cells. Untransfected
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Figure 4.20: Colocalization of GFP-topo I
with endogenous topo I. Untransfected
293 cells (left double column) and GFP-
topo I (right double column) were grown on
mic roscop ic  s l i des ,  PFA- f i xed ,
permeabilized, and double stained with
topo I-antibodies ( m i d d l e ) and DAPI
(b o t t o m ).  The top row shows
corresponding images of GFP fluorescence
(G F P ). Each double column shows
representative cells in interphase (left) and
pro-/metaphase (right). Figure adapted
from (Christensen et al., 2002a).
Figure 4.21: Distribution of GFP-topo I and
GFP-topo I723Phe in interphase nuclei.
Phase-contrast  images ( top) and
corresponding green fluorescence (bottom)
of living 293 cells expressing GFP-topo I
(left) and GFP-topo I723Phe (right). The insert
shows image of nucleoli subjected to contrast
enhancement.
cells gave rise to antibody-derived signals only, whereas cells expressing GFP-topo I also
emitted GFP fluorescence. The patterns of GFP fluorescence and immunofluorescence were
virtually the same, confirming colocalization of the GFP-signal with endogenous topo I.
Moreover, immunostaining patterns of untransfected and transfected cells were similar (Fig.
4.20, compare left and right) excluding that transgenic expression of GFP-topo I disrupted
localization of the endogenous enzyme. Thus, the transgenic cell lines had fully integrated the
GFP-chimera into their cellular pool of topo I and could be used to study the behaviour of the
enzyme.
4.3.3 Distribution of Topoisomerase I in the Interphase Nucleus
Fig. 4.21 shows interphase nuclei of cells expressing GFP-topo I, or GFP-topo I723Phe.
Both enzymes were exclusively located in the nucleus and resided in the nucleoplasm and the
nucleoli. Normal topo I accumulated in the nucleoli, whereas the active site mutant did not.
Moreover, the nucleoplasmic pattern of normal topo I appeared to be more homogeneous that
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Fig 4.22: Colocalization of
GFP-Topo I with RNA
polymerase I. GFP-Topo I
expressing cells were grown
on microscope slides, PFA-
fixed, permeabelized, and
doublestained with specific
RNA polymerase I antibody
(middle), and DAPI (right). Left
image shows corresponding GFP fluorescence (GFP-Topo I). The inserts show images of nucleoli
subjected to contrast enhancement.
that of the active site mutant. These differences will later be explained by differences in
mobility between GFP-topo I and GFP-topo I723Phe (refer to section 4.3.7).
4.3.4 Topoisomerase I Accumulates at the Fibrillar Centers of the Nucleolus
The most distinct feature of normal GFP-topo I was its nucleolar accumulation and,
more precisely, its accumulation in small globular substructures inside the nucleoli (Fig 4.21,
insert). Since topo IIα-GFP and IIβ-GFP were excluded from similar nucleolar substructures
(compare insert, figs. 4.6 and 4.21), might be that diverse nucleolar functions of type I and
type II topoisomerases correlate to the association with different nucleolar subcompartments.
Currently, three structurally distinguishable constituents of the nucleolus are described: the
fibrillar centers (FC), the dense fibrillar component (DFC), and the granular component (GC).
A model, though not shared by all investigators, proposes that the FC contains rDNA, RNA
polymerase I, and associated transcription factors, and that transcription of rDNA occurs
mostly at the boundary between the FC and DFC (rewired in (Lamond and Earnshaw, 1998;
Shaw and Jordan, 1995)). Taking into account the undisputed role of topo I in rDNA-
transcription (Muller et al., 1985), it seems feasible to assume that the substructure, at which
topo I accumulates inside nucleoli, might be the FC.
To follow up on this hypothesis, we counterstained cells expressing GFP-topo I with
antibodies against RNA polymerase I, which delineates the FC of mammalian nucleoli
(Gilbert et al., 1995; Scheer and Rose, 1984). As shown in Fig. 4.22, a similar nucleolar
substructure was delineated by antibodies against RNA polymerase I (middle) and by the
fluorescence of GFP-topo I (left). High-resolution images of single nucleoli (insert) show that
the two signals indeed colocalized. It should furthermore be noted that these images obtained
in fixed cells faithfully reflected the in vivo-situation, because the fluorescent pattern of topo
I-GFP was similar in the nucleoli of fixed and living cells (compare Fig. 4.22, left with Fig.
4.21, bottom, insert). Thus, it can be concluded that in a living cell nucleus topo I accumulates
in the fibrillar centers of the nucleolus. This structure is actually the most distinct working
place of the enzyme at interphase.
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Figure 4.23: Time-lapsed imaging of a GFP-topo I expressing cell proceeding from late G2- to
early G1-Phase. Cells expressing GFP-topo I were cultured at 37 °C under an inverted
epifluorescence microscope. A cell in late G2-Phase was selected and imaged at the indicated time
points by phase contrast (top) and green fluorescence (bottom) until it reached G1-phase. Figure
adapted from (Christensen et al., 2002a).
4.3.5 Topoisomerase I is Chromosome-Associated throughout Mitosis
Fig. 4.23 shows time lapsed epifluorescence microscopy of a cell expressing GFP-topo
I, as it goes through mitosis. Monitoring begins in late G2-phase/early prophase (0 min),
where GFP-topo I was concentrated still in the nucleoli. As the cell moved into prophase (4
min), nucleoli disappeared and a granular fluorescent pattern emerged indicating association
of GFP-topo I with the condensing chromatin from early on. The enzyme stayed chromosome
bound until telophase (12 – 48 min). Finally, during G1-phase (77 min – 3 h) it accumulated
again in the reforming nucleoli and was otherwise distributed in the nucleoplasm in a uniform
manner.
Clearly GFP-topo I was closely associated with chromosomes throughout the mitotic
cell division. We did not observe an accumualtion of topo I at the centromeric regions, at any
time of the mitotic cycle. This is in clear contrast to topo II and again emphasizes the specific
function of the type II enzyme at the centromers. It should also be noted that the active site
mutant was also closely associated with mitotic chromosomes (not shown), although it is
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Figure 4.24: FRAP analysis of living
cells expressing GFP-topoiso-
merase I. Circular areas (Ø = 2 µm) of
the nucleoplasm (top) or a nucleolus
(bot tom ) of interphase nuclei were
bleached. Consecutive images at 1.6 s
time intervals were taken before and at
the indicated time points after the bleach
pulse. Areas to be bleached are in-
dicated by a circle in the pre-bleach
panels. Corresponding quantitative data
of FRAP kinetics are plotted below.
Fluorescence intensities in the bleached
nucleoplasmic () or nucleolar
() region were measured  and expressed as the relative recovery over time after the bleach pulse
(at 0 s). Mean values from at least 6 individual cells and 3 independent experiments are shown.
Standard deviations were in each case less than 5 % of the mean values (not displayed). Hatched
lines represent the results of nonlinear regression analyses of the data. The insert shows FRAP
kinetics obtained with cells expressing unfused GFP (), or GFP-histone H3 (). Figure adapted
from (Christensen et al., 2002a).
catalytically inactive. This finding is consistent with biochemical data showing that the active
site mutant possesses DNA binding properties similar to those of the wild type enzyme
(Madden et al., 1995). Thus, GFP-topo I and GFP-topo Iphe723 had the same localization in
mitotic cells, but a different one in the interphase nuclei.
4.3.6 Mobility of Topo I in Interphase
The mobility of topo I in the living cell nucleus was studied by photobleaching. To
determine FRAP kinetics, cells expressing GFP-topo I were cultured under a confocal laser
scanning microscope and GFP-fluorescence was irreversibly bleached by high-powered laser
pulses in circular areas of the nucleoplasm or the nucleoli, respectively (Fig 4.24).
Subsequently, fluorescence recovery in the bleached spots as a consequence of other GFP-
topo I molecules moving in from unbleached areas was recorded over time by sequential
imaging scans (Fig. 4.24). As a control for a freely diffusible protein we used cells expressing
GFP alone, which exhibited FRAP kinetics too fast for recording with our experimental
settings (Fig. 4.24, insert). As a control for immobile proteins we used cells expressing GFP-
histone H3 (Fig. 4.24, insert) known to be firmly chromatin-bound (Kimura and Cook, 2001).
FRAP of GFP-topo I was complete after 30 s in nucleoplasm and nucleoli, indicating that the
enzyme is entirely mobile in both compartments (as opposed to histone H3). However, GFP-
topo I was clearly much slower than GFP alone, suggesting that the enzyme is not freely
diffusible. Moreover, fluorescence recovery of GFP-topo I in the nucleoli was slower than in
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Figure 4.25: FLIP analysis of cells
expressing GFP-topoisomerase I. A
circular area (Ø = 3 µm; white circle) of a
nucleolus was repeatedly bleached. Cells
were imaged before each new bleach pulse
(selected images are shown in the top).
Fluorescence intensities of neighboring
nucleoli and nucleoplasm (black and white
circles, resp.) were determined, and plotted
below ( , nucleoplasm; , nucleolus).
Figure adapted from (Christensen et al.,
2002a).
the nucleoplasm, demonstrating that the enzyme’s mobility at the two locations was restrained
to a different extent. Nonlinear regression of these data (hatched lines in Fig. 4.24) indicated
with significance (p<0.0001) that in both cases two different mobility states of the fluorescent
enzyme contributed to the apparent FRAP kinetics. A major portion appeared to be moving
fast (t1/2 = 1.1 ± 0.1 s and 1.9 ± 0.2 s for nucleoplasm and nucleoli, resp.), whereas a minor
portion was moving much slower (t1/2 = 14.3 ± 2.3 s and 12.5 ± 1.4 s for nucleoplasm and
nucleoli, resp.). The slow portion amounted to 28 ± 3 % in nucleoli as opposed to only 16 ± 2
% in nucleoplasm. This difference explains, why overall mobility of GFP-topo I in the
nucleoli was about 2-fold less than in the nucleoplasm. Thus GFP-topo I appears to be
moving slow in areas where it is upconcentrated
Rapid fluorescence recovery in nucleoli and nucleoplasm, as observed here with GFP-
topo I, suggests free and unrestricted exchange of the protein between nuclear compartments.
We corroborated this notion by the FLIP approach (White and Stelzer, 1999). These
experiments are summarized in Fig. 4.25. When one nucleolus was repeatedly bleached, all
topo I-linked GFP-fluorescence was eventually lost from other nucleoli of the same nucleus
and also from the surrounding nucleoplasm. Similar results were obtained, when repeated
bleaching was applied to the nucleoplasm (not shown). These data imply that fluorescent topo
I molecules originally localized in both compartments were eventually hit by bleach pulses
aimed to only one of them, thus demonstrating a rapid, continuous, and unrestricted traffic of
all enzyme molecules between individual nucleoli, and between nucleoplasm and nucleoli.
4.3.7 Correlation between Mobility and Localization of Topoisomerase I
The apparent link between localization and mobility of GFP-topo I suggested to us
that the different localization of GFP-topo I and GFP-topo Iphe723 in the interphase nucleus
might also be reflected by a difference in mobility of the two enzyme variants. This notion is
strongly supported by the altered mobility of the active site tyrosine mutant of topo I.
In contrast to the normal enzyme, FRAP-kinetics of GFP-topo Iphe723 were virtually the
same in nucleoli and nucleoplasm (Fig. 4.26, compare circles and open triangles), indicating
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Figure 4.26: The impact of camptothecin
on localization and mobility of GFP-
topo IPhe723. FRAP analysis in nucleoli ()
and in the nucleoplasm () of untreated
cells, and in the nucleoplasm of cells
treated with camptothecin (; 20 µM, 20
min). The insert shows representative
images of an individual cell expressing
GFP-topo IPhe723 before (0 min) and 20 min
after addition of 20 µM camptothecin.
Figure adapted from (Christensen et al.,
2002a).
that the inactive enzyme had the same mobility in both compartments. This may explain, why
it did not accumulate in nucleoli. Interestingly, FRAP-kinetics of topo Iphe723 were in general
slower (t1/2 = 2.5 ± 0.2 s and 22.4 ± 2.2 s for fast and slow subpopulations in both
compartments, resp.) than those of the active enzyme. We can only speculate at the reason for
this phenomenon. Taking into account current concepts of the catalytic cycle of topo I (Fig.
1.17), it can be envisaged that DNA-catalysis (cleavage, strand rotation, religation) somehow
facilitates the subsequent detachment of the enzyme from its DNA binding site. Since both
proteins are able to interact with DNA, but only GFP-topo I performs DNA catalysis, such a
model may explain the different interphase localization and mobility of topo Iphe723.
4.3.8 The Impact of Camptothecin on Topoisomerase I Mobility
In the light of these findings, we were curious how mobility and distribution of topo I
would be influenced by camptothecin, which stabilizes covalent enzyme·DNA complexes. For
this purpose, we cultured cells expressing GFP-topo I under a confocal laser scanning
microscope and added camptothecin to the culture medium, while taking serial confocal scans
every 3.1 seconds (Fig. 4.27 A). The first image (0 s) recorded immediately before adding
camptothecin shows the normal nucleolar accumulation of topo I. Subsequent images
demonstrate a very rapid redistribution of topo I from the nucleoli to the nucleoplasm. After
20 - 30 seconds nucleoli were largely reduced in fluorescence and most of the enzyme was
localized in radial substructures within the nucleoplasm. The time scale of this phenomenon
seemed to be independent of the CpT concentration, since depletion of the nucleoli took place
within the same time frame (30 seconds) when CpT was added at concentrations ranging from
2 to 200µM CpT. Only at the lowest concentration of CpT tested (0,01 µM) we did not
observe any nucleolar depletion, whereas a partial depletion was observed at 0,1 µM and an
almost complete depletion at concentrations of 1µM and higher (not shown). With all
effective concentrations the full effect was achieved within 30 seconds. Thus, mechanisms
acting beyond the time frame of 30 seconds should not play a role in CpT induced nucleolar
depletion of topo I.
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Figure 4.27: The impact of camptothecin
on localization and mobility of GFP-
topoisomerase I. (A)  T ime- lapsed
confocal images of a cell exposed to
camptothecin. Cells expressing GFP-
topoisomerase I were cultured at 37 °C
under the microscope and confocal
midsection scans of green fluorescence
were taken every 3.1 seconds.
Representative images of an individual cell
are shown before (0 s) and at the indicated
time points after addition of 20 µM
camptothecin. The complete sequence can
be viewed in the supplemental QuickTime
movie (TopI/CPT.mov). (B) FRAP analysis
(comp. Fig. 2 B) of GFP-topoisomerase I in
the nucleoplasm of cells exposed to
increasing concentrations of camptothecin
(, control; , 1 µM; , 4 µM; , 20 µM; ,
200 µM). For clarity, data points are
displayed by a connecting line, and only
selected time points are marked by a
symbol. Hatched lines represent the results
of nonlinear regression analyses of the
data. (C) Half times of slow () and
fast () fractions of GFP - topoisomerase I
derived   from  nonlinear regression  of  the
data in (B) are plotted over the log molar concentration of camptothecin. (D) Percentages of slow (),
fast (), and immobile () fractions of GFP-topoisomerase I derived from nonlinear regression of the
data in (B) are plotted over the log molar concentration of camptothecin. (E) Comparative FRAP
analysis of GFP-topoisomerase I in nucleoli ( and ) and nucleoplasm ( and ) of untreated cells
(open symbols) and cells treated with camptothecin (20 mM, 20 min; closed symbols). Data acquisition
and plotting was done as in (B). Figure adapted from (Christensen et al., 2002a).
Although, the cellular distribution of GFP-topo I was equally effected within a broad
range of CpT concentrations, there must be a concentration dependent effect on GFP-topo I
based on the fact that the cellular toxicity of CpT varies greatly within this range. This is also
illustrated by the correlation between extent of immuno band-depletion and CpT
concentration shown in Fig. 4.19. Since CpT stabilizes covalent enzyme DNA complexes, one
would expect a concentration-dependent response in the mobility of GFP-topo I. To test
whether such a relationship exists, we determined FRAP-kinetics in the nucleoplasm of cells
treated for 20 min with various concentrations of camptothecin (Fig. 4.27 B). Evidently,
fluorescence recovery of GFP-topo I became increasingly slower with increasing doses of
CpT administered to the cells.
The existence of two states of different mobility in untreated cells (Fig. 4.24) raised
the question if CpT preferentially targeted one of these states. To investigate this, we
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subjected the recovery curves of GFP-topo I in Fig. 4.27 B to nonlinear regression analysis
(hatched lines). Again the contribution of two different mobility states of the fluorescent
enzyme to each of the curves was significantly (p<0.0001). Upon plotting the half times
against the log molar concentration of CpT (Fig. 4.27 C), it became apparent that the drug
acted preferentially on the slow fraction of topo I (). This fraction was retarded by CpT in a
dose dependent manner, becoming slower and slower as CpT concentration increased. In
contrast, recovery half times of the fast fraction () were not significantly altered by the drug
(Fig. 4.27 C). Upon plotting of the relative proportions (Fig. 4.27 D) of slow (), fast () and
immobile ( ) enzyme fractions against the log molar concentration of CpT, it becomes
apparent that, an increasing proportion of the enzyme was recruited to the slow state, whereas
only an insignificant portion actually became immobile (Fig. 4.27 D, compare  ,  and ).
These findings suggest that CpT recruits GFP-topo I to the slow state, which becomes
increasingly slower as the dose is increased.
A comparison of FRAP-kinetics determined in nucleoli and nucleoplasm of
camptothecin treated cells (Fig. 4.27 E), showed that in the nucleoli topo I was retarded to a
much lesser extent than in the nucleoplasm, suggesting that camptothecin acted preferentially
on topo I in the nucleoplasm. As a consequence, the enzyme was moving much faster in the
nucleolus than in the nucleoplasm of a camptothecin treated cell, whereas in an untreated cell
it was the other way around (Fig. 4.27 C, comp. open and closed symbols). Thus, nucleolar
accumulation and camptothecin- induced nucleolar delocalization of topo I seem to be driven
by differences in mobility.
Support of this notion was gained from the behaviour of the catalytically inactive
mutant topo Iphe723. CpT does not induce covalent GFP-topo Iphe723 DNA complexes (Fig 4.18)
and FRAP-kinetics of GFP-topo Iphe723 were virtually the same with and without camptothecin
(Fig 4.26, compare open and closed triangles), attesting to the fact that mobility of the
inactive enzyme was the same in both compartments and not affected by exposure to CpT at
concentrations as high as 20 µM. Consequently, topo Iphe723 did not delocalize from nucleoli
upon exposure to camptothecin (Fig. 4.26, insert, compare 0 with 20 min). This was also true
for higher CpT concentrations (data not shown). These findings confirm, that catalytically
inactive topo I is not targeted by CpT and that CpT-induced relocations of topo I are a direct
consequence of mobility changes.
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Fig 4.28: Expression of GFP-Topo I, GFP-Topo I-C and GFP-
Topo I-N. Immunoblotting of 293 cells expressing GFP-Topo I
(lane 1), GFP-Topo I-C (lane 2), or GFP-Topo I-N (lane 3).
Blot was probed with antibodies against GFP. The position of
GFP-linked topo I are indicated on the right margin.
4.4 Its Non-conserved N-terminal Domain Anchors Topoisomerase I
at Fibrillar Centers of Nucleoli and Nucleolar Organizer Regions
of Mitotic Chromosomes
The nonconserved N-terminal region of eukaryotic topo I is considered to be
dispensable for catalytic activity in vitro but essential in vivo (Alsner et al., 1992; Stewart et
al., 1996b; Stewart et al., 1998). Until now, the biological role of the N-terminal region (first
210 amino acids) has mainly been credited to 5 putative NLS sequences contained therein
(Alsner et al., 1992). We describe here that this domain plays an essential role in directing
topo I to nucleolar substructures and fixing the enzyme at these structures during the entire
cell-cycle. These data were obtained from 293 cells expressing biofluorescent chimera of (i)
full-length topo I (GFP-TopoI), (ii) the C-terminal domain of human topo I (GFP-TopoI-C:
amino acids 210-765, supplemented with an artificial NLS sequence of SV40 NLS at the N-
terminus), and the N terminal domain (GFP-TopoI-N: amino acids 1-210 from human topo I),
all fused at their N-termini to GFP.
4.4.1 Expression of Chimeras of GFP with N- and C-terminal Domains of
Topoisomerase I
To verify that GFP fusion proteins of expected size were expressed, we subjected
lysates of stably expressing cell lines to immunoblotting. Use of a GFP-specific antibody (Fig
4.28) detected full length GFP-topo I (lane 1), GFP-topo I-C (lane 2) or GFP-Topo I-N (lane
3) as single protein bands of expected size in transfected cells, which were not apparent in
untransfected cells or cells expressing GFP alone (data not shown). Thus, we could exclude
rearrangements of the chimeric genes, and ascertain that green fluorescence of the cells was
due to expression of the intended proteins. Interestingly, the expression level of the two
deletion mutants was higher than that of the full length GFP-topo I.
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Figure 4.29: Distribution
of GFP-topo I, GFP-topo
I-N, and GFP-topo I-C in
interphase nuclei. Phase-
contrast images (top) and
corresponding green
fluorescence (bottom) of
living 293 cells expressing
GFP-topo I (left), GFP-topo
I-N (middle) and GFP-topo
I-C (right). The insert
shows images of nucleoli
subjected to contrast
enhancement.
4.4.2 The N-Terminal Domain Directs Topo I to Fibrillar Centers of Nucleoli
The subcellular distribution of GFP-topo I, GFP-topo I-N and GFP-topo I-C in
interphase cells was examined by fluorescence microscopy. Fig 4.29 shows representative
examples. Apparently, adding an SV40 NLS to the C-terminal domain was sufficient to
achieve a mostly nuclear localization of this domain that does not contain an endogenous NLS
(fig 4.29 right), whereas GFP-topo I (Fig 4.29, left) and GFP-topo I-N (Fig 4.29, middle) were
exclusively located in the nucleus. All three GFP-chimeras showed a similar homogenous
distribution in the nucleoplasm and accumulated in the nucleoli. However, distribution within
the nucleoli differed (Fig 4.29, inserts). As shown above (section 4.3.4) the full-length
enzyme showed an accumulation in the fibrillar centers (FCs) of nucleoli. This feature was
even more pronounced in cells expressing only the N-terminus, whereas the C-terminus did
not accumulate in FCs. Instead, it was evenly distributed through the entire nucleolar space
(Fig 4.29, compare inserts). This suggested that nucleolar accumulation of topo I is a general
phenomenon, whereas the specific recruitment to FCs is mediated by the non-conserved N-
terminal domain. In an attempt to discriminate a defined targeting signal within the N-
terminal domain, we constructed GFP fusions of various smaller fragments of this domain. To
our surprise, none of these fusion proteins accumulated at the FC, when expressed in the cells
(data not shown). Thus, the entire N-terminus seems to be required to direct topo I to FCs.
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Figure 4.30: Distribution
of GFP-topo I, GFP-topo
I-N, and GFP-topo I-C in
metaphase cells. Phase-
contrast images (top) and
corresponding green
fluorescence (bottom) of
living 293 cells expressing
GFP-topo I (left), GFP-topo
I-N (middle) and GFP-topo
I-C (right).
Figure 4.31: GFP-topo I-N is
concentrated in paired dots on
metaphase chromosomes. Ce l ls
expressing GFP-topo I-N were imaged
by confocal microscopy. 6 consecutive
confocal sections (A-F) are shown.
Arrows indicate positions of paired dots,
and such pairs are indicated by numbers
(e.g., 1a and 1b)
4.4.3 On Mitotic Chromosomes, The N-Terminal Domain Allocates
Topoisomerase I to Nucleolar Organizer Regions
Next, we examined the distribution of the N- and C-terminal domains on metaphase
chromosomes (Fig. 4.30). GFP-topo I (Fig 4.30, left) and GFP-topo I-C (Fig 4.30, right) were
closely associated with metaphase chromosomes. This was expected since the C-terminus
contains the core domain responsible for DNA binding of topo I (Madden et al., 1995). In
contrast, large parts of GFP-topo I-N (Fig 4.30, middle) resided in the mitotic cytoplasm.
However, the protein was not entirely excluded from the condensed mitotic chromosomes,
and we consistently observed small globular aggregations of this domain within in the
metaphase planes. This observation was a puzzling finding, because the N-terminus is not
considered to be involved in DNA-interactions.
To obtain a more detailed picture of the distribution of the N-terminus of topo I in
chromosomes, we performed high-resolution confocal microscopy of a metaphase cell
expressing GFP-topo I-N. Fig 4.31. shows 6 consecutive confocal planes of such a cell (A-F).
It is apparent, that the metaphase plane itself has the same fluorescence intensity as the
surrounding cytosol, indicating again that GFP-topo I-N is not excluded from the mitotic
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Fig 4.32: Confocal time-
lapsed imaging of a GFP-
topo I-N-expressing cell
proceeding from meta- to
early G1-Phase. Cells
expressing GFP-topo I-N
were cultured at 37 °C
under the microscope. A
cell in metaphase was
selected and confocal
sections were obtained at
the indicated time points
until it reached G1-phase.
4 selected confocal
sections are shown for
e a c h  t i m e  p o i n t .
Arrowheads indicate areas
of increased fluorescence.
For clarity arrows from
ana- (12’) until telophase
(31’) are only shown for
the left daughter cell.
Reforming nucleoli in G1-
phase (36’-45’)  are
indicated by arrowheads.
chromosomes. Moreover, intense speckles could clearly be detected within the metaphase
plate (Fig. 4.31, arrows), and it appeared as if these dots were paired (Fig. 4.31, numbered
arrows). This is most apparent for the dots 3a and 3b (Fig. 4.31, compare panels B, C, and D).
This pairing of GFP-topo I-N labelled dots suggested that they might be attached to
related structures of sister chromatids. If the latter was the case, each pair of dots should be
separated in anaphase and equally distributed into the two daughter cells. This hypothesis was
tested by acquisition of confocal images of a cell expressing GFP-topo I-N as it proceeds
under the microscope from meta- (0 min) to early G1-phase (45 min) (fig 4.32). For each time
point four corresponding confocal sections are shown (rows). In metaphase (Fig 4.32, 0 min)
paired dots were clearly detectable. However, as the cell proceeded to anaphase (12-17 min)
the dots were separated and distributed into the two daughter plates (Fig 4.32, see arrows in
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Fig 4.33: Colocalization of GFP-Topo I-N with RNA
polymerasee I. GFP-Topo I-N expressing cells were
grown on microscope slides, PFA-fixed, permeabilzed,
and doublestained with specific RNA polymerase I
antibody (middle) and DAPI (right). Top image show
corresponding GFP fluorescence (GFP-Topo I-N).
left daughter cell). The total number of dots appeared to be the same in the two anaphase
plates. These observations are consistent with an association of the dots with corresponding
structures of sister chromatids. In early telophase, the entire population of GFP-topo I-N
rapidly relocated to the reforming nucleus (19 min). As the cells further proceeded into
telophase, the dots increased in size and intensity and moved into close vicinity of each other
(19-31 min). In late telophase / early G1 phase, they finally converged to a single larger
structure (Fig 4.32, 36-45 min, arrowheads), which in transmitted light could be identified as
the nucleoli (not shown).
In summary, these data (Fig 4.31 and 4.32) indicate that the N-terminus plays a role in
directing topo I to defined sites of metaphase chromosomes, of which there exists a limited
number (less than one per chromosome). Since at interphase topo I is heavily involved in
rDNA transcription and prominently located in FCs (Fig 4.22), we speculated that the distinct
chromosomal accumulation of the enzyme might also be related to rDNA, a view supported
by the observation that these structures merged with pre-nucleolar bodies and nucleoli in early
G1.
During mitosis, the major ribosomal genes in humans are located in five chromosomal
locations called nucleolar organizer regions (NOR) (Mikelsaar et al., 1977a; Mikelsaar et al.,
1977b). In interphase, the NORs are located in nucleolar FCs and are bound to the machinery
for rRNA-transcription (i.e. polymerase I and UBF). It has been suggested that during cell
division most of these components remain associated with NORs, thus forming defined
protein attachment sites on condensed chromosomes (Chan et al., 1991; Scheer and Rose,
1984). Earlier immunohistochemical observations suggested that topo I resides at NORs of
mitotic chromosomes (Suja et al., 1997). The data in Figs. 4.31 and 4.32 suggest that topo I
indeed was bound to such NORs in vivo and that this binding (like the association of the
enzyme with FCs of interphase nucleoli) is mediated by the N-terminus of the enzyme. This
notion was corroborated by counterstaining against RNA polymerase I, which is an
established marker of NORs. Fig 4.33 shows a cell at anaphase (see DNA stain at bottom)
expressing GFP-topo I-N and labelled with an antibody specific for RNA polymerase I. Upon
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comparing topo I-specific GFP-fluorescence (top) and RNA polymerase I specific
immunofluorescence (middle), it becomes apparent that both proteins colocalize. Thus, we
concluded that the N-terminus directs topo I to NORs and mediates its binding to this
structure throughout the entire cell-cycle. It should be noted that our data add significantly to
previous immunohistochemical data in as much as they show that in a living cell.
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5. Discussion
In this work, an experimental model is presented enabling the study of DNA
topoisomerases in living cells. Thus, we could monitor the localization of these enzymes in
interphase and during the cell-cycle, and we could measure the mobility of topoisomerases at
various locations in the nucleus of a living cell. These investigations allowed us to address
and in some cases clarify several issues regarding the biological functions of mammalian
topoisomerases, which, up to now, have been a subject of intense debate.
Firstly, we could address the question, whether the two isoforms of mammalian topo II
have specific functions, and, if so, what these might be. 
Secondly, we could investigate whether topo IIα and/or topo IIβ are mobile or not, and
thus, whether they are likely to partake in the building of a fixed nuclear matrix/chromosomal
scaffold.
Thirdly, we could address questions regarding the role that topoisomerases I and II
might play in the nucleolus, and the related issue of the association of topo I with the
machinery of rDNA-transcription.
Finally, we could for the first time observe in a direct manner the primary cellular
effects of substances stabilizing covalent catalytic DNA-intermediates of topoisomerases
(topoisomerase poisons). This last issue is of considerable interest to clinical oncology,
because poisons of topo I and II are frequently used in the clinic for tumour chemotherapy.
5.1 Topoisomerase I and II are Entirely Mobile Nuclear Proteins.
5.1.1 Mobility of Topoisomerase I and its Implications
We found that topo I is entirely mobile within the cell nucleus, which is in clear
contradiction to previous speculations of many sorts suggesting a compartmentalization of
several distinct enzyme pools (Danks et al., 1996; Mo et al., 2000b; Mo et al., 2002; Muller et
al., 1985). The enzyme is clearly not compartmentalized in the nucleus of a living cell.
Despite its apparent accumulation in nucleoli, it is in continuous flux between nucleoli and the
nucleoplasm and this finding conforms to a recent concept proposing that nuclear
compartments are generated by a binding equilibrium of entirely mobile proteins (Misteli,
2001). Photobleaching techniques have shown that only a few components of the nucleus are
immobile, i.e. the chromatin itself, chromatin-bound core histones, and structural components
building the nuclear lamina (Moir et al., 2000), whereas most other nuclear proteins move
rapidly throughout the nucleus. Moreover, the components of nuclear compartments, e.g.
nucleoli, seem to be in continuous flux between the compartment and the nucleoplasm
(Misteli, 2001). In keeping with this, we show here that topo I is not restricted to the nucleoli
but imposes as a nucleolar protein, because it is moving more slowly in nucleoli than in the
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nucleoplasm. This concept of a stringent correlation between mobility and localization is
strongly supported by our data obtained with the inactive mutant topo IPhe723, which has the
same mobility in both compartments and is therefore more evenly distributed between them.
A comparison of FRAP kinetics shows that GFP-tagged topo I moves slower than
GFP alone. While movements of GFP are solely governed by free diffusion, topo I is
obviously restricted in its mobility by additional factors. It has been proposed that these must
be less mobile nuclear components (Misteli, 2001). However, the nature of such components
– the chromatin, a putative karyoskeleton, or both - is an unsolved issue (Misteli, 2001;
Shopland and Lawrence, 2000). Such an attenuated mobility is a common feature of many
nuclear proteins that are mobile (Misteli, 2001). However, we show here in addition that in
each nuclear compartment topo I is divided into a slow and a fast fraction. We do not know
whether these fractions are inter-convertible, but the most plausible interpretation is that the
enzyme switches between an off state, where it is more or less freely diffusible (t1/2 = 1 – 2 s),
and an on state, where it’s mobility is about 10-fold reduced (t1/2 = 12 – 14 s). Since topo I is
continuously scanning the entire nuclear space, interactions of the enzyme with processes and
places where its activity is required must implicitly be transient. It stands to reason that such
interactions will involve less mobile nuclear components, such as chromatin, nuclear matrix,
multi protein complexes etc., and, therefore, slow down the enzyme (Misteli, 2001; Shopland
et al., 2001). Thus, the slow fraction (the on state) most likely represents topo I engaged in
processes, whereas the fast fraction (the off state) represents topo I moving between
processes. This interpretation of our data is in good agreement with a “stop-and-go” model
recently suggested for the interaction of histone H1 with chromatin (Hendzel et al., 1999;
Misteli et al., 2000).
5.1.2 Mobility of Topoisomerase II and its Implications
We show here, that the two isoforms of human topo II isoforms also belong to the
class of entirely mobile proteins, and it is reasonable to assume that their distribution between
nucleoli and nucleoplasm is governed by the same principles as that of topo I. As that may be,
it is beyond doubt that the entire pools of the type II enzymes are mobile and exchange
rapidly between nuclear compartments in interphase and between chromosomes and the
cytoplasm in mitosis. This came as a surprise, considering the general opinion on the dual role
of topo II as an enzyme and as a structural protein forming a mitotic scaffold or interphase
nuclear matrix (Adachi et al., 1991; Berrios et al., 1985; Earnshaw et al., 1985; Gasser et al.,
1986). Our observation that at each stage of the cell-cycle bleached areas were rapidly and
completely replenished with fluorescent topo II molecules, makes it unlikely that even a
subpopulation of topo II could be an integral component of immobile structures such as a
putative karyoskeleton or chromosome scaffold. However, we cannot rule out that topo II
transiently associates with such structures. In fact, the colocalization of topo II with the
chromosomal core often reported by others and our own observations on the distribution of
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topo II-GFP in native chromosome spreads even suggests a tight (but dynamic) interaction of
topo II with something like a chromosomal scaffold.
5.2 Topoisomerase I and II at the Nucleolus
During interphase, the most prominent feature of topo I and II is their accumulation in
nucleoli. Closer inspection shows that topo IIα and IIβ  have the same subnucleolar
distribution, whereas topo I is clearly different in this respect. Thus, topo IIα and IIβ seem to
have similar nucleolar functions, whereas a different set of functions is attended to by topo I.
5.2.1 Putative Nucleolar role of Topoisomerases IIα and β
Genetic studies in yeast suggest that type II topoisomerases are required for the
organization of the rDNA genes, as a cofactor of RNA polymerase I, and for the topological
organization of the nucleolar chromatin (Hirano et al., 1989). They are also believed to be
required in the nucleoli to relax DNA supercoils generated during the transcription of rDNA
(Christman et al., 1988). These functions imply that the enzyme must be present at the
nucleolus, a proposal supported by the observation that topo II poisons induce double
stranded cleavage of rDNA (Govoni et al., 1994). While these studies indicate that type II
topoisomerases in general must be present at the nucleolus, they do not answer the question, if
both of the two mammalian isoforms are working there, or just one.
Isoform specific nucleolar functions have been suggested by immunohistochemical
localization studies of mammalian topo IIα and IIβ, proposing that one isoform is present in
nucleoli, whereas the other is not. One study claimed that topo IIβ is the isoform responsible
for organization and regulation of nucleolar rDNA (Zini et al., 1992; Zini et al., 1994).
Another study proposed the opposite (Meyer et al., 1997). Here, we were able to settle the
argument by showing that in a living cell nucleus both isoforms accumulate in the nucleoli.
Actually, they do so to such an extent that both of them impose as mainly nucleolar proteins.
This finding argues against specific functions of topo II isoforms in the nucleoli, a view also
supported by complementation studies in yeast, indicating that both human isoforms can
suppress intra-chromosomal excision recombination of the rDNA locus in yeast, which is a
hall-mark of ∆topo II mutants (Jensen et al., 1996b).
We clearly demonstrate, that fixation and permeabilization of cells in the course of
immunostaining changes the nucleolar localization of topo II (see fig. 4.5). Similar
observations have been made in Drosophila, where topo II was excluded from the nucleoli of
fixed cells (Berrios et al., 1985), whereas the enzyme was present in the nucleoli of living
cells (Swedlow et al., 1993). In the light of these observations it becomes overwhelmingly
plausible that the previous controversy regarding the nucleolar localization of topo II must be
due to artefacts introduced by the immunostaining procedure. Our data and the previous study
of topo II microinjected into drosophila embryos (Swedlow et al., 1993) show that the
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association of topo II with nucleolar structures is quite delicate and can easily perturbed. We
show furthermore, that topo IIα and IIβ are getting depleted from nucleoli upon exposure to
topo II poisons. This indicates that their nucleolar accumulation is not entirely dependent on
DNA-interactions, but rather seems to be effected by an altered mobility due to protein-
protein interactions. Considering, on the other hand, the dense packing of topo IIα and IIβ in
the nucleoli of living cells, and considering that among numerous topo II-interacting proteins
described in the literature, none is a nucleolar protein, it could also be imagined that
polymerization of topo II (Vassetzky et al., 1994) might create a transient, less mobile
structure thus contributing to accumulation of the enzymes in nucleoli. Both mechanisms are
suitable to explain why the association of topo IIα and β with nucleoli is so fragile and easily
perturbed. 
Our data allow some speculations about the biological significance of topo IIα and
topo IIβ at the nucleolus. Firstly, we observed that the enzymes are excluded from small
globular structures inside the nucleoli. We have not yet been able to devise an immunstaining
procedure preserving this pattern in such a way that a comparison with other markers would
be possible. Thus, the identity of the globular structures remains unsolved. However, based on
their appearance, we believe that these globules, from which topo IIα and IIβ are excluded,
are most likely fibrillar centers. This would mean that topo IIα and IIβ  do not play a
prominent role in rDNA-transcription, which is in clear contrast to topo I, as will be discussed
later.
Along this reasoning the question arises of why topo IIα and topo IIβ accumulate in
nucleoli to such an extent that in a living interphase nucleus they impose as proteins that are
almost exclusively based at the nucleolus.
One possible explanation would be that nucleoli serve as storage places for enzyme
molecules that should not be active in the chromatin at a given time. Thus, dosage of topo IIα
and topo IIβ in the extra-nucleolar chromatin might be regulated by nucleolar accumulation
and release. Four considerations add feasibility to this concept: (i) The margin of cellular
tolerance to topo II levels is extremely narrow, making it likely that a cell needs a rapid
mechanism for adapting the level of topo II active in the chromatin. (ii) Nucleolar
accumulation of topo IIα and IIβ seems mainly not to involve catalytic DNA-interactions,
making it likely that this portion of the enzyme is neutral with respect to the genomic DNA.
(iii) Nucleolar and nucleoplasmic pools of the enzyme are rapidly interchanging, and thus
suited for rapid regulational processes. (iv) At any given time, the nucleoli contain more topo
II than can plausibly be required for the organization of the topological organization of the
nucleolar chromatin, which is small in comparison to the entire genome.
On the other hand, our data might indicate that topo IIα and IIβ play some role in
nucleolar structure, which is independent of DNA. Actually, the enzymes could be involved
in the early steps of nucleologenesis. We consistently observed that at late telophase both
isoforms concentrated at multiple light dense structures, which are most likely pre-nucleolar
bodies (Bell et al., 1992), because they converge to nucleoli, as daughter nuclei reform and
cells progress into G1-phase.
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5.2.2 Tight Association of Topoisomerase I with FCs and NORs Throughout
the Cell-cycle.
In the literature, nucleolar localisation of topo I is much less controversial than that of
topo II (Baker et al., 1995; Bharti et al., 1996; Danks et al., 1996; Meyer et al., 1997; Mo et
al., 2000b; Muller et al., 1985; Wadkins et al., 1998). Moreover, genetic studies in yeast show
that the enzyme must have a prominent function in the maintenance and the use of the rRNA-
genes, because rDNA-recombination increases in the absence of topo I (Gangloff et al., 1994).
Therefore, we found it most puzzling that in several recent studies (Mo et al., 2000a; Mo et
al., 2000b; Mo et al., 2002), only 15% of cells transiently expressing GFP-topo I showed
nucleolar accumulation of the biofluorescent enzyme, whereas the rest showed a globular
aggregation in the nucleoplasm and the cytosol. Here, we show clearly that biofluorescent
topo I constitutively expressed at normal levels and in an active form accumulates to a major
part in the nucleoli and does not at all form nucleoplasmic or cytosolic globules. Thus, our
data are in good agreement with the older literature, whereas conflicting observations more
recently made with transient expression, are most probably due to an aberrant cellular
placement of topo I not properly folded, and/or to the observation of cells gone into apoptosis
due to overexpression of the enzyme.
With our more physiological expression system we could even distinguish the
subnucleolar distribution of topo I. We demonstrate that the enzyme is highly accumulated in
the FC-subcompartment of the nucleolus, where it co-localizes with RNA polymerase I
(Gilbert et al., 1995; Scheer and Rose, 1984). Actually, these two proteins are known to
copurify (Rose et al., 1988). Thus, our data fit the long standing concept that rDNA-
transcription is a focus of topo I function, and that the enzyme is most probably a component
of the RNA-polymerase holoenzyme. Interestingly, we show here that this specific sub-
function is under the direction of the non-conserved N-terminus of topo I, a domain that
distinguishes the full length mammalian enzyme from a minimal variant encoded by vaccinia
virus (Shuman and Moss, 1987), and from the distantly related tyrosin recombinases (Grainge
and Jayaram, 1999). Studies in Drosophila have shown that this N-terminal domain can target
topo I to sites that are transcriptionally active (Shaiu and Hsieh, 1998), whereas it seems to
contribute very little (if anything at all) to the enzyme’s activity in vitro (Lisby et al., 2001).
We show here quite clearly that the main function of the N-terminus is, to associate topo I
with nucleolar FCs. When expressed alone, the N-terminus localizes almost exclusively to
FCs of interphase nucleoli. Some of it even stays bound to corresponding loci on mitotic
chromosomes (i.e. the NOR), and it colocolizes with RNA-polymerase I at both locations.
These data are supported by older immunohistochemical studies also demonstrating topo I at
the NORs of mitotic chromosomes (Guldner et al., 1986; Suja et al., 1997). They suggest that
at all times a certain fraction of topo I is integrated into the RNA-polymerase I holoenzyme
by virtue of its N-terminus. One is tempted to speculate that in this way the enzyme remains
associated with the rDNA during the entire cell-cycle.
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However, the precise localization of transcriptionally active rDNA within the
nucleolus is still open to discussion. Some authors suggest that rDNA transcription occurs
largely at the boundaries between the FC and the DFC, whereas the FC is believed to serve as
a storage place for inactive RNA polymerase I and other transcription factors (Stanek et al.,
2001). In controverse to this, other studies suggest that the FC is the place, where the
transcriptionally active rDNA is confined (Mais and Scheer, 2001). This controversy provides
us with two alternative interpretations of our data. One is that topo I at the FC is a storage
form, and the other is that topo I at the FC is heavily involved in the relaxation of supercoils
generated during transcription of rDNA. The second model is supported by the published
observation that ongoing transcription is crucial for the nucleolar localization of topo I (Mao
et al., 2002). The inverse should be the case, if the enzyme was stored there in an inactive
form. The second model is also more appealing from a teleological point of view. The rRNA
genes are the most heavily transcribed genes in the cell, and it is sense making that a
substantial portion of the machinery required for this process including topo I should stay
associated with the sites where these genes are. The second model is however somewhat
disfavoured by our observation that CpT treatment causes a rapid depletion of topo I from the
nucleoli. If topo I was heavily engaged in DNA catalysis at the FC, then it should be fixed
there by CpT, and not become depleted. However, we do not know if the nucleoli are as
accessible to CpT as the nucleoplasm.
5.3 Specific Roles of Topoisomerases IIα and β during Cell Division
While the in vivo-morphology of topo IIα and IIβ is very similar at interphase, the two
isozymes differ significantly from each other, when it comes to their localization during the
mitotic cycle. We find that in metaphase topo IIβ is scarcely chromosome-associated. This fits
with the recent observation that disruption of the TOP2β gene has little effect on early
embryonal development in mouse (Yang et al., 2000) and with our previous finding that in a
mammalian cell topo IIβ cannot substitute topo IIα during mitosis (Grue et al., 1998). It
seems now quite clear that topo IIβ is not required for mitotic cell division. Yet, in a living
cell topo IIβ is not fully excluded from metaphase chromosomes, and it retains to some extent
the ability to engage in catalytic DNA-turnover in the chromosome. This might be sufficient
to support mitotic topo II functions in yeast (Jensen et al., 1996b), but not in mammals (Grue
et al., 1998), and thus explain discrepancies between yeast complementation studies and
mammalian knock out-approaches. In keeping with this, only topo IIα accumulates at the
centromers. This feature seems to be restricted to those stages of the cell-cycle, where the two
chromatids are still linked together at the centromeric region. Such findings were also hinted
at by previous immunohistochemical studies (Rattner et al., 1996; Sumner, 1996; Taagepera
et al., 1993). They suggest that topo IIα accumulates at centromers until the centromeric DNA
is segregated at anaphase and that it is released immediately thereafter. This phenomenon
most probably reflects a requirement of a high topo II activity during the segregation of the
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centromeric heterochromatin ensuring simultaneous and fast separation of the centromeric
regions of all chromosomes upon initiation of sister chromatid-separation.
5.4 Immobilisation of Topoisomerases by Topoisomerase Poisons.
Inhibitors of DNA topo I and II play an important role in anti-cancer chemotherapy.
Actually, there are very few therapy protocols currently in use that do not employ a
topoisomerase-targeted drug at one stage or another. Most important in this respect are those
compounds that inhibit the second transesterification step of the catalytic cycle and thus
prolong the half-life of the covalent catalytic DNA-intermediate. As reviewed in sections
1.2.4 and 1.3.4 of the introduction, a host of biochemical data indicates this mechanism of
action. However, until now direct evidence has been lacking that shows these drugs to
actually immobilize topoisomerases on the genomic DNA. It has not been possible to access
the primary in vivo-effect of these drugs in quantitative terms. It has not been possible to
investigate, where in the genome it actually happens. It has not been possible to measure the
extent to which the half-life of the covalent intermediates is prolonged. And it has not been
possible to determine how much of the cellular complement of the enzymes is actually
affected, and how this will influence the general disposition of the enzymes in the cell
nucleus. The data presented here, allowed us to address most of these issues.
First of all, we show here for the first time that topoisomerase poisons actually render
topoisomerases less mobile in the genome of a living cell, and that, given a sufficient dose,
most if not all of the enzyme molecules present in the cell nucleus are affected. Secondly, we
show that these drugs target topoisomerases preferentially in the nucleoplasm, whereas the
enzyme is much less affected in the nucleolus. Thus, they induce a relocation of the enzyme
from the nucleolus to the nucleoplasm. Thirdly, we show that drugs targeting topo I act in a
manner distinctively different from drugs targeting topo II. Topo II is simply immobilized as
long as the drug is present, whereas in the case of topo I a more complex situation is
encountered, which was investigated in more detail.
5.4.1 The Impact of CpT on the Mobility of Topoisomerase I
CpT is known to bind and stabilize the covalent topo I·DNA intermediate (Hertzberg
et al., 1989). At least in living cells, the drug does not immobilize topo I completely, which
fits some previous biochemical data (Straub et al., 1997) showing that topo I·DNA
intermediates stabilized by camptothecin have a comparatively short half life (< 1 min). In
keeping with this, the drug attenuates the mobility of the enzyme in a gradual manner.
Apparently, CpT attenuates preferentially the slow fraction of topo I, and it does so
preferentially in the nucleoplasm. This supports the notion of this fraction being the one
engaged in DNA-turnover, thus fitting the on/off state-model suggested in 5.1.1. Why does
topo I disappear so rapidly from its favoured nucleolar residence when camptothecin is
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present? It has been proposed that nucleolar delocalization is triggered by conjugation of the
enzyme with small ubiquitin-like modifiers (Mo et al., 2002). However, this process is
operating on a minute scale (Mao et al., 2000a), whereas we show here that nucleolar
delocalization occurs within seconds. Moreover, it is unlikely that an entirely mobile protein
like topo I should require specific signals in order to move from one place in the nucleus to
another. As elaborated in section 5.1.1, topo I is prone to accumulate in the nucleoli, because
here it is moving more slowly than in the nucleoplasm. In the presence of CpT, however, the
situation is rapidly reversed: Now, the enzyme is moving more slowly in the nucleoplasm
than in the nucleoli. Accordingly, it accumulates in the nucleoplasm and delocalizes from
nucleoli, although it is still freely exchanging between the two compartments. Thus, nucleolar
delocalization of topo I upon exposure to camptothecin seems to be a plausible
epiphenomenon of the enzyme’s nuclear traffic and not a reflection of some specific cellular
response to the drug. In keeping, topo IPhe723, which cannot be stabilized in covalent DNA-
complexes by camptothecin, does not delocalize from nucleoli upon exposure to the drug, as
should be the case, if nucleolar delocalization was due to some kind of a coordinated stress
reaction and not a direct consequence of the altered mobility of the enzyme. Although our
data strongly argues against a direct role of sumoylation in nucleolar delocalization this
process may very well be involved in later steps of cellular response to CpT.
5.4.2 Mobility of Topoisomerases as a Means to Characterize Topoisomerase-
directed Drugs
Mobility measurements of bio-fluorescent topoisomerases expressed in mammalian
cells provide a powerful tool for the study of topoisomerase directed anti-cancer agents. For
example it is possible to assess by this means the isoform-selectivity of established topo II
poisons. We show here that the podophyllotoxin VM 26 has a certain preference for the α-
form of topo II. It is not known yet how other classes of established topo II poisons (e.g.
anthracyclins or aminoacridines) behave in this respect. Recently, new compounds have been
discovered, which are claimed to be selective poisons of topo IIβ (Barthelmes et al., 2001;
Gao et al., 1999). The scope of tumours targeted by these new compounds differs markedly
from that targeted by established topo II poisons. Thus, it is conceivable that isoform
selectivity determines the efficacy of topo II poisons against various tumour types and should
be taken into account, when applying these drugs in the clinic. The experimental system
described here would allow such an assessment in a very rapid and precise manner. It could
moreover been used to screen substance libraries for new topo II poisons and again the focus
could be put on the identification of isoform-selective substances, e.g. ones that are specific
for the α-form.
With topo I poisons the situation of drug development is even more open.
Camptothecins constitute so far the only class of substances that are indeed specific poisons
of topo I. Some camptothecin derivatives have just entered clinical use as tumour
therapeutics. We show here that camptothecin immobilises topo I to a lesser extent and much
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more transiently than VM 26 immobilises topo II. This explains, why camptothecins have to
be administered as a continuous dose in order to be clinically efficient (Slichenmyer et al.,
1993). Continuous administration provokes a number of extremely unpleasant side effects
(e.g. nausea) that would be much less, if the drug could be given as a bolus. Thus, it would be
desirable to find a topo I poison that immobilises topo I more permanently, and again we
provide here the ideal tool to find and characterise such a drug.
Finally, it has been proposed that dual drugs poisoning at the same time type I and
type II topoisomerases, would be the ideal cancer therapeutics. So far such substances have
not been found and we propose that they could be found if our experimental system was used
for screening.
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6. Summary
The first goal of this study was to develop cell lines with a stable expression of bio-
fluorescent topo II and topo I. This was successfully achieved using a bicistronic vector
system. Control experiments showed that proteins of expected size were expressed, and that
GFP-tagged topos I, IIα, and IIβ  were active in the cells and fully integrated in the
endogenous pools of the enzymes. These cell-lines provided a novel tool for investigating the
cell biology of human DNA topoisomerases.
Our most important finding was, that both types of mammalian topoisomerases are
entirely mobile proteins that are in continuous and rapid flux between all compartments of the
nucleus and between the cytososl and the chromosomes of mitotic cells. This was particularly
surprising with regard to topo II, which is considered to be a structural component of the
nuclear matrix and the chromosome scaffold. We must conclude that if this was the case, then
these architectural structures appear to be much more dynamic than believed until now. In this
context it should also be mentioned, that the alignment of topo II with the central axes of the
chromosome arms, which has until now been considered a hall-mark of the enzyme’s
association with the chromosomal scaffold, is not seen in vivo and can be demonstrated to be
to some extent an artefact of immunohistochemistry. Furthermore, we show that the two
isoforms of topo II (α and β) have a different localisation during mitotic cell division,
supporting the general concept that topo II functions at mitosis are exclusively assigned to the
α-form, whereas at interphase the two isoenzymes work in concert.
Despite unrestricted mobility within the entire nuclear space, topoisomerases I and II
impose as mostly nucleolar proteins. We show that this is due to the fact that in the nucleoli
they are moving slower than in the nucleoplasm. The decreased nucleolar mobility cannot be
due to DNA-interactions, because compounds that fix topoisomerases to the DNA deplete
them from the nucleoli. Interestingly, the subnucleolar distribution of topoisomerases I and II
was complementary. The type II enzymes filled the entire nucleolar space, but excluded the
fibrial centers, whereas topo I accumulated at the fibrial centers, an allocation directed by the
enzyme’s N-terminus. During mitosis, it also mediates association with the nucleolar
organising regions of the acrocentric chromosomes. Thus, topo I stays associated with the
rDNA during the entire cell-cycle and consistently colocalizes there with RNA-polymerase I.
Finally, we show that certain cancer drugs believed to act by stabilising covalent
catalytic DNA-intermediates of topoisomerases, do indeed immobilize the enzymes in living
cells. Interestingly, these drugs do not target topoisomerases in the nucleoli but only in the
nucleoplasm.
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7. Zusammenfassung
Diese Arbeit hatte zunächst zum Ziel, humane Zelllinien zu etablieren, in denen GFP-
Chimären der humanen DNS-Topoiosmerasen I, IIα und IIβ stabil und constitutiv exprimiert
werden. Dies wurde mit Hilfe eines bicistronischen Expressionsvektors erreicht, der eine
quasi physiologische Expression der GFP-Chimären in humanen Zellen ermöglichte. Wir
zeigen, dass die chimärischen Proteine die erwartete Größe haben, aktiv sind, und vollständig
in die jeweiligen endogenen Enzympopulationen integriert werden. Damit halten wir ein
ideales Werkzeug zur Untersuchung der Zellbiologie der Topoisomerasen in Händen.
Der wichtigste Befund dieser Arbeit ist, dass sowohl Topoisomerase I, als auch die
beiden Typ II-Enzyme innerhalb des Zellkerns vollständig mobil sind und zwischen
Nukleoplasma und Nukleolen, sowie zwischen Zytosol und Chromosmen mitotischer Zellen
ständig austauschen. Dieser Befund ist insbesondere hinsichtlich der Topoisomerase II
erstaunlich, da man bisher davon ausgeht, dass dieses Enzym eine zentrale Rolle bei der
Konstituierung der Kernmatrix bzw. des Chromosomengerüstes spielt, was mit einem
vollständig und rasch beweglichen Protein unvereinbar scheint. Falls Topoisomerase II
tatsächlich eine solche Rolle spielen sollte, müssen die Kernmatrix und das
Chromosomengerüst sehr viel dynamischere Strukturen sein, als bisher angenommen. Es sei
in diesem Zusammenhang auch darauf hingewiesen, dass wir in der lebenden Zelle keine
Konzentrierung der Topoisomerase entlang der zentralen Längsachsen der Chromosmenarme
gesehen haben, was bisher als Markenzeichen von deren Gerüstfunktion galt. Vielmehr
konnten wir zeigen, dass eine solche axiale Anordnung überwiegend ein Artefakt
immunhistologischer Methoden darstellt. Wir zeigen weiterhin, dass die beiden Isoformen der
Topoisomerase II (α und β) während der Zellteilung unterschiedlich lokalisiert sind, was mit
dem generellen Konzept zusammenpasst, dass nur die α-Form mitotische Funktionen
wahrnimmt, während die beiden Isoenzyme in der Interphase konzertiert arbeiten.
Ungeachtet ihrer unbegrenzten Mobilität innerhalb des gesamten Zellkerns,
imponieren Topoiosmerase I und II in der lebende Zelle als überwiegend nukleoläre Proteine,
was damit zusammenhängt, dass sie sich hier etwas langsamer bewegen, als im
Nukleoplasma. Diese relative Abbremsung kann nicht auf DNS-Interaktionen beruhen, weil
chemische Susbtanzen, die Topoisomerasen an der DNS fixieren, eine Entleerung der
Nukleolen bewirken. Interessanterweise ist die subnukleoläre Verteilung von Topoisomerase I
und II komplementär. Die Typ II- Enzyme füllen den gesamten nukleolären Raum aus, sparen
aber die fibrillären Zentren aus, während das Typ I- Enzym fast ausschließlich an den
fibrillären Zentren zu finden ist. Diese Assoziation wird durch den N-Terminus des Enzyms
vermittelt, der darüber hinaus während der Mitose auch die Bindung an die nukelolären
Organisationszentren der akrozentrischen Chromosomen bewirkt. So bleibt Topoisomerase I
über den gesamten Zellzyklus hinweg mit der rDNS physisch verbunden und kolokalisiert
hier mit der RNS-Polymerase I.
Schließlich konnten wir zeigen, das bestimmte Tumnortherapeutika, von denen man annimt,
dass sie über eine Stabilisierung der kovalenten katalytischen DNS-Intermediate der
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Topoiosmerasen wirken, diese Enzyme in der lebenden Zelle tatsächlich immobil machen.
Interssanterweise treffen diese Substanzen überwiegend im Nukleolplasma und nicht in den
Nukleolen.
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8. List of Abbreviations
5-FOA 5-fluoroorotic acid
2-AP 2-aminopurine
ACF ATP-dependent chromatin assembly and remodeling factor
AMPPNP Adenosine 5’-[β,γ-imido]triphosphate (a non-hydrolysable ATP analogue)
ATP Adenosine triphosphate
CAP Catabolite activator protein
CHRAC Chromatin accessibility complex
CpT Camptothecin
DAPI 4, 6-diamidino-2-phenylindole
DFC Dense fibrillar component
IRES Internal ribosome entry site
EtBr Ethidium bromide
EM Electron microscopy
FC Fibrillar center
FLIP Fluorescence loss in photobleaching
FRAP Fluorescence recovery after photobleaching
GAM Goat anti-mouse
GAR Goat anti-rabbit
GC Granular component
GFP Green fluorescent protein
G-segment Gate segment (the DNA segment to be cleaved and opened to form a gate)
Gyr A A-subunit of DNA gyrase
Gyr B B-subunit of DNA gyrase
HTH Helix turn helix
kb Kilo base
kDa Kilo dalton
kDNA Crithidia fasciculata kinetoplast DNA
LK Linkage number
MCS Multiple cloning site
NLS Nuclear localization signal
NORs Nucleolar organizer regions
NURF Nucleosome remodeling factor
pac Pyromycin-N-acetyltransferase (puromycin resistance)
PARP Poly(ADP-ribose)polymerase
Pat 1 Protein associated with topoII
PCR Polymerase chain reaction
PFA Para formaldehyde
PKC Protein kinase C
PK CK2 Casein kinase II
PNBs Prenucleolar bodies
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Rb Retinoblastoma protein
S/MAR Scaffold/matrix attached region
SDS Sodium dodecyl sulfate
Sc2 Scaffold protein 2
Sgs 1 Slow growth suppresser
SUMOs Small ubiquitin-like modifiers
T2C Structure of the DNA-closed gyrase fragment
T2O Original topoII DNA-open conformation of the yeast 92 kDa fragment
TDP1 Tyrosine-DNA phosphodiesterase
T-segment Transport-segment (the DNA segment transported through the gate in the G-
segment)
Topo II DNA topoisomerase type IIA
Topo I DNA topoisomerase type IB
TOP2A Gene encoding topoIIα
TOP2B Gene encoding topoIIβ
TPI Triose phosphate isomerase
Tw Twist
T-X-100 Triton X-100
VM 26 Teniposide
Wr Writhe
Wt Wild type
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